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The need for X chromosome inactivation was created by the evolution of 
the Y chromosome 
 
Sex determination systems 
Sexual reproduction offers the advantage of increased genetic variation in offspring, which 
creates detrimental mutations, but also an increased adaptability for a species to select for 
fitness in a changing environment. As a result of sexual reproduction a variety of sex 
determination systems have evolved, that either use environmental conditions or genetic 
factors to determine sexual differentiation of an individual. Environmental sex determination is 
used by many egg-laying reptile species, where the temperature during embryonic 
development permanently determines the sex of the embryo. A disadvantage of 
environmental sex determination is that the balance between the sexes is not guaranteed and 
might be disturbed by changes in the environment. 
In genetic sex determination, which is the topic of  this PhD research, sexual 
differentiation of an individual is determined by a sex-determining gene, or by the ratio 
between sex chromosomes and autosomes. In the non-parasitic worm Caenorhabditis elegans 
the X: autosome ratio is used for sex determination. Males have one X chromosome and 
hermaphrodites have two X chromosomes and both have a similar set of autosomes. The ratio 
between autosomal factors and X chromosomal factors determines the expression of the male-
specifying gene xol-1 (Carmi et al., 1998; Miller et al., 1988). In the fruit fly Drosophila 
melanogaster sex is also determined by the X: autosome ratio, with males being 
heterogametic, having an X and a Y chromosome, and females being homogametic, having two 
X chromosomes. Again the ratio between X-encoded factors and autosomal factors regulates 
the expression of a sex-determining gene. In this case, the sex-determining gene SXL promotes 
female differentiation (Cline, 1983; Salz et al., 1989). 
In birds, sex is determined by the Z and W chromosomes, with females being 
heterogametic, carrying a Z and a W chromosome, and males having two Z chromosomes. 
Whether the Z chromosome or W chromosome is sex determining in birds is still unresolved. A 
role for the Z chromosome as male sex-determining chromosome is supported by the presence 
of the male sex determining gene Dmrt1 on the Z chromosome, with a double dose of Dmrt1 
resulting in male gonadal development. A sex determining role for the W chromosome in 
females is hypothesized based on the location of the Fet1 and Asw genes, which are expressed 
during female development (Pace and Brenner, 2003; Reed and Sinclair, 2002). The avian ZW 
sex-chromosomes and mammalian XY sex-chromosomes are unrelated, as they have probably 
evolved from a different pair of autosomes (Nanda et al., 2002; Nanda et al., 1999).   
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In placental mammals, including humans, males are heterogametic carrying an X and Y 
chromosome, whereas females carry two X chromosomes. Sex is determined by the presence 
of the Y-chromosomal gene Sry, for Sex Determining region on the Y. The Sry gene is critical for 
induction of male sexual differentiation, leading embryonic development away from female 
development, which occurs by default. The requirement of Sry for sex determination is shown 
by XY mice lacking a functional copy of Sry, which develop a female phenotype, and XX mice 
carrying a Sry transgene, which develop a male phenotype (Kato et al., 2013). The location of 
Sry on the Y chromosome made it the sex-determining chromosome in mammals.  
At present, the X and Y chromosome are two heteromorphic chromosomes, with the 
human X chromosome being the larger chromosome, containing 819 coding genes. The human 
Y chromosome contains 72 coding genes, of which most are involved in sex determination and 
male fertility. The heteromorphic nature of the X and Y chromosome creates a potential 
imbalance for X chromosomal gene dosage between XY males and XX females. To correct this 
imbalance in number of X-chromosomal genes a dosage compensation mechanism has 
evolved, involving (i) the two-fold upregulation of X-chromosomal genes in males and (ii) the 
subsequent inactivation of one of the X chromosomes in females (Lyon, 1961; Ohno, 1967). 
The mechanism of X chromosome inactivation (XCI) has been subject of study for decades, and 
still has not revealed all its secrets. 
 
Dosage compensation evolved parallel to the degeneration of the Y chromosome  
Although the X and Y chromosome are remarkably different at present, it is commonly 
accepted that they find their origin in a single set of identical autosomes. This hypothesis is 
based on studies comparing sex-chromosomal sequences between eutherian mammals, other 
eutherians, marsupials, and monotremes. The diversion of two identical autosomes into the 
current X and Y chromosomes has driven the evolution of XCI. It is thought that the diversion of 
the ancestral autosomes started 160-180 million years ago with the acquisition of Sry by one of 
the autosomes, together with an inversion involving the Sry region (Lahn and Page, 1999). By 
acquiring Sry this autosome became the future Y chromosome (Fig. 1). In addition, the 
inversion that occurred must have served the prevention of meiotic recombination of the Sry 
region with the future X chromosome. As the inverted region was no longer able to recombine, 
this region on the future Y chromosome became susceptible to acquiring mutations and as a 
consequence started to lose genetic material. To compensate the loss of genetic material in 
the Sry region in males, dose-sensitive homologous genes on the future X were upregulated 
twofold. Simultaneously in females, the upregulated region on the future X chromosome 
became subject to XCI (Gribnau and Grootegoed, 2012).  
As the Sry region accumulated the aforementioned mutations, the region that was 
unable to recombine must have expanded (Bachtrog, 2013; Ellegren, 2011). This did not only 
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result in the additional loss of genetic material, but also in the acquisition of male-beneficial 
genes (Rice, 1987). As more genes were disrupted or deleted on the future Y, their homologous 
counterparts on the future X were upregulated in males, and became subject to female specific 
silencing. During the accumulation of deletions and mutations the Y chromosome lost most of 
its genes (Skaletsky et al., 2003). Since the X chromosome remained able to recombine during 
female meiosis it was not subject to the degeneration observed for the Y chromosome, but it 
became almost completely subject to XCI.  
 
 
 
 
 
 
Figure 1. 
The need for dosage compensation evolved in parallel with the degeneration of the Y chromosome. 
The X and Y chromosome in their current state originate from a single set of identical autosomes. On one 
of the ancestral autosomes Sox3 mutated into Sry, thereby designating this autosome as the future Y 
chromosome. On the future X chromosome the remaining Sox3 allele was upregulated twofold to 
compensate for the loss of the Y chromosomal allele. As the Sry-containing region on the future Y was no 
longer able to recombine with the future X during male meiosis, this region started to lose genetic 
material, thereby expanding the non-homologous region between X and Y. The loss of functional genes in 
the non-homologous region between X and Y prompted the compensatory upregulation of X 
chromosomal genes. Finally the X and Y chromosome are able to recombine only at the pseudoautosomal 
region (PAR, see main text). The X-chromosomal genes outside the PAR are upregulated twofold, and are 
subject to inactivation in females. 
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In its current status the X and Y chromosomes are still able to recombine at one or two 
small segments, named PseudoAutsomal Regions (PARs). In humans there are two PARs at the 
distal tips of both the X and Y chromosomes. The human PAR1 at the tip of the short arm is 2,6 
Mb in size and contains at least 24 genes. The human PAR2 at the tip of the long arm is 330 kb 
and contains  4 genes (Ross et al., 2005). In mouse there is one PAR only, which varies in size 
between different strains of laboratory mice. The mouse PAR is between 700 kb and 1100 kb 
long and contains at least two genes. 
 
X chromosome inactivation 
XC occurs early in embryogenesis. In mouse two forms of XCI take place successively, which 
results in different XCI patterns in the embryo and extraembryonic tissues (Fig. 2). First, from 
the 2 to the 16 cell stage imprinted XCI is initiated, resulting in the exclusive inactivation of the 
paternal X chromosome (Xp) in all cells of the slowly cleaving embryo (Huynh and Lee, 2003; 
Nesterova et al., 2001a; Okamoto et al., 2004; Sheardown et al., 1997; Takagi and Sasaki, 
1975). At the blastocyst stage the different cell lineages that have emerged will exhibit 
different forms of XCI. Cells of the trophectoderm (TE) and the primitive endoderm, which both 
contribute to the extraembryonic tissues, will maintain imprinted XCI. In contrast, the 
remaining cells of the inner cell mass (ICM) that will make up the embryo proper, reactivate 
the inactive Xp to prepare for the second round of XCI (Mak et al., 2004). This second round of 
XCI is initiated around day 5.5 of development and is random with respect to the parental 
origin of the X chromosomes, meaning that both X chromosomes will have an equal probability 
to be inactivated. Once the inactive state is established, this will be maintained for a near 
infinite number of cell divisions. As a result of this random choice which X chromosome is 
inactivated the female embryo is a mosaic of cells with either an inactive maternal X 
chromosome (Xm) and cells with an inactive Xp. 
 
 
 
Pluripotent cells as model system for XCI 
 
Embryonic stem cells 
XCI occurs during early embryogenesis, which is an obstacle for functional studies of the 
underlying mechanisms for XCI in humans. In vivo studies would require the use of human 
embryos, which are sometimes available as surplus material from IVF procedures, but only in a 
very limited amount (Van den Berg 2009). Given the limited amount of material to study 
human XCI and the lack of a good human in vitro system, most of our knowledge regarding XCI  
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Figure 2. 
XCI occurs during early mouse embryogenesis 
In the zygote of the mouse both X chromosomes are active after zygotic genome activation. Around the 
morula stage imprinted  inactivation of the Xp takes place, resulting in the exclusive expression of the Xm 
in all cells. In the pre-implantation blastocyst the cells of the epiblast reactivate the Xp to prepare for 
subsequent random XCI. The cells of the hypoblast and and trophoblast maintain an inactive Xp. In the 
post-implantation blastocyst the cells of the epiblast initiate a second round of XCI, which is random with 
respect to the parental origin of the X chromosomes.  After the cells of the epiblast have selected and 
inactivated one of their X chromosomes, the inactive state of this chromosome is passed on to all 
daughter cells.  As a result the female embryo is a mosaic of cells that express either the Xp or the Xm.  
The cells of the extra-embryonic tissues will maintain the imprinted inactive state of the Xp throughout 
female embryonic development.  
 
 
 
 
comes from mouse model systems. Especially mouse Embryonic Stem (ES) cell lines have been 
of great importance to study XCI in the past decades, as female mouse ES cells carry two active 
X chromosomes and, when induced to differentiate in vitro, these cells undergo random XCI. 
Mouse ES cells are derived from the epiblast of (E3,5-4,5) pre-implantation blastocysts (Fig. 2). 
In the pre-implantation blastocyst three morphologically different cell types can be 
distinguished. The trophectoderm (TE) is a monolayer of cells on the outside of the blastocyst, 
that serves implantation, and will later give rise to most of the fetal part of the placenta. 
Located on the inside of the blastocyst are the epiblast (EPI) cell population and the cells of the 
primitive endoderm (PE). The cells of the epiblast will form the entire fetus and contribute to 
the yolk sac and amnion. The cells of the epiblast are covered by a layer of the primitive 
endoderm cells, which will later cover the entire cavity of the fluid-filled blastocyst. After 
implantation of the blastocyst, the primitive endoderm will give rise to parietal and visceral 
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endoderm, of which the latter will form the endodermal layer of the yolk sac. From the pre-
implantation stage embryo, epiblast cells can be isolated and cultured and kept in an 
undifferentiated pluripotent state as mouse ES cells (Boroviak 2014). Due to their capability of 
self-renewal, the ability to undergo XCI during differentiation, and the possibility to perform 
genetic targeting, mouse ES cells have been instrumental as  an in vitro system for studying the 
mechanisms of XCI. 
 
Human ES cells 
Unfortunately a similar human model system as the aforementioned mouse ES cells is not 
available, as human ES cells seem to represent a more differentiated pluripotent stem cell than 
mouse ES cells. Most human ES cell lines carry an inactivated X chromosome (Xi), and those 
that have two active X chromosomes (Xa’s) do not always undergo XCI upon differentiation 
(Silva et al., 2008). This dissimilarity between human and mouse ES cells in this respect is 
striking, given that they are both isolated from a pre-implantation blastocyst. Over the last few 
years it has become clear that human ES cells are more resembling mouse epiblast stem cells 
(epiSC), which are a more differentiated type of pluripotent stem cell. EpiSCs can be derived 
from the epiblast of the mouse post-implantation blastocyst, where ES cells are derived from 
mouse a pre-implantation blastocyst. As a result, epiSCs represent the cells of the epiblast that 
are primed for differentiation, where ES cells represent the naïve epiblast. As a consequence 
epiSCs cannot contribute to the germline of chimaeric mice, while ES cells can. Mouse epiSCs 
carry an inactive X chromosome, like most human ES cells. Human ES cells and mouse epiSCs 
are grown in similar culture conditions, as both depend on Activin/Nodal and FGF signaling for 
self-renewal. In contrast, mouse ES cells require Leukemia Inhibitory Factor (LIF) and Wnt 
signaling for staying undifferentiated ex vivo and for self- renewal (Brons et al., 2007; Smith et 
al., 1988; Tesar et al., 2007). When kept in culture both mouse epiSCs and human ES cells grow 
in colonies with a flat morphology, while mouse ES cell colonies are dome-shaped. The 
transcriptome of human ES cells overlaps more with that of mouse epiSCs, instead of mouse ES 
cells (Huang et al., 2014). 
The identified differences between cultured pluripotent mouse ES cells and human ES 
cells can be the result of the derivation itself, an adaptation to culture conditions or intrinsic 
differences between human and mouse early embryogenesis. An interesting phenomenon in 
mouse embryos, which might facilitate isolation of ES cells is embryonic diapause. Mouse 
embryos have the ability to arrest their development at the late blastocyst stage, when 
entering an unfavorable uterine environment. When restored into an estrogen-rich 
environment, these blastocysts resume their arrested development normally. In diapause the 
embryos thus cease to develop and remain un-implanted in the uterus, which can persist for 
several weeks without losing the ability to continue development. Interestingly, mouse ES cells 
16  |  Chapter 1 
 
 
were in fact first derived from such diapause embryos and appear to be derived more 
efficiently from diapause embryos than from normal blastocysts (Brook and Gardner, 1997; 
Evans and Kaufman, 1981). Interestingly, diapause is dependent on LIF, which is required for 
mouse ES cells establishment (Nichols and others 2001). Altogether, it seems that the window 
of naïve pluripotency can be extended for a longer period of time in the mouse, facilitating the 
derivation of ES cell lines. In human, the existence of diapause is unlikely, although this is still 
under debate (Ptak 2012, Ptak 2013). The absence of diapause in humans would explain why 
the derivation of naïve human ES cells carrying two active X chromosomes is difficult.  
 
Mouse induced pluripotent stem cells 
Another type of pluripotent stem cell frequently used to study the mechanism of XCI is the  
induced pluripotent stem (iPS) cell. iPS cells have first been generated from somatic cells (e.g. 
fibroblasts) by forced expression of the transcription factors Klf4, Sox2, Oct4 and c- Myc 
(Takahashi and Yamanaka, 2006). Forced expression of these pluripotency factors in somatic 
cells resulted in reversion of these cells into a pluripotent state morphologically and 
functionally indiscernible from ES cells. When injected into a mouse blastocyst iPS cells can 
contribute to all germ layers, including the germ line (Maherali et al., 2007; Okita et al., 2007; 
Wernig et al., 2007). Moreover, when injected into a mouse tetraploid blastocyst, iPS cells can 
generate a complete embryo proper (Boland et al., 2009; Stadtfeld et al., 2008; Zhao et al., 
2009). In mouse, the reversion of female somatic cells to such a pluripotent state is 
accompanied by reactivation of the Xi. This reactivation occurs late during the reprogramming 
process, around the moment where iPS cells become independent of the expression of 
exogenous pluripotency transcription factors (Stadtfeld et al., 2008).  Interestingly, the 
numerous events that take place during XCI do not happen in the reverse order during 
reprogramming, as some of the events that occur late during XCI are not reversed early during 
reactivation (Pasque et al., 2014). Importantly, when mouse iPS cells are induced to 
differentiate they undergo random XCI like ES cells, making them suitable for studying the 
mechanisms underlying XCI (Maherali et al., 2007). 
 
Human induced pluripotent stem cells 
Human iPS cells hold great promise as a model system for studying human XCI (Takahashi et al., 
2007). Unfortunately the generation of human iPS cell lines containing two active X 
chromosomes turned out to be difficult. Since the first human iPS cells were derived by many 
research groups, iPS cells have been generated using different reprogramming strategies (e.g. 
using other combinations of transcription factors). These studies reported different results 
with respect to X chromosome status. Although a number of studies indicated X chromosome 
reactivation (XCR) in all or a limited number of generated iPS cell lines, a comparable number 
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of studies found no XCR at all (Amenduni et al., 2011; Ananiev et al., 2011; Bruck and 
Benvenisty, 2011; Cheung et al., 2011; Kim et al., 2011; Marchetto et al., 2010; Tchieu et al., 
2010). Importantly, iPS cell lines that reactivated their Xi initiated random XCI upon 
differentiation (Bruck and Benvenisty, 2011; Kim et al., 2011; Marchetto et al., 2010). To force 
human iPS cells to reactivate the Xi, new culture conditions have been developed to induce a 
naïve state (Hanna et al., 2010; Lengner et al., 2010; Silva et al., 2008; Ware et al., 2009). Two 
studies successfully and efficiently generated naïve iPS cell lines containing two active X 
chromosomes, using a combination of different cytokines and small molecule inhibitors (Gafni 
et al., 2013; Hanna et al., 2010). Upon differentiation, these iPS cells upregulate the gene Xist, 
suggestive of random XCI, although additional studies need to confirm this. Although these 
results seem promising with respect to the usefulness of iPS cells to model human XCI in vitro, 
these findings still need to be reproduced in independent studies before human iPS cells can be 
used on a large scale for human XCI studies. 
 
 
 
The X-inactivation center (XIC) 
 
The X-inactivation center (XIC) 
From genetic studies of X chromosome rearrangements and translocations it was deduced that 
a single region on the X chromosome is required for XCI to occur. This region, termed the X-
inactivation center (XIC in humans and Xic in mouse), was defined as “the minimal required 
region that was both necessary and sufficient to induce XCI” (Rastan and Robertson, 1985). As 
the Xic was defined by naturally occurring X chromosome alterations it was redefined several 
times, with newly identified translocations or rearrangements reducing the size of the Xic 
(Rastan, 1983; Rastan and Robertson, 1985; Russell and Montgomery, 1970). The mouse Xic 
was finally narrowed down to the breakpoints of the Searle’s t(X;16) translocation, and the 
HD3 truncation (Rastan, 1983; Rastan and Robertson, 1985). It was hypothesized that the 
single Xic locus was not only required for the cis-inactivation of the X chromosome it is located 
on, but also for trans-inactivation of the other X chromosome, as deletion of the Xic region 
resulted in the inability of the unaffected X chromosome to inactivate (Rastan, 1983; Rastan 
and Robertson, 1985). Inherent properties of the Xic therefore include counting the number of 
X chromosomes in a cell, determining which X chromosome will be inactivated, and next the 
implementation of this choice along the entire X chromosome.  
Similar to the mouse Xic, the human XIC was also defined by naturally occurring X 
chromosome rearrangements and translocations. The human XIC was first limited to a size of 
at least 0.8 Mb and maximally would be 2.89 Mb long. This region was defined by the 
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breakpoints of a X;14 translocation in a male individual, and an isodicentric X chromosome in a 
female Turner patient (Allderdice et al., 1978; Brown et al., 1991b; Pettigrew et al., 1991). 
Later, the distal breakpoint was redefined by a complex rearrangement of the X chromosome 
in a female individual, now leading to an estimated human XIC of 0.68 to 1.2Mb in size (Leppig 
et al., 1993). 
As the genes of the Xic and their function in XCI were identified one by one, it became 
clear that the Xic is not a single locus, but rather that its genetic elements are spread across the 
entire X chromosome. Consequently, the Xic can currently be separated in a cis-acting part and 
a trans-acting part (Fig. 3) (Gribnau and Grootegoed, 2012). The cis-acting Xic comprises the 
genes and elements that exert their function in XCI in-cis, on the X chromosome they are 
located on. The cis-acting elements are involved in the inactivation of an X chromosome, and 
determine which X chromosome will be inactivated, by generating an X chromosome-specific 
chance to inactivate. In contrast, the genes that comprise the trans-acting Xic have an effect on 
both X chromosomes. They are involved in counting the number of active X chromosomes in a 
cell and  dictate whether inactivation of additional X chromosomes is required. The trans-
acting Xic comprises X-encoded activators of XCI that are required for counting the number of 
active X chromosomes, but also encompasses autosomally encoded inhibitors of XCI, which 
prevent premature initiation of XCI. At this moment identification of elements of the Xic is still 
ongoing. 
 
Xist 
XIST, for X-Inactive Specific Transcript is perhaps the most iconic gene in the cis-Xic, as it is 
absolutely required for XCI to take place (Brown et al., 1991a). XIST was identified as the first 
gene expressed from the inactive X chromosome and silenced on the active X chromosome. In 
both human and mouse, XIST/Xist is a non-coding gene that is expressed from the Xi and 
produces an RNA that strongly associates with the Xi. Accumulation of XIST/Xist RNA on the Xi 
is required for inactivation, as X chromosomes lacking a functional copy of Xist are unable to 
inactivate (Marahrens et al., 1997; Penny et al., 1996).  
In undifferentiated ES cells Xist is expressed extremely lowly, with at maximum 10 Xist 
RNA molecules per nucleus (Sun et al., 2006). Upon differentiation, Xist is upregulated. Initially, 
undifferentiated female ES cells display a small focus of Xist RNA molecules at its transcription 
site, using RNA-FISH. Upon ES cell differentiation, Xist RNA molecules accumulate over time 
and spread across the entire future Xi. As Xist transcripts accumulate, chromatin modifiers are 
recruited that silence gene expression. During Xist accumulation on the future Xi the Xist RNA 
concentration in the nucleus increases 30-fold, which is the result of increased transcription 
rather than transcript stabilization (Panning et al., 1997; Sheardown et al., 1997; Sun et al., 
2006). 
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Human XIST appears to function comparable to mouse Xist, as the Xi in human female 
somatic cells is similarly covered  by a large domain of XIST RNA molecules (Brown et al., 
1991a; Chureau et al., 2002). Human XIST contains 8 exons and produces a 19.3 kb full-length 
transcript (Hong 2000), while mouse Xist contains 7 exons and produces a 17.4 kb transcript 
(Hong et al., 1999). Both human and mouse XIST/Xist transcripts contain alternative splice 
variants (Brockdorff et al., 1992; Brown et al., 1992; Hong et al., 1999; Hong et al., 2000). While 
XIST is conserved between mouse and human, the overall XIST sequence conservation between 
  
 
 
 
 
 
Figure 3. 
The X inactivation center 
The top shows a schematic overview of the mouse X chromosome, with the location of the Xic indicated in 
green, and below a schematic representation of the genes located in the Xic. Tsix and its positive 
regulators are indicated in green, Xist and its positive regulators in red.  Arrows indicate the regulatory 
effect and the target genes of cis-acting elements. The stippled line indicates the trans-acting effect of 
Rnf12. 
At the bottom a schematic overview of the human X chromosome and XIC is shown. Whether the cis-
acting and trans-acting elements perform similar functions as in mouse is currently unknown. 
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human and mouse is relatively poor with 48-60% similarity (Brown et al., 1992; Hendrich et al., 
1993; Nesterova et al., 2001b). Instead, human XIST shows higher sequence homology to 
bovine Xist (76%), or leptine Xist (73%) (Hendrich et al., 1993). Conservation of XIST is not 
homogeneous across its entire sequence, but shows regions that are more conserved and 
regions that are not conserved at all. The strong conserved regions involve a number of repeat 
regions and XIST intron 4, suggesting that these regions were subject to a more stringent 
selective pressure, possibly because they are required for the function of XIST. Although the 
exact mechanisms by which XIST RNA exerts its function and the regions that are required to 
perform its function are still subject of ongoing studies, it is clear that XIST RNA is central to XCI 
in both mouse and human.   
 
Tsix 
The second gene that is central to the cis-acting Xic is Tsix, which is a non-coding gene, that 
acts as a negative regulator of Xist. Tsix completely overlaps with Xist, but is transcribed in the 
antisense direction (Fig. 3) (Lee et al., 1999). In mouse, Tsix contains 4 exons and is transcribed 
from 2 promoters, producing a 40kb-long transcript. In undifferentiated female mouse ES cells 
Tsix is expressed from both active X chromosomes. The transcripts stay in close proximity of 
the Xic , as can be seen by the presence of two pinpoints when performing RNA-FISH (Lee et 
al., 1999). When XCI takes place, Tsix first becomes silenced on the future Xi. On the Xa Tsix 
remains expressed for a longer period and becomes silent between day 4 and 11 of general ES 
cell differentiation (Lee et al., 1999). Tsix silencing on the future Xi correlates with the onset of 
Xist RNA coating. However, in some cells with immature Xist domains Tsix transcripts can still 
be detected inside these domains, indicating transcription of Xist and Tsix is not mutually 
exclusive (Lee et al., 1999; Sado et al., 2001).  
The function of Tsix as negative regulator of Xist was shown by deleting the Tsix 
promoter region. Mouse ES cells carrying this deletion exclusively inactivate the mutant X 
chromosome (Clerc and Avner, 1998; Lee and Lu, 1999). How Tsix exactly exerts its repressive 
function on Xist transcription is still unknown, although several hypotheses exist. One 
possibility is that Tsix affects Xist transcription through transcriptional interference, a process 
that has been observed for a number of antisense positioned genes (Palmer et al., 2011). This 
hypothesis is supported by the observation that Tsix transcripts are present in a decreasing 
gradient from the Tsix promoter towards the Xist promoter. At the Tsix 5’region there is 100-
fold more Tsix compared to Xist, while at the 3’region this is only 10-fold (Shibata and Lee, 
2003; Sun et al., 2006). Furthermore, Tsix transcription trough the Xist promoter seems 
required for its silencing, as a truncated form of Tsix is no longer able to induce silencing 
(Ohhata et al., 2008).  
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Another mechanism by which Tsix might repress Xist is trough RNA mediated 
recruitment of chromatin remodelers (Shibata and Lee, 2004). If antisense Tsix transcription is 
disrupted, inactive chromatin marks at the Xist promoter are reduced (Navarro et al., 2006; 
Ohhata et al., 2008; Sado et al., 2005; Sun et al., 2006). However, this finding might also be 
explained by a model where an actively transcribed promoter is targeted for inactivation by 
chromatin remodelers that target histone modifications associated with transcribed 
sequences.  
Lastly, Tsix has been proposed to repress Xist expression trough a RNA-interference 
(RNAi) mechanism. Indeed, small RNA molecules of 25-37 nucleotides from the Xist/Tsix locus 
have been detected and are hypothesized to be the result of RNAi (Ogawa et al., 2008). 
However, genetic inactivation of Dicer, which encodes an endonuclease that is a critical 
component of the RNAi machinery, has yielded contradictory results. One study observed Xist 
up-regulation after Dicer inactivation, while others found no effect on XCI (Kanellopoulou et al., 
2009; Nesterova et al., 2008). Whatever the mechanism by which Tsix represses Xist, it will not 
depend on Tsix splicing, as around 50% of the Tsix transcripts remains unspliced, and a mutant 
Tsix gene defective in splicing is still able to repress Xist (Sado et al., 2006). 
In humans, TSIX is poorly conserved and seems to be inactive. Several studies have 
compared the human and mouse Tsix region and found little sequence conservation. The little 
sequence conservation that was found, is mostly explained by the strong conservation of XIST. 
Importantly, the conserved sequences are found in the region overlapping with exons 5-8 of 
XIST, but not in the XIST promoter region (Chureau et al., 2002; Lee et al., 1999; Migeon et al., 
2001).  For mouse Tsix, transcription through the Xist promoter seems required for its silencing 
capability (Ohhata et al., 2008). Also, the DXPas34 region, that has been shown to be important 
for proper Tsix expression in mouse, is not conserved in humans (Chureau et al., 2002). 
Interestingly, despite the poor sequence conservation for TSIX, transcription antisense to XIST 
was detected from the TSIX region (Migeon et al., 2001; Migeon et al., 2002). However, when 
performing RNA-FISH on human fetal cells, transcription of TSIX was detected only from the Xi 
and never from the Xa, which is contradictory to expression patterns observed in mouse 
(Migeon et al., 2002). Since human TSIX is expressed in-cis with XIST it can be concluded that in 
humans TSIX might not be functional as a repressor of XIST (Migeon, 2003). 
 
Other non-coding genes 
The Xic contains several other non-coding genes that positively regulate either Xist or Tsix in-
cis. Located upstream of Xist are Jpx and Ftx, which positively regulate Xist (Fig. 3) (Chureau et 
al., 2011; Sun et al., 2013; Tian et al., 2010). Jpx (also named Enox, for Expressed neighbor of 
Xist) is a non-coding gene located 10kb upstream of Xist that is transcribed in the opposite 
direction of Xist, and escapes from XCI (Johnston et al., 2002). Several studies have shown that 
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Jpx  RNA is involved in the regulation of Xist promoter activity. Jpx is thought to achieve  this by 
altering the occupancy of the chromatin insulator CTCF (for CCCTC-binding factor) at the Xist P2 
promoter.  Low-level Xist expression is characterized by high CTCF occupancy at the Xist 
promoter, while Xist upregulation is accompanied by CTCF eviction. Jpx RNA has been shown to 
directly bind to CTCF and is thought to titrate CTCF away from the Xist promoter, thereby 
inducing Xist expression (Sun et al., 2013). Interestingly, deletion of Jpx abolishes Xist 
expression, but can be rescued by a trans-acting  autosomal copy, arguing that Jpx is a trans-
acting activator rather than a cis-regulatory element (Tian et al., 2010). However, the trans-
acting effect of Jpx on Xist expression needs to be considered with care, for the observation 
that a Jpx transgene induces low frequencies of ectopic Xist expression could not be 
reproduced in an independent study (Jonkers et al., 2009; Sun et al., 2013).  
Ftx (for Five prime to Xist) is less well investigated than Jpx. Like Jpx, Ftx is also a non-
coding gene, which partially escapes XCI, but is located 150 kb upstream of Xist. Ftx affects 
expression of genes in its downstream region, suggesting that extended transcription from the 
Ftx promoter is involved in this regulation. This is further supported by the observation that 
sense transcription in the downstream region of Ftx is reduced after Ftx deletion, but antisense 
transcription is unaffected. One of the genes that is negatively affected by deletion of Ftx is Xist 
(Chureau et al., 2011). To date, the function of Ftx has only been investigated by deletion in 
male ES cells, where the effect of deleting an Xist-activator will not be obvious as male cells do 
not upregulate XCI. A trans-acting effect of Ftx RNA seems unlikely, as Ftx transgenes in male 
mouse ES cells did not induce ectopic XCI (Jonkers et al., 2009). Both Ftx and Jpx are conserved 
between mouse and human, suggesting they might have a similar role in human XIST 
regulation (Chureau et al., 2002).  
Upstream of Tsix reside the non-coding genes Tsx and Xite, which positively regulate 
Tsix (Fig. 3). Xite (for X chromosome Intergenic Element) is a non-coding element that is located 
around 10 kb upstream of the Tsix major promoter and is transcribed in the same direction 
(Ogawa and Lee, 2003). Xite is thought to act as an enhancer of Tsix transcription, as deletion 
of Xite results in reduced Tsix expression and preferential inactivation of the mutated X 
chromosome (Ogawa and Lee, 2003; Stavropoulos et al., 2005). How Xite enhances Tsix 
transcription remains poorly understood, but this might involve the formation of an active 
chromatin domain through chromatin looping, as Chromatin Conformation Capture (3C)  
experiments identified a physical interaction between Xite and Tsix (Tsai et al., 2008). This 
interaction is present before XCI is initiated and is reduced after XCI, which is consistent with a 
change in interactions within the Tsix-TAD after initiation of XCI. Despite these results 
suggesting a role as enhancer of Tsix, the possibility that Xite acts as a minimal promoter of 
Tsix, cannot be excluded.  
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Tsx (Testes-Specific X-linked) is located around 36 kb upstream of Tsix and Xite, and is 
transcribed in the same direction, antisense to Xist (Simmler et al., 1996). Tsx functions as a 
positive regulator of Tsix, and deletion of Tsx in mouse ES cells results in ectopic XCI (Anguera 
et al., 2011). Originally, Tsx was thought to be protein coding, but later experiments suggested 
Tsx is non-coding, as the original immunostainings for TSX protein did not coincide with mRNA 
expression (Cunningham et al., 1998; Simmler et al., 1996). Furthermore, experiments testing 
several putative open reading frames for Tsx could not detect any protein, leading to the 
conclusion that Tsx is non-coding (Anguera et al., 2011). Apart from its potential role in XCI, Tsx 
might also be implicated in silencing of unpaired chromatin during male meiosis, as it is also 
expressed in meiotic cells and one of the few genes escaping from male sex chromosome 
inactivation (MSCI) (Anguera et al., 2011; Namekawa et al., 2006). In humans, TSX is poorly 
conserved and XITE is not conserved at all, which is coherent with the poor conservation and 
possible absence of a functional TSIX.  
One of the intriguing questions of gene regulation in general is how the genome is three 
dimensionally organized within the nucleus. Recent advances in a series of chromatin 
conformation capture techniques have made analysis of the spatial organization of the genome 
possible, and have shown that the genome is organized into topologically associated domains 
(TADs). These TADs are up to a Megabase in size and are characterized by an increased 
frequency of internal spatial interactions (Nora et al., 2012). Genes that are located within the 
same TAD not only show an increased frequency of interaction, but also a correlation in their 
expression, suggesting that genes located within the same TAD are co-regulated (Giorgetti et 
al., 2014; Nora et al., 2012). In the mouse the Xic maps as having two TADs, with Xist and its 
positive regulators located in one TAD and Tsix and its positive regulators in the other TAD. The 
boundary between the TADs is located in between the Xist and Tsix promoters, with 
transcription crossing the boundary (Nora et al., 2012). It is not surprising that Xist and its 
positive regulators are located in the same TAD, and also Tsix and its positive regulators are 
located in a single TAD.  
Apart from the abovementioned mechanisms by which the respective positive 
regulators of Xist and Tsix function, they are likely to regulate Xist and Tsix expression also by 
altering the transcriptional status of their respective TADs. After initiation of XCI the location 
and size of the TADs remain similar, but the internal contacts within each TAD are altered 
(Nora et al., 2012). The boundary between the Xist and Tsix TAD is characterized by a CTCF-
binding site and acts as an insulator (Spencer et al., 2011). Deletion of the boundary region 
compromises the separation of the two TADs and results in ectopic interactions between the 
respective Xist and Tsix-TADs (Nora et al., 2012). Another study showed that deletion of the 
boundary element in female mouse ES cells results in reduced  initiation of XCI, accompanied 
by low Xist expression and high Tsix expression (Spencer et al., 2011). This might implicate that 
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in absence of the boundary element the TADs of the Xic are unable to switch from a pre-XCI 
configuration to a configuration where Xist is activated. Altogether these data indicate that the 
cis-regulation of Xist and Tsix not only involves single gene regulation, but likely involves the 
cis-organization of entire, discernable chromatin domains. 
 
RNF12 
Where the elements of the cis-Xic are required for the cis-inactivation of an X chromosome and 
generating an X chromosome-specific threshold for XCI, several trans-acting factors are 
required to coordinate XCI  between the two X chromosomes. These trans-acting factors 
ensure that the correct number of X chromosomes will be inactivated, and involves activators 
of XCI that are X-encoded and inhibitors that are autosomally encoded. The X-encoded 
activators are required to count the number of active X chromosomes in a cell. To date, the 
only identified trans-acting activator is Ring finger protein 12 (Rnf12, also named Rlim for Ring 
finger protein LIM domain interacting), which was identified in the mouse. Rnf12 is an X-
encoded E3 ubiquitin ligase that induces XCI indirectly, by marking the pluripotency factor 
REX1 for proteasomal degradation (Gontan et al., 2012). REX1 is a transcription factor that is 
exclusively expressed in pluripotent stem cells, acting as an inhibitor of XCI. REX1 represses Xist 
and activates Tsix by binding their respective gene regulatory sequences. REX1 is encoded by 
the autosomally located Zfp42. In undifferentiated ES cells REX1 is present in high 
concentrations, thereby preventing preemptive Xist activation, while Rnf12 is moderately 
expressed. When differentiation is induced, Rnf12 mRNA and protein levels are upregulated, 
accompanied by a quick down regulation of REX1 protein levels (Fig. 4.). In female XX cells the 
concentration of REX1 is sufficiently low to result in activation of Xist and initiation of XCI 
(Gontan et al., 2012). Transgenic overexpression of Rnf12 in male and female ES cells results in 
aberrant XCI (Jonkers et al., 2009). 
The gene encoding Rnf12 is located 500kb upstream of Xist on the X chromosome, and 
this chromosomal location seems essential for performing its function. Its location on the X 
chromosome allows Rnf12 to induce XCI in a female-specific manner, due to the twofold 
dosage of Rnf12 in females compared to males. Furthermore, its close proximity to Xist allows 
a rapid feedback mechanism for XCI, preventing inactivation of a second X chromosome. As 
Xist RNAs spread along the X chromosome and induce silencing, Rnf12 will be one of the genes 
that is silenced early during the XCI process. After silencing one copy of Rnf12, the 
concentration of RNF12 protein will decrease to a level comparable to the level in male cells, 
which is insufficient to induce XCI on the second X chromosome (Gontan et al., 2012). Another 
essential requirement for the feedback loop of Rnf12 on XCI is the short half-life of both REX1 
and RNF12 proteins, as RNF12 degradation is mediated by auto-ubiquitination (Gontan et al., 
2012). 
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Figure 4. 
RNF12 functions as a trans-acting activator of XCI by targeting the pluripotency factor REX1 for 
proteasomal degradation. 
In pluripotent ES cells the concentration of the pluripotency factor REX1 is relatively high, and prevents 
Xist activation. When differentiation is induced Rnf12 transcription is upregulated. The increasing amount 
of RNF12 targets poly-ubiquitinates REX1 and thereby targets REX1 for degradation by the ubiquitin-
proteasome. The resulting decrease in REX1 permits Xist activation on both X chromosomes, resulting in 
Xist RNA spreading and silencing. While Xist RNA spreads on both X chromosomes, it is thought that that 
this does not occur synchronous. As a result Rnf12 will likely be silenced on one X chromosome, resulting 
in a decrease in RNF12. This decrease in RNF12 is thought to prevent further degradation of REX1 and 
inactivation of the second X chromosome. 
 
 
 
 
The function of Rnf12 has been extensively studied using loss-of-function approaches in 
mouse ES cells and mice. In mouse ES cells a heterozygous deletion of Rnf12 results in a clear 
XCI phenotype, in which the mutant allele is preferentially inactivated, and XCI is initiated at a 
reduced rate (Barakat et al., 2011; Shin et al., 2010). As Rnf12+/- ES cells  
are still able to initiate XCI, where male ES cells with one allele of Rnf12 do not initiate XCI, it is 
likely that other trans-acting activators exist. ES cells carrying a homozygous deletion of Rnf12 
almost do not initiate XCI (Barakat et al., 2011). When the effect of Rnf12 deletion was studied 
in vivo, a severe phenotype for imprinted XCI was observed, in a parent-of-origin specific 
manner. Since the paternal allele is always inactivated during imprinted XCI, a maternally 
inherited Rnf12 deletion, results in complete functional loss of Rnf12 in extraembryonic tissue. 
26  |  Chapter 1 
 
 
As a result Rnf12+/- females inheriting a maternally transmitted knockout allele display severe 
developmental defects of the extraembryonic tissues and as a result are not born. In contrast, 
Rnf12+/- females inheriting a paternal deletion of Rnf12 do not show any phenotype of 
imprinted XCI, and develop normally. When random XCI is analyzed in these females they show 
exclusive inactivation of the mutant X chromosome, comparable to ES cells (Shin et al., 2010).  
To circumvent the imprinted XCI phenotype, a recent study used a ICM-specific 
conditional deletion of Rnf12 to create Rnf12-/- embryos. Unexpectedly, Rnf12-/- embryos were 
viable, and seem to be able to undergo XCI, as Xist domains could be detected by RNA-FISH 
(Shin et al., 2014). These results are highly contradictory with results from ES cells, where one 
allele of Rnf12 needs to remain active to establish proper silencing of the Xi (Barakat et al., 
2014). The difference between these mice and ES cells is most likely caused by the use of 
different knockout approaches, targeting different critical exons and different genetic 
backgrounds. This is further illustrated by the observation that Rnf12-/- ES cells that are 
genetically similar to the Rnf12-/- embryos, were also able to undergo XCI, and did so at a rate 
comparable to Rnf12+/- ES cells (Shin et al., 2010). In addition to the different genetic 
background, the cell type specificity of the conditional knockout can be questioned, as well as 
the non-allele-specific methods that were used to analyze XCI in Rnf12-/- embryos. Therefore, 
the discussion whether embryonic Rnf12-/- cells are able to undergo XCI is still ongoing. 
While REX1 seems to be the primary target of RNF12 during XCI, several other proteins 
have been identified as such targets of RNF12. These are unlikely to be involved in XCI as they 
have not been identified in affinity purification experiments with mouse ES cells undergoing 
XCI (Gontan et al., 2012). Instead, they are involved in different cellular functions and signaling 
cascades. Among the targets of RNF12 are SMAD7 (for Mothers Against Decapentaplegic 
homolog 7) and SMURF2 (for SMAD Ubiquitination Related Factor 2). These proteins are both 
involved in the Transforming Growth Factor (TGF)-β family signaling pathway, and act as 
inhibitors of this pathway. This signaling system is essential for regulation of many cellular 
processes including  proliferation, differentiation, and apoptosis, but is also involved in 
regulating embryonic development. The TGF-β pathway is activated by a broad range of 
cytokines and hormones, including TGF-βs, Bone Morphogenic Proteins (BMP), Growth and 
Differentiation Factors (GDF), Activin, Nodal and Anti-Mullerian Hormone (AMH). These ligands 
activate signaling by binding a complex of TGF-β Receptor type I and type II, with different 
ligands being recognized by different receptor complexes. Ligand binding to the receptor 
complex results in activation of the type I receptor, which on its turn selectively phosphorylates 
the receptor activated SMAD proteins (R-SMADs, including SMAD1, SMAD2, SMAD3, SMAD5 
and SMAD8). These R-SMADs form a complex with the co-factor SMAD4 to act as transcription 
factors and regulate target genes. To date, several inhibitors of the TGF-β family signaling 
pathway have been identified, that inhibit signaling at different levels. These include SMAD6 
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and SMAD7, which were identified as inhibitory SMADs (I-SMAD), and the E3 ubiquitin ligase 
SMURF2. SMURF2 inhibits the TGF-β family signaling  by targeting its receptor complex for 
proteasomal degradation. In addition, SMURF2 is implicated in the targeted degradation of the 
R-SMAD SMAD2 (Huang et al., 2011). SMAD7 inhibits TGF-β family signaling by multiple 
mechanisms, involving inhibition and degradation of type I receptors, and disruption of 
functional SMAD transcription factor complexes (Stolfi et al., 2014). RNF12 has been shown to 
increase signaling by targeting both SMAD7 and SMURF2 for proteasomal degradation (Huang 
et al., 2011; Zhang et al., 2012). In mouse ES cells depletion of RNF12 using RNAi affects 
differentiation fates, through decreased sensitivity of signaling by BMPs and Activin (Zhang et 
al., 2012). A dysregulation of TGF-β family signaling by RNF12 could hypothetically also be 
involved in tumorigenesis and subsequent invasion and metastasis of tumor cells, as the TGF-β 
system is involved in these processes. Notably, SMAD7 was found to have both pro-tumor and 
anti-tumor actions, depending on the type of cancer analyzed and the tumor stage, similar to 
the known bimodal effects of other components of the TGF-β system in initial cancer 
suppression compared to later promotion (Stolfi et al., 2014). Through modulation of the TGF-β 
system, dysregulation of RNF12 might have profound effects on a number of important cellular 
and biological processes. 
RNF12 can also interact with the LIM domain of nuclear proteins. LIM domains are 
highly conserved protein domains that consist of two zinc fingers, and serve protein-protein 
interactions. These domains have been found in a variety of proteins, some of which consist of 
little more than two LIM domains, and these were therefore termed LIM domain only (LMO) 
proteins. LMO proteins are thought to regulate transcription by mediating interactions 
between proteins in transcriptional complexes. They are reported mainly to be involved in cell 
differentiation (Bach, 2000; Matthews et al., 2013). Of the four known LMO proteins, LMO2 
and LMO4 interact with RNF12, resulting in their poly-ubiquitination, and likely in their 
degradation (Bach, 2000; Ostendorff et al., 2002). Since overexpression of LMO proteins is 
associated with cancer development and progression, RNF12 might have a tumor-suppressive 
function by degrading LMO proteins. Another group of LIM domain containing proteins are the 
LIM-hd proteins that contain a homeodomain in addition to their two LIM domains. LIM-hd 
proteins act as transcription factors and are involved in regulating embryogenesis and 
specifying the body plan. Of the LIM-hd proteins, LHX1, LHX2, LHX3 and ISL1 have been shown 
to directly interact with RNF12, although this interaction does not result in their ubiquitination  
(Bach et al., 1999; Ostendorff et al., 2002). Nevertheless, RNF12 inhibits the transcription of 
target genes of LHX3, through recruitment of the SIN3A-Histone Deacetylase (HDAC) complex 
(Ostendorff et al., 2002). The recruitment of the SIN3A/HDAC complex by RNF12 indicates that 
not all interactions of RNF12 serve targeting the interacting protein(s) for proteasomal 
degradation. Two co-factors of LIM-hd transcription factors have been identified and were 
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termed LDB1 (for LIM Domain Binding protein 1, also known as Clim2 for Carboxy terminal LIM 
domain-binding protein 2, or NLI for Nuclear LIM Interactor) and LDB2 (for LIM Domain Binding 
protein 2, also known as Carboxy terminal LIM domain-binding protein 1). Both these LIM-hd 
co-factors directly interact with RNF12, resulting in their poly-ubiquitination and proteasomal 
degradation. In addition, RNF12 competes with LIM co-factors for binding of LMO proteins and 
DNA bound LIM-hd proteins, making RNF12 a negative co-regulator of LIM domain proteins 
(Bach et al., 1999; Ostendorff et al., 2002). The variety of processes LIM co-factors are involved 
in is illustrated by the phenotype of  Ldb1-/- mice, which are not born and display severe 
developmental defects, including truncated head structures, posterior axis duplication, and 
lack of heart and foregut formation. In addition, conditional knockout studies have shown that 
Ldb1 is essential for erythropoiesis and for neuronal development in the central nervous 
system (Li et al., 2010; Zhao et al., 2014). Interestingly, RNF12 seems not only capable of 
targeting LDB1 for proteasomal degradation by poly-ubiquitination, but also of stabilizing LDB1 
by mono-ubiquitination. (Bach et al., 1999; Howard et al., 2010). Taken together, RNF12 is an 
important negative co-regulator of LIM protein regulated transcription.  
Another target of RNF12 is the telomeric protein TRF1 (for Telomeric Repeat binding 
Factor 1), which is also targeted for proteasomal degradation by poly-ubiquitination. TRF1 is 
involved telomere length regulation, and promotes telomere shortening by inhibiting the 
access of telomerase to telomere termini. TRF12 directly binds to telomeric DNA, thereby 
preventing telomerase in adding telomeric repeats. Upon depletion of RNF12 in a human cell 
line TRF1 levels increase, resulting in gradual telomere shortening and reduced cell 
proliferation (Her and Chung, 2009). Notably, another E3 ubiquitin ligase, Fbx4 (for F-box 
protein 4), is also capable of targeting TRF1 for proteasomal degradation through poly-
ubiquitination, independent of RNF12 (Lee et al., 2006). 
Another protein that is involved in cell proliferation and is targeted for proteasomal 
degradation by RNF12 is STMN1 (for Stathmin 1). STMN1 is a cytosolic protein involved in 
regulating microtubule dynamics, and promotes destabilization of microtubules by direct 
interaction with microtubule ends, and sequestration of  tubulin heterodimers (Belmont et al., 
1996; Curmi et al., 1997). Upon depletion of Rnf12 STMN1 concentrations increase, while 
overexpression of RNF12 results in a decrease in STMN1 and inhibits cell proliferation (Chen et 
al., 2014). 
RNF12 also interacts with the Estrogen Recepter alpha (ERα), which is a nuclear 
hormone receptor that is activated by the sex-hormone estrogen. The activated ER relocates 
from the cytosol to the nucleus, where ER-dimers regulate gene transcription either by binding 
to genomic Estrogen Responsive Elements (ERE) or by association with other DNA-binding 
factors to induce ERE-independent transcription. Estrogen signaling is essential for sexual 
development, but is also involved in tumorigenesis. RNF12 is capable of poly-ubiquitinating 
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ERα, but this does not seem to alter its stability, indicating ERα ubiquitination does not result in 
its degradation by the ubiquitin-proteasome. The interaction with RNF12 is specific for ERα, as 
other steroid hormone receptors like the Estrogen Receptor β (ERβ), the androgen receptor 
(AR), or glucocorticoid receptor (GR) do not interact with RNF12. RNF12 enhances estrogen 
signaling, as ERE-driven transcription increases in the presence of RNF12. Like for LIM-hd 
regulated transcription, RNf12 and Ldb1/2 seem to antagonize each other in ERE-driven 
activation (Johnsen 2009). Given the involvement of estrogen signaling in breast cancer, with 
ER+ tumors generally having a better prognosis, LDB1/2 expression were documented in 
human breast cancer samples. Increased expression of LDB1/2 was found to correlate with ER+ 
status, and poor prognostic tumor characteristics. Unfortunately, analysis of RNF12 protein 
levels in breast cancer was not performed in this study (Johnsen et al., 2009). 
Presently, several interaction partners of RNF12 have been identified, and it is likely that 
more will be identified in the future. A number of the abovementioned interaction partners of 
RNf12 were identified in studies that were not truly aimed at identifying them. Instead, they 
were directed to identify the interacting partners of another protein of interest, which 
identified RNF12 as an interactor (Bach et al., 1999; Chen et al., 2014; Zhang et al., 2012). 
Several other directed studies were performed to identify interaction partners of RNF12, but 
used a candidate-based approach (Her and Chung, 2009; Huang et al., 2011; Johnsen et al., 
2009). Therefore, it is unlikely that all proteins interacting with RNF12 have been identified. To 
date, only one study investigated the proteins interacting with RNF12 in mouse ES cells, using 
co-immunoprecipitation (Gontan et al., 2012). However, as not all previously identified 
interaction partners were co-purified, it seems that some interactions of RNF12 might be cell-
type specific.  
 
Inhibitors of XCI 
Where XCI activators are required to count the number of active X chromosomes present in a 
cell, XCI inhibitors prevent premature initiation of XCI during development as well as ES cell 
differentiation. Therefore it is not surprising that most XCI inhibitors identified to date are 
pluripotency associated genes, as loss of pluripotency is accompanied by down-regulation of 
pluripotency factors and initiation of XCI. This relation between pluripotency and XCI is further 
illustrated by experiments showing that ES cells with two active X chromosomes have 
difficulties exiting their pluripotent state without performing XCI. The presence of two active X 
chromosomes blocks the exit from the pluripotent state by inhibition of the MAPK and GSK3β 
pathways (Schulz et al., 2014). 
Different pluripotency factors inhibit XCI by repressing Xist, or by stimulating Tsix, or 
both. The pluripotency factors NANOG, OCT4, SOX2 and PRDM14 have been shown to repress 
Xist in undifferentiated ES cells by binding to a region in Xist intron 1 (Ma et al., 2011; Navarro 
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et al., 2008). Tsix is repressed by OCT4, KLF4, REX1 and C-Myc (Donohoe et al., 2009; Navarro 
et al., 2010). Although C-Myc is in fact not a pluripotency factor, it is used as a factor to 
reprogram differentiated cells back to a pluripotent state. Finally, OCT4, SOX2 and NANOG act 
as negative regulators of Rnf12 trasncription, adding another constraint on the XCI system 
(Navarro et al., 2011; Payer et al., 2013). These inhibitory mechanisms act synergistically to 
prevent initiation of XCI in pluripotent cells. The redundancy of these mechanisms is 
demonstrated by deleting Xist intron 1. Even if this abolishes pluripotency factor binding to 
Xist, it does not result in clear Xist activation (Barakat et al., 2011; Minkovsky et al., 2013; 
Nesterova et al., 2011). 
 
 
 
Initiation of XCI: Models for counting and choice 
 
Counting and choice 
The process of XCI can be divided into several phases. During the “initiation” phase a cell 
determines if it needs to inactivate an X chromosome and which X chromosome is inactivated. 
After an X chromosome is chosen to be inactivated it is silenced in the “establishment” phase. 
Finally, during the “maintenance” phase the silent state of the inactive X chromosome is 
clonally passed-on to all daughter cells. 
Shortly after discovering the phenomenon of XCI, it was recognized that the mechanism 
of XCI must function in such a way that it keeps only one X chromosome active per diploid 
genome. If additional X chromosomes are present, like in 47, XXX females or 47, XXY Klinefelter 
patients, all X chromosomes except but one are inactivated, while in 45, X0 Turner patients the 
single X chromosome is never inactivated (Grumbach et al., 1963; Jacobs et al., 1959; Maclean 
and Mitchell, 1962). In tetraploid embryos 2 of the 4 X chromosomes are inactivated, indicating 
that the number of X chromosomes that is kept active is also dictated by the ploidy of the cell 
(Carr, 1970; Webb et al., 1992). To explain how XCI invariably results in one active X 
chromosome per diploid genome, its mechanism should involve properties that allow it to 
count both the number of X chromosomes and the ploidy of a cell. Several models have been 
proposed to explain for the counting property in XCI (Fig. 5). All these models have to take into 
account not only that one X chromosome per  diploid genome set stays active, but also that XCI 
is random with respect to the parental origin of the X chromosomes. Notably, most of these 
models were proposed before the identification of RNF12 as a trans-acting activator. 
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The blocking factor model 
The blocking factor model proposes that every diploid cell contains a blocking factor, which is 
only present as a single molecule in every nucleus. This blocking factor randomly associates 
with one of the two X chromosomes and protects it from inactivation. The blocking factor was 
hypothesized to bind the X chromosome at a region termed the “counting element”. From 
studies analyzing X chromosome truncations and translocations the counting element was 
thought to be located within the Xic.  The nature of the blocking factor is not specified so far, 
and could be protein or nucleic-acid. However, the location of the blocking factor gene was 
hypothesized, as it should be autosomally encoded to relate cell ploidy to the number of X 
chromosomes (Rastan, 1983). An extension to the blocking factor model was proposed in the 
form of the symmetry breaking model. In this model the blocking factor is not present as a 
single molecule in a diploid nucleus, but instead is assembled on one of the X chromosomes 
from a larger number of diffusible blocking factor molecules (Nicodemi and Prisco, 2007).  
 
The competence factor model 
In the competence factor model, an X-encoded competence factor was introduced in addition 
to the blocking factor. In this model the X chromosome that initiates XCI is selected by 
association with the competence factor. The competence factor model was proposed after 
experiments with Xist+/- ES cells yielded results that could not be explained by a model 
featuring only a blocking factor. In these ES cells the wildtype X chromosome was exclusively 
inactivated, which is incompatible with the blocking factor model, as deletion of the counting 
element should result in exclusive inactivation of the mutant X chromosome as it can no longer 
associate with the blocking factor. These results could be explained by the introduction of a 
competence factor, which should associate with the deleted Xist region and therefore always 
selects the wildtype X chromosome for inactivation. The competence factor is X-encoded to 
allow counting of the number of X chromosomes. The blocking factor is required in addition to 
count the ploidy of a cell (Marahrens et al., 1998).  
 
The transvection model 
The transvection model does not rely on diffusible factors to mark the X chromosomes as 
active or inactive, but proposes that counting and choice are regulated by a transient 
interaction between the Xic’s of the two X chromosomes. This model is based on the 
observation that during initiation of XCI the Xic’s of the two X chromosomes move in closer 
proximity to each other (<2µm) (Bacher et al., 2006; Xu et al., 2006). This pairing event lasts for 
approximately 45 minutes, and is accompanied by a decrease in nuclear mobility of the two 
Xic’s. Although pairing is defined as a distance of <2µm between Xic’s, and complete overlap of 
the two Xic’s could be observed in 7% of cells (Masui et al., 2011). It is thought that during 
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Figure 5. 
Models explaining XCI counting and choice 
a. The blocking factor model: a blocking factor is present as a single entity in the nucleus and prevents one 
of the two X chromosomes from inactivating. 
b. The symmetry breaking model: the blocking factor is a complex of diffusible molecules that assembles 
on one of the two X chromosomes and prevents it from inactivating. 
c. The competence factor model: a competence factor promotes inactivation of one of the two X 
chromosomes, while the other X chromosome is protected from inactivation by the blocking factor. 
d. The transvection model: the two X chromosomes transiently co-localize in the nucleus to determine the 
future active and inactive X chromosome. 
e. The model of alternate states: the two X chromosomes differ epigenetically already before the onset of 
XCI. 
f. The stochastic model: XCI is stochastic, with both X chromosomes having a probability to inactivate. As a 
result all combinations of inactive and active X chromosomes occur after a single “choice round” of 
inactivation (XaXa, XaXi, XiXi). Cells that retained two active X chromosomes are subject to another 
“choice round”. 
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pairing transcription factors are asymmetrically distributed between the two Xic’s resulting in 
mono-allelic silencing of Tsix and the consequent upregulation of Xist. Interestingly, not all cells 
show asymmetric Tsix expression after pairing, which might indicate that some cells require 
multiple rounds of pairing (Masui et al., 2011). Several regions of the Xic were identified as 
required for co-localization, and included Tsix, Xite and a region overlapping with Slc16a2 that 
was termed the X-pairing region (Xpr) (Augui et al., 2007; Bacher et al., 2006; Xu et al., 2006). 
However, several subsequent studies argue against a functional effect of co-localization 
in counting and choice. In ES cells carrying a deletion of all the elements involved in co-
localization of the Xic’s, counting is unaffected (Barakat et al., 2014). Also, in heterokaryons 
obtained by fusion of male and female ES cells, XCI is initiated on the single X chromosome in 
the male nucleus upon differentiation, indicating that co-localization of the Xic’s does not 
require a physical interaction (Barakat et al., 2014). Instead, counting and XCI initiation seem 
dependent on diffusible factors. Together, these results suggest that the observed transient co-
localization during initiation of XCI is a consequence of the XCI process, in which the spatial 
movement of the Xic’s might be caused by the changes in gene transcription that occur at the 
two Xic’s. Gene transcription occurs in the nucleus at foci that are enriched for RNA 
polymerase II (RNA pol II), and are termed transcription factories. When a gene is actively 
transcribed it relocates to a transcription factory, and multiple genes located in-cis or in-trans 
can share the same transcription factory (Osborne et al., 2007). Therefore, the observed co-
localization of the two Xic’s might be the consequence of their change in transcriptional 
activity, as they co-localize at the same or neighboring transcription factories. 
 
The alternative states model 
The alternative states model hypothesizes that the two X chromosomes are epigenetically 
marked prior to XCI. As the two X chromosomes switch between these two epigenetic states, a 
random choice for XCI is generated (Mlynarczyk-Evans et al., 2006). This model was based on 
the observation that in undifferentiated ES cells the two X chromosomes differ in sister 
chromatid cohesion after DNA replication. Thus far an epigenetic mark distinguishing the two 
states the X chromosomes adopt has not been identified. 
 
The stochastic model 
The abovementioned models all hypothesize that XCI is a deterministic process, in which one X 
chromosome is determined to remain active and in which every cell inactivates exactly the 
correct number of X chromosomes. The stochastic model however, proposes that XCI is not 
deterministic, but instead is a stochastic process in which each X chromosome has its own 
probability to inactivate within a developmental time window (Monkhorst et al., 2008). This 
model was based on the observation that tetraploid XXXX ES cells preferably inactivate two X 
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chromosomes, but a significant number of these cells inactivate more or less X chromosomes 
during ES cell differentiation (Monkhorst et al., 2008). Also, diploid ES cells show a small 
proportion of cells that initiate XCI on both X chromosomes (Lee, 2005; Monkhorst et al., 
2008). This outcome of XCI is unexpected if XCI would be regulated by a deterministic process. 
A stochastic mechanism for XCI is further supported by observations in mouse tetraploid 
embryos, where a significant number of cells inactivate one or three X chromosomes, similar to 
the in vitro ES cell differentiation studies (Webb et al., 1992). In this model the probability for 
an X chromosome to inactivate depends on the relative concentrations of XCI activators and 
inhibitors. The genes encoding XCI inhibitors are  autosomally located to facilitate counting the 
ploidy of a cell. The genes encoding XCI activators are X-chromosomally encoded and subject to 
XCI to provide feedback that prevents inactivation of too many X chromosomes in most cells. 
This feedback mechanism is not completely foolproof, as both in vivo and in vitro, a small 
percentage of cells was found to initiate XIST/Xist spreading on too many X chromosomes, 
despite this feedback mechanism. With the identification of RNF12 as a trans-acting activator 
of XCI and several pluripotency factors as XCI inhibitors this model seems most plausible to 
date.  
 
 
 
Establishment of XCI 
 
Establishing the Xi 
After the initiation phase, where a cell determines whether XCI needs to be initiated and which 
X chromosome will be inactivated, the inactive state of the X chromosome must be 
established. During establishment of the Xi a cascade of molecular events take place to ensure 
that the active X chromosome is silenced and kept so. A number of epigenetic modifications 
are applied to ensure that the Xi stays inactive during subsequent cell divisions. These 
epigenetic modifications stay on the inactive Xi during mitosis (Chaumeil et al., 2002; Jeppesen 
and Turner, 1993; Jonkers et al., 2008; Mak et al., 2002). Most of the studies analyzing the 
establishment of the inactive state have used mouse ES cells to determine the order in which 
these modifications are acquired, however the use of immunocytochemistry precludes fair 
conclusions about the precise order of events. 
XCI initiation starts with the accumulation of Xist RNA along the entire X chromosome. 
The earliest event that follows Xist RNA accumulation is the cessation of active transcription as 
RNA pol II and transcription factors are excluded from the Xi (Chaumeil et al., 2006; Smeets et 
al., 2014). This exclusion is first established in the center of the Xi, where repetitive elements 
are clustered, while genes at the border of the Xi are still transcribed and silenced at a later 
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stage (Chaumeil et al., 2006). As active transcription stops, a number of histone modifications 
associated with active chromatin are removed from the Xi (Chaumeil et al., 2002; Heard et al., 
2001; Jeppesen and Turner, 1993). Histone modifications are an important mechanism to 
regulate gene transcription in an inheritable, but reversible way. They are generally covalent 
modifications of the histone tails, including methylation, acetylation and phosphorylation. 
Combinations of different histone modifications may act synergistic or antagonistic to regulate 
gene expression (Strahl and Allis, 2000). After the removal of histone modifications that mark 
active chromatin, the Xi acquires many repressive histone modifications. Of these trimetylation 
of lysine27 of histone H3 (H3K27me3), and monoubiquitination of lysine 119 of histone H2 
(H2AK119Ub1) are most extensively studied (Chadwick and Willard, 2003). These modifications 
are catalyzed by the polycomb repressive complexes PRC2 and PRC1, respectively (de Napoles 
et al., 2004; Mak et al., 2002; Plath et al., 2003; Silva et al., 2003). 
After acquiring these modifications the Xi becomes late-replicating during mitosis, 
which is a hallmark of inactive chromatin. To maintain the inactive state several other 
epigenetic modifications are applied to the Xi. The histone variant macro H2A becomes 
incorporated (Costanzi and Pehrson, 1998). This variant is thought to be involved in 
maintenance of XCI rather than establishment, because it is acquired late during XCI. One of 
the last modifications established on the Xi is DNA methylation of gene promoters and 
regulatory sequences like CpG islands (Lock et al., 1987). DNA methylation seems to 
permanently lock in the silent state of the Xi (Sado et al., 2000). Interestingly, in vivo deletion 
of macroH2A does not result in obvious X reactivation however, but requires the additional 
treatment with the demethylating agent 5-AZA-DC or the histone deacetylase inhibitor 
trichostatin A, indicating that multiple epigenetic layers are involved in maintained repression 
of the Xi (Hernandez-Munoz et al., 2005; Pehrson et al., 2014). 
 
The developmental time window of establishing the Xi  
In mouse, Xist can establish the silent state of the Xi only during a specific developmental time 
window. This time window was defined by experiments in differentiating mouse ES cells 
carrying an inducible Xist transgene. These experiments showed that Xist transcription must be 
induced within 48 hours of differentiation to result in gene silencing. When Xist is induced after 
72 hours Xist RNA still accumulates along the chromosome, but no longer results in gene 
silencing (Wutz and Jaenisch, 2000).  
In contrast to mouse Xist, which is unable to induce silencing outside its developmental 
window, it is likely that human XIST can induce silencing at later stages of development. In 
human somatic cells (human fibrosarcoma  HT-1080) induction of an XIST transgene results in 
silencing of gene transcription and accumulation of silent chromatin marks, including histone 
hypoacetylation, H3K27me3 and H4K20me1, incorporation of the histone variant macroH2A, 
36  |  Chapter 1 
 
 
late replication of DNA and chromatin condensation (Chow et al., 2007; Chow et al., 2002; Hall 
et al., 2002; Smith et al., 2004). However, this silent state is lost over the subsequent passages, 
probably due to selection against the cells that have become functionally hemizygous for the 
inactivated autosomal region (Chow et al., 2002; Hall et al., 2002).  
Whether this difference in timing of XIST/Xist functionality between human and mouse 
is caused directly by properties of the XIST/Xist RNA remains to be seen. It is very well possible 
that the observed difference is the result of a difference in permissive chromatin state or the 
species-specific requirement of co-factors, rather than species-specific properties of XIST/Xist 
RNA. The studies analyzing  human XIST transgenes used HT-1080 cells and Human Embryonic 
Kidney (HEK) cells, which may have a nuclear environment that is more supportive to active 
epigenetic remodeling, compared to the differentiating ES cells that were used to analyze 
mouse Xist. 
 
The role of Xist in Xi establishment 
One of the most intriguing questions is how Xist RNA molecules induce gene silencing with  
accompanying epigenetic modifications and maintain the silent state of genes along an entire 
chromosome. Many studies have assessed the role of different regions of the Xist RNA, and the 
involvement of other chromatin modifiers in inducing silencing. The repeat regions of Xist are 
most highly conserved and have therefore been the focus point of functional studies. Both 
mouse and human Xist/XIST RNA contain 5 repeat regions, termed repeat element A-E 
(Brockdorff et al., 1992; Brown et al., 1992). Of these repeats the first two repeat elements are 
conserved in sequence and repeat number, while the other three have been differentially 
amplified.  Stronger conservation of the first two repeats might indicate a functional 
significance. Indeed, repeat A, located in exon1, is required for the silencing function of Xist, as 
deletion of this repeat still allows proper localization of Xist RNA, but completely abolishes its 
silencing capacity (Chaumeil et al., 2006; Wutz et al., 2002). Several studies have suggested 
that the A repeat directly recruits PRC2, that is required for the establishment of the 
H3K27me3 mark (Maenner et al., 2010; Zhao et al., 2008). The silencing capacity of the A 
repeat is independent of its position in Xist RNA as moving the A repeat to the 3’end of Xist 
does not affect silencing capability (Wutz et al., 2002). However, while Xist RNA lacking the A 
repeat region cannot induce gene silencing, it still induces exclusion of RNA pol II, repression of 
Cot-1 transcription, accumulation of H3K27me3 and macroH2A incorporation, suggesting that 
these effects are mediated by other elements of Xist RNA, and indicate that H3K27me3 
accumulation is not sufficient for silencing the X (Chaumeil et al., 2006; Wutz et al., 2002). Even 
more puzzling are the observations from two recent studies using superresolution microscopy 
which did not observe any co-localization of Xist RNA with PRC2 or H3K27me3, arguing against 
a direct recruitment of PRC2 by Xist (Cerase et al., 2014; Smeets et al., 2014).  
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The human repeat A region has similar silencing properties as the mouse repeat A, as 
deletion of human repeat A also abolishes silencing. However, unlike mouse Xist which still can 
properly localize without A repeat A, human XIST lacking the A repeat form smaller XIST RNA 
domains (Chow et al., 2007). Although this effect might be due to defective localization, 
another study suggests that the human A repeat is required for proper XIST RNA transcription 
levels as insertion of the human repeat A sequence into a luciferase reporter gene increased 
transcription >3 fold (Hendrich et al., 1997). The human repeat A consists of 9 palindromic 
repeats, of which the number of repeats correlates with the silencing capabilities of this repeat 
region. A minimum of two repeats still induces silencing of a flanking EGFP reporter gene, but 
not of more distally located genes (Minks et al., 2013).   
The C repeat region of mouse Xist seems required for correct localization of Xist RNA, as 
it is required for interaction with the matrix attachment protein hnRNP, also known as SAF-A 
(Pullirsch et al., 2010). hnRNP is essential for proper localization of Xist as knockdown of hnRNP 
results in dispersed Xist clouds (Hasegawa et al., 2010).  Also the properties of the C repeat 
seem conserved between mouse and human as deletion of the human C repeat also results in 
dispersed XIST RNA domains (Chow et al., 2007). Interestingly, the silencing properties of XIST 
RNA do not seem to depend on the C repeat as human XIST lacking repeat C is still able to 
induce silencing of a neighboring GFP transgene (Chow et al., 2007). 
Apart from the repeat regions, another conserved region between mouse and human is 
XIST exon4, a region that also shows homology to the Marsupial Lnx3, from which Xist might 
have been evolved (Duret et al., 2006; Elisaphenko et al., 2008) Deleting Xist exon 4 in vivo only 
affected Xist expression, which was lower compared to wildtype Xist expression, but did not 
affect Xist silencing, localization, or skewing of XCI (Caparros et al., 2002). Another Xist 
disruption, involving the same deletion of exon 4 and in addition a large inversion involving 
most of Xist exon 1 up to the deleted exon 4, showed impaired silencing capabilities and 
reduced localization to the X chromosome (Senner et al., 2011). Altogether these results 
indicate that Xist RNA contains several elements that have overlapping and redundant 
functions for the localization and silencing properties of XIST RNA. 
 
Xist spreading along the Xi 
Several models have been put forward to explain how Xist RNA spreads along the X 
chromosome. According to the LINE-1 hypothesis Xist RNA uses Long Interspersed Elements 
(LINE) as way stations to spread over the X chromosome (Lyon, 1998). Way stations along the X 
chromosome were proposed to facilitate Xist spreading based on observations that Xist RNA 
could efficiently spread over X chromosomal sequences, but not over autosomal sequences 
(Gartler and Riggs, 1983). Studies with mouse cells carrying X; autosome translocations or Xist 
transgenes on autosomes showed that when flanked by autosomal sequences Xist is unable to 
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completely spread across the autosomal sequence (Lee and Jaenisch, 1997; Rastan, 1983). Also 
silencing of flanking autosomal sequences is incomplete and takes place along a gradient with 
most effective silencing closest to the breakpoint. Also in human X; autosome translocations 
XIST RNA spreading and silencing was found less efficient on autosomal sequences. The 
proposed way stations were hypothesized to be present on the X chromosome but to a lesser 
extent on autosomes. As LINE-1 sequences are relatively enriched on the X chromosome, it was 
proposed that LINE-1 sequences act as these way stations (Lyon, 1998). As both the human and 
mouse the X chromosome are relatively enriched for LINE-1 sequences, this might explaining 
why XIST/Xist spreads more efficiently along the X chromosome (Bailey et al., 2000). Moreover, 
LINE-1 sequences are distributed unevenly along the X chromosome with a lower density at 
escaping genes, providing an explanation why certain genes might escape XCI (Bailey et al., 
2000).  
However, there are several studies that provide observations arguing against the LINE-1 
hypothesis. An important observation arguing against the LINE-1 hypothesis is the occurrence 
of XCI in the marsh rice rat, a rodent that lacks LINE-1 repeats (Cantrell et al., 2009). Also, the 
low efficiency by which Xist RNA spreads into autosomal sequences can also be explained by 
selection against cells that did successfully inactivate autosomal sequences and as a 
consequence became functional hemizygous. Indeed, a recent study managed to successfully 
inactivate a complete chromosome 21 in human iPS cells derived from a patient with trisomy 
21, further arguing that Xist spreading into autosomal sequences is hampered by functional 
hemizygosity (Jiang et al., 2013). 
Recent studies using next generation sequencing and pull-down assays provide a 
complete different picture of Xist RNA spreading and silencing. Two studies used an 
oligonucleotide-based pull-down of Xist RNA to determine its way of spreading. From these 
studies it seems that Xist uses the three-dimensional organization of the X chromosome to 
spread to sequences that are in close proximity to its own locus of transcription, and do not 
need to be close by on the linear chromosome. As a result Xist  first localizes to active genes 
and from there spreads into adjacent intergenic regions. In support of this proximity based way 
of spreading, no specific sequences were identified to characterize Xist binding sites (Engreitz 
et al., 2013; Simon et al., 2013). These two studies however are based on analyses of cell 
populations, and do not completely correspond with observations of single cells using 
superresolution microscopy. Where these cell population analyses showed a uniform 
distribution of Xist RNA, super resolution microscopy detected a focal pattern of Xist 
localization. From this discrepancy it can by hypothesized that Xist RNA does not stably bind to 
specific sites, but instead temporarily associates with potential binding sites in a stochastic way 
(Smeets et al., 2014). 
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Maintenance of Xi 
While Xist is required for the initiation of XCI, its role in maintaining the silent state of an X 
chromosome is less clear. Originally, it was thought that Xist was essential for initiation of XCI, 
but became dispensable after establishment of the Xi . This was based on the observation that 
in cultured cells deletion of Xist after establishment of the Xi did not result in robust 
reactivation of the Xi (Csankovszki et al., 1999; Splinter et al., 2011). Also, autosomal sequences 
that were silenced by Xist transgenes did not show reactivation after switching of Xist (Wutz 
and Jaenisch, 2000). Although these experiments suggest that Xist is not required for 
maintenance of the silent state, Xist remains expressed after establishment of the Xi during all 
subsequent cell divisions. Moreover, Xist remains transcribed throughout the cell cycle and Xist 
RNA molecules actually remain attached to the Xi throughout mitosis (Jonkers et al., 2008). The 
continuous association of Xist with the Xi suggest that Xist RNA is required for maintaining the 
inactive state, and indeed several recent studies have shown that loss of Xist expression results 
in Xi reactivation (Bhatnagar et al., 2014; Yildirim et al., 2013). In mice, in vivo deletion of Xist in 
hematopoietic stem cells results in reactivation of X-encoded genes and eventually leads to 
hematologic cancer (Yildirim et al., 2013). In addition, a RNA interference screen identified  
several factors required for maintaining the Xi. Inhibition of these factors in mouse liver cells 
resulted in Xist silencing and reactivation of X-linked genes (Bhatnagar et al., 2014). Moreover, 
mice defective for Stanniocalcin 1 (Stc1), which was one of the factors identified as a 
maintenance factor also show two active X chromosomes (Bhatnagar et al., 2014). It needs to 
be noted that in this study only four genes were analyzed to assess X chromosomal activity. 
Together it seems that in mice continuous Xist expression is required for long term 
maintenance of the silent state of the Xi. For human XIST there is only one study addressing 
this issue. In this study deletion of the XIC in somatic cell hybrids containing a human inactive X 
chromosome on a mouse background did not result in reactivation of X-encoded genes, 
suggesting that human XIST is dispensable for maintenance (Brown and Willard, 1994).   
 
Barr body organization 
A question that has intrigued researchers for years is how  DNA is organized within the nucleus 
of a cell. For long it has been recognized that chromosomes occupy their own distinct territory 
within the nucleus and do not intermingle too much.  How a chromosome is structurally 
organized within its territory has been studied extensively using a variety of techniques, and it 
is only with the recent development of techniques like super-resolution microscopy and 
Chromatin Conformation Capture that this organization is being further dissected. Also the 
three dimensional organization of the Xi has been subject of many studies and it seems that 
the structural organization of the Xi is not that different from active chromosomes. 
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In general, the three dimensional organization of chromatin seems to differ with the 
transcriptional activity of a cell (Derenzini et al., 2014). In active cells, with enhanced 
transcription rates, the borders of the chromosome territories are less well defined, and 
chromatin of different chromosomes intermingles. The chromatin of a chromosome does not 
contain a specific region where transcription takes place, as gene transcription is thought to 
take place throughout the entire chromosome territory (Branco and Pombo, 2006). In contrast, 
the chromosomes of resting cells, with a low transcription rate, occupy more distinct 
territories. Silent heterochromatin is located on the inside of a chromosome territory, while 
gene transcription takes place on the outside of the chromosome. In addition, chromosome 
territories are pervaded by a network of channels. These channels facilitate access of 
transcription factors to the chromatin, allowing gene transcription to occur not only at the 
outer rim of, but also inside a chromosomal territory (Cremer and Cremer, 2010; Fakan and van 
Driel, 2007; Markaki et al., 2010). 
The studies that have investigated the organization of the Xi have reported 
contradictory results, although in general the Xi seems to have an organization similar to 
autosomes and the Xa, with a core of silent heterochromatin, and gene transcription of XCI 
escaping genes taking place at the periphery of the Xi. As only a few genes escape from XCI the 
number of genes transcribed from the Xi is much lower compared to autosomes or Xa. The 
location of genes subject to XCI and genes escaping from XCI has been studied using DNA-FISH 
and RNA-FISH. While early studies agreed that XCI escaping genes are found at the periphery of 
the Xi territory, they disagreed on the localization of genes subject to XCI. While one study 
found that silenced genes are located at the periphery of the Xi together with escaping genes, 
another study found silenced genes in the core of the Xi (Chaumeil et al., 2006; Clemson et al., 
2006). This study demonstrated that during establishment of XCI active genes relocate from 
the periphery of the Xi towards the interior, as they are being silenced (Chaumeil et al., 2006). 
The organization of the Xi in a transcriptionally silent core and active transcription at the 
periphery is supported by Chromatin Conformation Capture on Chip (4C) experiments that 
analyzed the long range interactions of X-chromosomal loci with other DNA segments. These 
experiments showed that within the Xi, inactive genes preferentially interact together and 
active genes also preferentially interact together. As active genes were more frequently 
engaged in interactions with other chromosomes, they are likely to be located on the periphery 
of the Xi territory (Splinter et al., 2011). In contrast to these studies that suggest that XCI 
escaping genes are located at the periphery of the Xi territory, several other studies observed 
gene transcription of escaping genes throughout the Xi territory (Calabrese et al., 2012).  
Like other chromosomal territories, the chromosome territory of the Xi is also 
completely pervaded by a channel-like network, but the channels of  the Xi have a reduced 
diameter. Xist RNA molecules are located inside these channels and interact with the 
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surrounding chromatin, that is thought to be active (Smeets et al., 2014). This is in line with the 
observation that Xist seems to spread to active genic regions first (Engreitz et al., 2013). 
Interestingly, the organization of the inactive compartment of the Xi shows a high 
degree of variability between cells compared to other chromosomes. In 4C experiments the 
inactive compartment of autosomes and the Xa displays preferential interactions, indicating 
that these interactions were present in a substantial proportion of the cell population that was 
analyzed (Simonis et al., 2009; Splinter et al., 2011). In contrast, the inactive chromatin of the 
Xi is devoid of preferential interactions, indicative of a variable structural organization between 
cells. This lack of preferential interactions is induced by Xist RNA rather than by the larger 
amount of silent chromatin, as deletion of Xist results in a conformation of the Xi that more 
resembles that of the Xa (Splinter et al., 2011). Altogether, our understanding of the structural 
organization of the Xi still holds some contradictories, and completely understanding this 
organization might require the analysis of a larger number of X-encoded genes as the RNA-FISH 
studies performed to date have analyzed four genes at most. 
 
 
 
Extraembryonic XCI 
 
Extraembryonic XCI in human and mouse 
XCI differs between human and mouse in several ways. One of the most striking differences is 
the mechanism of XCI in extraembryonic tissues. As mentioned above, the cells of the early 
mouse embryo undergo imprinted XCI, resulting in the exclusive inactivation of the Xp. In 
contrast to mouse, XCI in human extraembryonic tissues does not seem to be imprinted, and 
silencing is not as strict (Moreira de Mello et al., 2010). A number of studies observed random 
XCI patterns in human placenta (Looijenga et al., 1999; Migeon and Do, 1978, 1979; Zeng and 
Yankowitz, 2003). In contrast, several other studies concluded that in human extraembryonic 
tissues Xp is preferentially inactivated (Goto et al., 1997; Harrison, 1989; Harrison and 
Warburton, 1986; Ropers et al., 1978).  
These seemingly contradictory results can be explained by the relatively large patch size 
of the placenta, with 8mm3 biopsies consisting of a single patch (Looijenga et al., 1999; Moreira 
de Mello et al., 2010). In perspective, the patch size of human muscle and liver is smaller than 
0.008mm3 (unpublished results). A large patch size, as in placenta, can confound XCI analysis if 
the patch size approaches the size of the sample taken for XCI analysis. Interestingly, almost all 
studies reporting preferential Xp inactivation in placenta, did observe random XCI in a subset of 
samples. Moreover, expression analysis of multiple X-chromosomal loci shows that silencing of 
the inactive X chromosome in human extraembryonic tissues is not as stringent as in mouse 
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(Moreira de Mello et al., 2010). This is further underscored by the observation that the human 
Xi is relatively easily reactivated in hybrids from human chorionic villi and mouse A9 cells 
(Migeon et al., 2005; Migeon et al., 1986).  
The difference between mouse and human extraembryonic XCI is further underscored 
by the difference in coping with supernumerary maternal X chromosomes. In mouse, an 
additional Xm cannot be inactivated, resulting in almost absence of extraembryonic tissues 
(Takagi and Sasaki, 1975). In humans in contrast, additional X chromosomes from either 
paternal or maternal origin can be inactivated, and instead of being embryonic lethal lead to 
Klinefelter syndrome (Jacobs and others 1988) 
 
Mouse imprinted XCI 
Several locations for the imprint responsible for exclusive Xp inactivation during imprinted XCI 
have been considered. This imprint could be located on Xp, marking it for future inactivation, 
on Xm, preventing it from inactivating itself, or both. For a long time it was assumed that at 
least the maternal X chromosome contains an imprint preventing it from inactivation, as 
parthenogenetic embryos carrying a double maternal genome (XmXm) embryos do not initiate 
XCI in extra-embryonic tissues until the late blastocyst stage (Kay et al., 1994). Although 
considered a likely candidate, DNA methylation is not the main epigenetic mark characterizing 
the maternal imprint, because mice deficient for de novo methyltransferase (DNMT3a/b) still 
show Xist repression on Xm (Chiba et al., 2008).  
A recent report identified H3K9me3 at the Xist promoter region on the maternal X 
chromosome as the imprint preventing inactivation of the maternal X chromosome (Fukuda et 
al., 2014). Whether additional imprints in maternal repression of Xist are involved remains to 
be seen. The imprint on Xm is established during late oogenesis, as was shown in nuclear 
transfer experiments using nuclei from different stages of germ cell development (Oikawa et 
al., 2014). Interestingly the maternal Xist repressing imprint is not only erased in the epiblast, 
prior to random XCI, but also in the trophectoderm at E4.5, explaining initiation of XCI in XmXm 
blastocysts after initial repression of Xist (Oikawa et al., 2014). 
An imprint on the paternal X chromosome is considered unlikely, as this would require 
an imprint that silences Xist repressing elements, the most likely candidate being Tsix. 
However, Tsix is not expressed in the mouse embryo until the blastocyst stage, well after the 
implementation of imprinted XCI (Fukuda et al., 2014; Sado et al., 2001). Interestingly, a 
deletion of Tsix on the maternal X chromosome is lethal during post-implantation 
development, as this result in ectopic upregulation of Xist from the Xm in extra-embryonic 
tissues (Ohhata et al., 2011). 
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Order of events during mouse extraembryonic XCI 
In  both mouse and human, XCI seems to coincide with activation of the embryonic genome. In 
mouse embryonic genome activation occurs at the 2-cell stage, while in human this occurs a 
little bit later, around the 4-8 cell stage (Dobson et al., 2004; Huynh and Lee, 2003; Schultz and 
Heyner, 1992). Embryonic genome activation does not occur simultaneously in all cells, nor 
does Xist accumulation (Huynh and Lee, 2003).  
In mice, both X chromosomes are active at the two cell stage (Kalantry et al., 2009; 
Namekawa et al., 2010; Okamoto et al., 2004; Patrat et al., 2009) and Xist is transcribed at a 
low level. Using RNA-FISH Xist RNA is visible as a small pinpoint signal on one or two X 
chromosomes. From the 2-cell stage to the 16-cell stage the Xist pinpoint of the Xp enlarges 
and spreads along the X chromosome (Namekawa et al., 2010; Okamoto et al., 2004). 
Spreading of Xist coincides with repression of Cot-1 transcription  and exclusion of RNA pol II 
(Namekawa et al., 2010; Okamoto et al., 2004). The future inactive X chromosome first loses its 
active histone modifications, and subsequently acquires repressive histone modifications, 
similarly to random XCI. Immunofluorescent studies showed that the loss of active histone 
modifications and accumulation of repressive chromatin marks does not happen 
simultaneously in all cells of the early embryo (Mak et al., 2004; Okamoto et al., 2004). This 
heterogeneity in the early embryo probably explains why early studies using pools of embryos 
and cells to define the time-point of actual gene silencing concluded imprinted XCI to start at a 
later time-point, compared to studies that have used single cell analyses (Hadjantonakis et al., 
2001; Kalantry et al., 2009; Latham and Rambhatla, 1995; Lebon et al., 1995; Okamoto et al., 
2004; Singer-Sam et al., 1992; West et al., 1977). RNA-FISH analysis of X-linked expression in 
single cells showed Xp silencing occurring from the 8-cell stage onwards (Kalantry et al., 2009; 
Okamoto et al., 2004). During silencing, repeat regions are silenced first, followed by silencing 
of genes (Namekawa et al., 2010). Furthermore, genes located I closer proximity to the Xist 
locus on the linear chromosome, including Rnf12,  are silenced earlier compared to gene 
located further away (Huynh and Lee, 2003; Namekawa et al., 2010). 
 
Order of events during human extraembryonic XCI 
Few studies have investigated the onset of human XCI, because of the ethical restrictions on 
studies of human embryos. Two studies that have been able to analyze human embryos from 
the 8-cell stage onwards have yielded contradictory results. One study found that XCI starts 
from the 8-cell stage onwards and shows much similarity to mouse XCI, as XIST RNA 
accumulation was observed on one X chromosome, which coincided with repression of COT-1 
transcription and accumulation of H3K27me3 and macroH2A enrichment (van den Berg et al., 
2009). Another study analyzed embryos from the 8-cell stage to the blastocyst stage and 
detected two XIST RNA clouds from the 8-cell stage onwards. Interestingly, in this study XIST 
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accumulation did not coincide with silencing, as no H3K27me3 methylation was observed and 
several X-encoded genes were found to be biallelically expressed using RNA-FISH (Okamoto et 
al., 2011). A third study also did not observe any H327me3 foci in early blastocysts. Only after 
prolonged culture of embryos on decasualized endometrium stromal cells, H327me3 foci were 
detected in late blastocysts. These H3K27me3 foci were never detected in cells of the ICM, only 
in trophectoderm and to lesser extend in the hypoblast (Teklenburg et al., 2012). These latter 
two studies suggest that human XCI is executed differently from mouse XCI, as XIST 
accumulation does not lead to gene silencing, not even in the late blastocyst. 
The observation of two XIST clouds in human embryonic cells might have interesting 
implications for the choice which X chromosome will be inactivated in random XCI. In mouse, 
random XCI is tightly regulated ensuring mono-allelic Xist expression and factors influencing 
Xist up-regulation or Xist spreading  will determine the choice which X chromosome will be 
inactivated. However, when two Xist clouds are present prior to actual silencing, the choice 
which X chromosome will be inactivated will not be determined by Xist spreading anymore, but 
instead by factors effecting silencing. Also the observation that in early embryos XIST clouds 
are more dispersed compared to somatic cells, might indicate that to effect silencing XIST 
needs to associate with the X chromosome and factors recruiting XIST to the X chromosome 
are instructive in the regulation of a mutual exclusive outcome of the XCI process. 
 In mouse, feedback of XCI, that prevents inactivation of too many X chromosomes, is 
tightly controlled by Xist mediated-silencing of its own activator Rnf12. However, if Xist is 
accumulated over the entire X chromosome prior to inactivation, a trans-acting factor 
regulating XCI feedback does not necessarily needs to be in close proximity to the XIST locus, 
allowing other factors than Rnf12 to have taken over this role during evolution. Until now it is 
not known whether the trans-activating function of Rnf12 is conserved from mouse to man. 
The observation that male human embryos also contain an XIST cloud, suggests that in the 
initial phase XIST upregulation is independent of the presence of two X chromosomes 
(Okamoto et al., 2011). 
 
 
 
Skewed XCI 
 
Skewed XCI 
As a result of XCI every female individual consists of two cell populations that have a different 
active X chromosome. These two cell populations are intermingled and make every female a 
mosaic of cells with an active Xp or an active Xm. The relative size of these two populations can 
be expressed as the X-inactivation ratio (XIR). Most female individuals have an XIR of 50:50, but 
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deviations from this 50:50 ratio are common. In general, an XIR greater than 80:20 is termed 
“skewed” XCI, while an XIR of more than 90:10 is termed “extremely skewed” XCI. 
 
Primary vs Secondary skewed XCI 
Two different mechanisms causing skewed XCI can be distinguished. Primary skewed XCI is a 
result of processes influencing the choice which X chromosome is inactivated, while secondary 
skewed XCI is a result of post-XCI cell selection (Fig. 6). Primary skewed XCI can be the result of 
mutations in genes involved in XCI, but could also occur naturally. Since the choice which X 
chromosome is inactivated is random, most cells of the early embryo might inactivate the same 
X chromosome by chance, thus resulting in primary  
skewed XCI. The chance of this happening, increases if a smaller number of cells is present at 
the time of XCI. Unfortunately, the number of stem cells present at the time of human XCI  is 
unknown, as studies of XCI in human embryos can only be performed up to day 8 of embryonic 
development, which is insufficient to analyze post-implantation random XCI (Teklenburg et al., 
2012). Therefore, the chance of spontaneous primary skewed XCI in humans is unknown. 
Several studies have tried to deduce the number of cells at the time of XCI from the 
distribution of XIR’s in a female population, assuming that the number of skewed individuals 
reflects the number of stem cells during XCI. However, as these studies used blood samples to 
determine an XIR, they only allow an estimation of the number of hematopoietic stem cells at 
the time of XCI, and not the total number of stem cells during XCI. These studies estimated that 
there are 8-16 hematopoietic stem cells present when XCI is initiated (Amos-Landgraf et al., 
2006; Puck et al., 1992). Another study used the intra-individual difference for XIR between 
blood cell lineages to calculate the number of stem cells and estimated there are 14-16 
hematopoietic stem cells during XCI (Tonon et al., 1998). However, all the above mentioned 
studies do not take into consideration the effects of secondary skewing. Instead, they assume 
that the frequency of skewed XCI among newborns or adults is comparable to embryos at the 
time of XCI. Also, when comparing different blood cell populations within an individual, 
secondary skewing specific for these cell populations cannot be taken into consideration. 
Therefore, the reported numbers are likely an underestimation of the true number of 
hematopoietic stem cells, and the total number of cells during XCI remains unknown.   
Primary skewed XCI can also be caused by mutations in genes involved in XCI, as is 
illustrated by mutations in the XIST promoter that showing exclusive activation or inactivation 
(Plenge et al., 1997; Pugacheva et al., 2005). Although only two mutations in the XIST promoter 
are reported to date, it is not unlikely that many more mutations occur in the XIST promoter or 
XIST regulatory elements without being discovered as they are not accompanied by a clinical 
phenotype. From mouse studies involving deletion of different parts of the Xic, it can be 
deduced that mutations involving Tsix, Xite and Rnf12 will also result in primary skewed XCI , 
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Figure 6. 
Skewing of X chromosome inactivation  
Two forms of skewing of X chromosome inactivation exist. The top part of the figure shows primary 
skewed XCI: cells of the epiblast randomly inactivate the paternal or the maternal X chromosome. As a 
result most embryos will have an X-inactivation ratio around 50:50, but by chance some embryos may 
consist of cells where the majority cells has inactivated the same X chromosome, resulting in skewed XCI.  
The lower part of the figure shows secondary skewed XCI: as a result of post-inactivation cell selection, 
one cell population might have an advantage in cell growth or differentiation, resulting in a relative 
increase of this cell population over the other. 
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either by affecting Xist expression directly or by impacting on Xist through feedback 
mechanisms. 
Secondary skewed XCI is the result of a selective pressure applied to a heterozygous X-
encoded gene, resulting in a proliferative or differentiating advantage of one X chromosome 
over the other. Such a selection can theoretically occur at any age and can be tissue-specific. 
 
Skewed XCI in a healthy female population 
In a healthy human female population the XIR follows a normal distribution. Most females have 
an XIR around 50:50, but deviations from 0:100 up to 100:0 occur. The proportion of females 
displaying skewed XCI in a healthy population varies between studies from 0% to 58% (Amos-
Landgraf et al., 2006; Bolduc et al., 2008; Busque et al., 1996; El Kassar et al., 1998; 
Hatakeyama et al., 2004; Mossner et al., 2013; Sharp et al., 2000; Tonon et al., 1998). This 
variation between studies is partially explained by the age of females that were included in the 
studies, as skewing of XCI seems to increase with age and especially above the age of 60 years. 
Many studies have analyzed the putative association of skewed XCI in blood with increasing 
female age, and reported varying results. In general, the proportion of females with skewed 
XCI increases throughout female life. This increase in females with skewed XCI is thought to be 
small below the age of 30-60 years, but increases substantially after this age (table 1). Where 
the increase in skewed XCI in elder women is obvious, and reported by all studies, the increase 
during early female life is small and remains controversial. The studies that have compared 
skewed XCI in neonates to adult women, mostly found that skewing increases from neonatal 
life onwards (Amos-Landgraf et al., 2006; Bolduc et al., 2008; Busque et al., 1996; El Kassar et 
al., 1998; Tonon et al., 1998). However, studies that did not include a large number of 
neonates, but a smaller number of children from 0 years and older did not detect any obvious 
increase in skewed XCI before the age of 30 years (Fey et al., 1994; Hatakeyama et al., 2004; 
Mossner et al., 2013). This might indicate that a large number of subjects is required to detect 
the small increase in skewed XCI during early female life. Where almost all these studies are 
cross-sectional, one study performed an elaborate longitudinal analysis of 178 females by 
measuring XCI ratios with an interval of 13 to 21 years. This analysis confirmed the small 
increase in skewed XCI during female life (with a maximum increase of 12% during 16.5 years), 
and the more dramatic increase after the age of 60 (Sandovici et al., 2004).  
Several hypothesis have been postulated to explain the increase in skewed XCI during 
female life. It might be possible that with increasing age the number of stem cells decreases, 
which will result in an oligoclonal expansion and an increased chance that the majority of these 
cells has the same inactive X chromosome (Amos-Landgraf et al., 2006). This is supported by a 
recent report of a 115-year old women where the majority of peripheral white blood cells 
originate from two hematopoietic stem cell clones (Holstege et al., 2014). Although this 
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number is extremely low, and therefore can be disputed, it supports the idea of a decreasing 
stem cell pool during female life. In addition, the increase of skewed XCI at later age could also 
be caused by secondary cell selection during female life. 
Although many studies have reported an age-related increase in skewed XCI, it has also 
been proposed that the detected increase in skewed XCI does not represent actual X-
inactivation, but rather is the result of changes in DNA methylation patterns in elderly women. 
Most studies analyzing skewing of XCI use methylation of the Androgen Receptor locus to 
determine the XIR, and one study found a discrepancy between AR methylation and expression 
in their study population (Swierczek et al., 2008). In contrast, other studies  found a good 
agreement between DNA methylation and expression (Amos-Landgraf et al., 2006; El Kassar et 
al., 1998). 
In laboratory mice the distribution of the XIR is different from human due to the inbred 
nature of these mice. Although the XIR is still normally distributed, it has a much smaller 
variation. The inbred nature of laboratory mouse strains allowed the identification of genetic 
elements that affect the XIR, which is most clearly observed when analyzing an F1 of different 
mouse strains. In for example the F1 of Mus musculus domesticus (C57BL/6) and Mus musculus 
castaneus mice, the average XIR is 70:30 favoring the Mus musculus castaneus X chromosome 
for inactivation. The genetic element responsible for this difference has been termed the X 
choosing element (Xce) (Cattanach, 1975). Different mouse strains carry different Xce alleles 
that affect the probability of an X chromosome to initiate XCI. As a result, an F1 with 
homozygous Xce alleles will result in an XIR around 50:50, while heterozygosity for the Xce 
results in an XIR deviating from 50:50. Originally, four Xce alleles, termed Xcea- Xced, were 
identified and are ordered by their probability to initiate XCI, with Xcea having the largest 
probability and Xced the lowest (Cattanach, 1991, 1994; Cattanach and Isaacson, 1967; 
Cattanach et al., 1969; Cattanach and Williams, 1972; Forrester and Ansell, 1985; Fowlis et al., 
1991). Recently, a fifth Xce allele has been identified, termed Xcee, with a probability 
intermediate to Xcea and Xceb (Calaway et al., 2013). It has been suggested that the probability 
of an X chromosome to initiate XCI is not only determined by the Xce, but also by its parental 
inheritance and by autosomal factors (Chadwick and Willard, 2005). However, the general 
consensus is that the effect of a parent of origin effect and autosomal factors is relatively small 
compared to that of the Xce allele (Chadwick et al., 2006; Chadwick and Willard, 2005; 
Forrester and Ansell, 1985). The location of the Xce was first mapped to the Xic and a recent 
study narrowed down the region of the Xce to a 194 kb interval centromeric of Xist and Tsix 
(Calaway et al., 2013). The identification of a human Xce seems unlikely, as the variation of a 
human Xce will be too extensive to identify individual Xce alleles. Furthermore, a study 
comparing 500 mother-neonate pairs did not detect any heritability of skewed XCI, further 
arguing against a human Xce (Bolduc et al., 2008). 
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Skewed XCI and human disease 
Skewing of XCI becomes of clinical importance when an X-encoded disease or trait is involved. 
It can easily be envisioned that in case of a heterozygous mutation, skewed XCI in which the 
affected allele is predominantly inactivated, or kept active, modulates disease phenotype. This 
has been established for Rett syndrome, a neurodevelopmental disorder that is caused by 
mutations in the MECP2 gene. Rett syndrome occurs almost exclusively in females, as males do 
not survive until birth (Amir et al., 1999). The phenotype of Rett syndrome females is 
modulated by their XIR, and results in an increased prevalence of skewed XCI among Rett 
syndrome patients (Archer et al., 2007; Huppke et al., 2006; Weaving et al., 2003). The same 
modulating effect has been established for Fragile X syndrome, a neurodevelopmental disorder 
caused by a loss of function of the FMR1 gene due to a CGG repeat expansion (Fryns and Van 
den Berghe, 1988; Heine-Suner et al., 2003; Martinez et al., 2005; Martorell et al., 2011; 
Schmidt et al., 1990). 
Skewing of XCI does not only affect disease phenotype, but X-linked mutations can also 
induce secondary skewing. This is clearly illustrated in Incontinentia Pigmenti, a 
genodermatosis that is caused by a mutation in the IKBKG gene. Cells that lack IKBKG are more 
prone to undergo apoptosis, resulting in a completely skewed XCI pattern in females carrying a 
mutation in IKBKG (Smahi et al., 2000). 
 
Skewed XCI and autoimmunity 
Generally, skewed XCI is associated with diseases for which a causative X-chromosomal locus is 
identified. Interestingly, also a number of diseases for which no X-linked disease causing locus 
is known, have been associated with skewed XCI. Despite the lack of a causative X-
chromosomal locus, an increased prevalence of skewed XCI is found in patient populations for 
these diseases. Among these diseases are several autoimmune disorders, including 
Rheumatoid Arthritis, Multiple Sclerosis and Autoimmune Thyroiditis (AITD) (Chabchoub et al., 
2009; Ozbalkan et al., 2005; Uz et al., 2008). The association between these autoimmune 
disorders and skewed XCI has been explained by an increased autoimmunity against X-encoded 
antigens. This hypothesis states that in females with skewed XCI several X-encoded antigens 
escape from presentation in the thymus or other peripheral sites, leading to inadequate 
deletion of self-reactive T-cells and loss of T-cell tolerance. As a result, autoimmunity will occur 
more frequently among women with skewed XCI. This hypothesis is based on two 
observations. First, autoimmune disorders occur more frequently in females compared to 
males (Whitacre, 2001). Although this sex-bias for autoimmunity could also be explained by 
immune modulating effects of sex hormones, involvement of XCI in the pathogenesis of 
autoimmunity cannot be ruled out. Second, mouse studies have shown that a lack of exposure 
to self-antigens increases the risk of autoimmune reactions (Klein et al., 2000; Laufer et al., 
Introduction  | 51 
 
 
1996). To date, this hypothesis is not confirmed and alternatively the association between 
autoimmunity and skewed XCI might be explained by X-encoded genes that regulate immune 
processes. 
Although for these diseases no X-linked locus has been identified yet, Genome Wide 
Association (GWA) studies might identify the X-chromosomal loci responsible for their 
association with skewed XCI. Unfortunately, the X chromosome has been poorly analyzed in 
GWA studies until now, as analysis of the X chromosome requires sex-specific analysis for X-
chromosomal sequences is required. Of the GWA studies performed between 2010 and  2014, 
only 33% analyzed the X chromosome (Wise et al., 2013). Attention for this hiatus in GWA 
analysis and the consequential missing data is growing, and two recent studies have re-
analyzed published GWA data sets from autoimmune disorders for X-chromosomal 
involvement. One study focused on GWA data sets for Graves’ disease, that together with 
Hashimoto’s disease comprises AITD, and identified an X-chromosomal variant in the G-protein 
coupled receptor GPR174 (Chu et al., 2013). This variant is validated in an independent study 
and although the function of GPR174 still needs to be investigated, it provides an explanation 
for the association of skewed XCI and Graves’ disease (Szymanski et al., 2014). Another study 
that analyzed published X-chromosomal GWA data and found several X-encoded variants 
associated with different autoimmune disorders, including rheumatoid arthritis (Chang et al., 
2014). These results seem promising for identifying new X-encoded, disease-associated 
variants. Considering that the X chromosome is increasingly analyzed in GWA studies, it is not 
unlikely that more X-encoded variants associated with autoimmune disorders will be identified. 
However, a shortcoming of the abovementioned studies is that they did not take skewing of 
XCI into account in their analyses, which might result in under detection of X-encoded variants. 
To fully utilize the X-chromosomal data provided by GWA studies, skewing of XCI should be 
implemented in the analysis. 
  
Skewed XCI and PCOS 
Another disorder for which no X-linked locus has been identified, but which is also associated 
with skewed XCI is Polycystic Ovary Syndrome (PCOS). PCOS is an endocrine disorder and is one 
of the leading causes of subfertility in women, affecting 5-10% of the women of reproductive 
age (Azziz et al., 2004). It is characterized by oligo- or anovulation, hyperandrogenism and 
polycystic ovaries. Oligo ovulation is clinically characterized by oligomenorrea, a menstrual 
cycle of more than 35 days. If ovulation is completely absent, this results in amenorrhea, the 
absence of menstruation. Hyperandrogenism, the increased action of male sex hormones, can 
clinically result in hirsutism or acne. Polycystic ovaries can be visualized using ultrasound 
technology and appear enlarged with a large number of small follicles. PCOS is considered a 
very heterogenic syndrome, and therefore women suffering from PCOS do not necessarily 
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experience all three of the abovementioned characteristics. According to the 2003 Rotterdam 
consensus criteria an individual must have two out of three of these characteristics to validate 
the diagnosis PCOS (Rotterdam, 2004). The heterogeneity of PCOS is further illustrated by the 
fact that two other diagnostic schemes exist. The 1990 National Institutes of Health (NIH) 
criteria uses the combination of hyperandrogenism and oligo-ovulation to diagnose PCOS,  
while the 2006 criteria from the Androgen Excess and PCOS Society, consider PCOS 
predominantly a hyperandrogenemic disorder and only use the combinations of the three 
characteristics that include hyperandrogenism to diagnose PCOS (Azziz et al., 2006; Azziz et al., 
2009). In addition, PCOS often involves a metabolic syndrome, that is characterized by insulin 
resistance and obesity. While the association for autoimmunity with skewed XCI seems 
established, an association of skewed XCI with PCOS remains subject of debate. 
The cause of PCOS is currently unknown, but there are strong indications that a genetic 
component is involved. Involvement XCI in the pathogenesis of PCOS has been hypothesized 
through the modulation of the sensitivity of the AR. The hyperandrogenemic phenotype in 
PCOS patients is exerted by androgens through the AR. Of all androgens, testosterone and 
dihydrotestosterone are the two hormones that are able to bind to the AR, with 
dihydrotestosterone being the more potent activator. When inactive, the AR is located in the 
cytoplasm, and upon binding of testosterone or dihydrotestosteron the newly formed complex 
translocates to the nucleus where it acts as a DNA-binding transcription factor to regulate gene 
expression. The sensitivity of the AR to androgens is modulated by two trinucleotide repeats, 
located in its first exon. These repeats are both located in the transactivation domain that is 
required for binding additional co-factors (Alen et al., 1999; Burd et al., 2005; Markus et al., 
2002). Of these two repeats,  the CAG repeat, encoding a poly-glutamine tract, is mostly 
studied. An inverse correlation exists between CAG repeat number and androgen sensitivity, 
with a shorter CAG repeat resulting in a more sensitive AR (table 2) (Beilin et al., 2000; 
Chamberlain et al., 1994). This increased sensitivity is the result of an increased capability to 
activate target genes, and not of an increase in AR transcripts. The CAG repeat is highly 
polymorphic in a population, with its repeat number ranging from 4 to 33 repeats with a mean 
of 19-22 repeats, and following a normal distribution (Ferk et al., 2008; Ibanez et al., 2003). In a 
female population around 80% of all female individuals are heterozygous for the CAG repeat, 
and as a result they probably have AR alleles with different sensitivities. Moreover, the 
distribution of CAG repeat length differs by ethnic background. Compared to Caucasians a 
Chinese population has a slightly longer CAG repeat, while an African population has a shorter 
CAG repeat (Edwards et al., 1992; Irvine et al., 1995; Kim et al., 2008; Liu et al., 2008; Mifsud et 
al., 2000; Sartor et al., 1999). Repeat length in an Indian population is comparable to 
Caucasians (Dasgupta et al., 2010). 
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The other repeat region is an incomplete repeat, consisting mainly of GGC repeats but 
containing several GGN repeats in addition, and has therefore been termed GGN repeat. The 
GGN repeat encodes a poly-glycine tract, and is not as polymorphic as the poly-glutamine tract. 
In a Caucasian population there are two common GGN alleles that represent 85% of all alleles. 
This low diversity has hampered the study of the effect of the GGN repeat on androgen 
sensitivity. The several studies that explored the effect of the GGN repeat on androgen 
sensitivity have reported contradictory effects of this repeat (Brockschmidt et al., 2007; Ding et 
al., 2005; Werner et al., 2006). Therefore, it is still unresolved if the correlation between GGN 
repeat number and androgen sensitivity is a direct or an inverse correlation. The effect of GGN 
repeat on androgen sensitivity might not only be mediated by activating capability of the AR, 
but also by higher AR protein levels (Brockschmidt et al., 2007). Also for the GGN repeat, the 
population distribution seems to be different for different ethnic populations, as in a Chinese 
population one common allele was found where two are present in a Caucasian population 
(Kovacs et al., 2009; Sasaki et al., 2003). To really understand the effect of the GGN repeat on 
androgen sensitivity further studies are needed. To date, most studies have focused on the 
relation between CAG repeat number and hyperandrogenemic disorders. 
The involvement of XCI in androgen sensitivity was first demonstrated in women with 
idiopathic hirsutism, where the longer AR CAG allele was preferentially inactivated (Vottero et 
al., 1999). Since then, a large number of studies have investigated the relationship between 
PCOS and CAG repeat number, but yielded contradictory results. These contradictory results 
might be explained by differences in study populations, as AR repeat length differs between 
ethnic backgrounds (Shah 2008, Platz, 2009, Edwards 1992). Alternatively, contradictory results 
might also be the result of the different measures that have been used to quantify the CAG 
repeat number of the two alleles of a single individual. Several studies used the bi-allelic mean 
of the CAG repeat number for each individual, while other studies used a cumulative CAG 
repeat number or used only the shorter AR allele to quantify AR sensitivity. In addition, a large 
number of studies measured CAG repeat number but did not correct for XIR, thereby 
disregarding the relative expression levels of the two AR alleles. Three recent meta-analyses 
investigated the association between CAG repeat length and PCOS, but only one of these 
corrected for XIR(Peng et al., 2014; Rajender et al., 2013; Zhang et al., 2013a). In this meta-
analysis no association between XIR-corrected CAG repeat length and PCOS was found (Zhang 
et al., 2013a). Given the controversy in results it might be possible that the association 
between CAG repeat number and PCOS exists only in a subpopulation and not in all PCOS 
patients. Additionally, one might also question if peripheral blood samples that are generally 
used to assess CAG repeat number and XIR are representative of ovarian tissue, where 
differences in AR sensitivity are likely to have their effects in PCOS patients. 
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Escape from XCI 
 
The clinical relevance of escape from XCI 
While most genes on the Xi are silenced, not all the genes located on the Xi are subject to XCI. 
A subset of genes escapes from XCI and remain expressed from the Xi, both in human and in 
mouse. These XCI-escaping genes are of particular clinical interest for syndromes involving 
numerical X chromosome abnormalities, like 45, XO Turner syndrome and 47, XXY Klinefelter 
syndrome. The phenotype in these syndromes is unlikely to be caused by genes subject to XCI, 
as these genes are always expressed from a single X chromosome, despite the total number of 
X chromosomes present. Therefore, the genes that escape silencing are the most likely 
candidates to explain the phenotype in these syndromes. At first, it was hypothesized that the 
genes on the PAR cause the phenotype of numerical abnormalities of the X chromosome, as 
this region was first recognized to be not included in the XCI process (Lyon, 1962). Later it was 
recognized that besides the genes located in the PAR, also genes located elsewhere on the X 
chromosome escape the XCI process partially or completely.  
 
Technical difficulties in defining escape from XCI 
The first studies addressed escape from XCI at the level of single genes (Brown et al., 1995; 
Carrel and Willard, 1999; Greenfield et al., 1998). With recent technological advances in RNA-
sequencing (RNA-seq) X chromosome wide analysis of allele-specific gene expression has 
become possible, identifying many more XCI escaping genes. The first studies employing this 
method analyzed XCI escape in mouse, and paved the way for studies analyzing XCI escape in 
human (Calabrese et al., 2012; Li et al., 2012; Yang et al., 2010). Escape from XCI is detected by 
RNA-seq studies using heterozygous SNPs to determine the balance in expression between two 
alleles of a certain gene. This method will work most robust on a sample where the parental 
origin of the Xi is the same in all cells, i.e. a sample that is 100% skewed. In such a sample, 
genes subject to XCI will have an allelic balance of 1 or 0, while genes escaping XCI will have an 
intermediate allelic balance. From mice or mouse cell lines, a sample that is 100% skewed can 
be obtained after genetic modification or enrichment of a sub-population of cells (Calabrese et 
al., 2012; Wu et al., 2014; Yang et al., 2010). However, in human individuals XCI is rarely a 100% 
skewed and several studies have dealt with this in different ways (Carrel and Willard, 2005; 
Cotton et al., 2013; Zhang et al., 2013b).  
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Escape from XCI is more common in human  
When comparing the number of genes escaping from XCI between human and mouse, a larger 
number of genes is found to escape in humans. This suggests that XCI is much more complete 
in mouse compared to human. In mouse somatic tissues, the number of genes found to escape 
from XCI is fairly consistent among different studies ranging from 5-13 genes and represents 2-
3% of the analyzed X-encoded genes (table 3) (Li et al., 2012; Wu et al., 2014; Yang et al., 
2010). In human somatic tissues 94 genes were found to escape from XCI, representing  15% of 
all human analyzed X-linked genes (table 4) (Carrel and Willard, 2005). The lower number of 
XCI escaping genes in mouse corresponds with the less severe phenotype of 39X0 mice 
compared to 46X0 Turner women (Lynn and Davies, 2007). 
In addition to a larger number of XCI escaping genes in human, the distribution of 
escaping genes along the X chromosome is also different between mouse and human. When 
considering the distribution of XCI escaping genes across the X chromosome the PAR contains 
the highest concentration of XCI escaping genes in both human and mouse. In both species 
almost all genes located in the PAR have been confirmed to escape from XCI (Carrel and 
Willard, 2005; Keitges and Gartler, 1986; Salido et al., 1996). When considering the escaping 
genes that are located outside the PAR, their distribution along the X chromosome differs 
between human and mouse. Where in human XCI escaping genes cluster together, while the 
few escaping genes in mouse do not show any clustering but appear more evenly distributed 
along the X chromosome (Carrel and Willard, 2005; Cotton et al., 2013; Yang et al., 2010; Zhang 
et al., 2013b). Interestingly, the human XCI escaping genes cluster together on the evolutionary 
younger regions of the human X chromosome, that contain a higher proportion of genes with a 
Y-encoded homolog. The human X chromosomal sequence outside the PAR can be divided in 5 
evolutionary strata, with stratum 1 having the highest conservation and stratum 5 the lowest 
(Lahn and Page, 1999). The more ancient strata 1 and 2 contain a lower amount of escaping 
genes, compared to the evolutionary younger strata 3, 4 and 5 (Carrel and Willard, 2005). This 
is consistent with the hypothesis that the mammalian X and Y chromosome originate from the 
same set of ancestral autosomes, and that the ability of a gene to be X-inactivated is acquired 
after loss of its Y-chromosomal homolog, which occurred more frequently for genes located in 
the evolutionary ancient strata (Carrel and Willard, 2005).  
The observations that human escapees cluster together, lead to the hypothesis that in 
humans escape from XCI might be regulated at the level of chromosomal domains. However, 
this does not exclude that escape is also regulated at the single gene level, as the human X 
chromosome also contains escapees that map far from other escapees and do not contain a Y-
homolog (Carrel and Willard, 2005). In contrast to this hypothesis, escape from XCI in mouse is 
thought to be intrinsic to the DNA sequence of a gene, and independent of its chromosomal 
position. This hypothesis was assessed by integrating a BAC containing the X- encoded Jarid1C  
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gene that normally escapes XCI on different parts of the X chromosome. The generated 
transgenes maintained the XCI status of their original locus (Li and Carrel, 2008). Although the 
specific sequence and the mechanism by which Jarid1C escapes inactivation in a position-
independent manner remains to be elucidated, but might involve recruitment of CTCF. It is also 
tempting to speculate that a similar mechanism might be involved in the expression of isolated 
single escapees on the human X chromosome. 
Although one might expect XCI escaping genes to be expressed at a level comparable to 
their homologs located on Xa, this is surely not the case. The highest expression is found for 
the genes located in the human PAR1, and is at maximum 73% of the expression of their Xa 
homologs (Cotton et al., 2013; Zhang et al., 2013b). The expression of human escapees located 
outside the PAR is highly variable, and a continuum of expression is observed ranging from 10% 
to 73% of the levels of their Xa homologs. Genes that have a Y-chromosomal or autosomal 
homolog tend to have higher expression levels (Carrel and Willard, 2005; Cotton et al., 2013; 
Zhang et al., 2013b). Also in mouse, XCI escaping genes showed various levels of expression, 
with none reaching the level of their Xa homolog (Calabrese et al., 2012; Yang et al., 2010). The 
extent of escape is reflected by histone modifications H3K4me3, H3K27me3, H3K36me3, 
H3K27Ac, with stronger escaping genes showing less accumulation of inactive modifications 
(Cotton et al., 2013). 
 
Human individual variation in escape from XCI 
In human, escape from XCI is influenced by ethnic background for a subset of the genes that 
have been identified to escape. Two independent studies found differential escape between 
HapMap individuals with a central European (CEU) and Yoruban (YRI) background (Cotton et 
al., 2013; Zhang et al., 2013b). This ethnicity specific escape is further supported by comparing 
male to female expression levels, assuming that escaping genes will be higher expressed in 
females (Johnston et al., 2008). In mouse, a similar phenomenon might exist with strain specific 
escape. So far, this has only been demonstrated for mouse TS cells where 8 to 11 (22.9% - 
31.4%) of the 35 escapers in 262 analyzed genes shows strain specific escape (Calabrese et al., 
2012). If mouse somatic tissues also show strain specific escape from XCI has not been 
investigated yet. 
Apart from ethnicity specific escape, some genes seem to exhibit tissue specific escape. 
Although a direct comparison of RNA-seq profiles from different tissues has not yet been 
performed, cell lines derived from different tissues can be compared between studies that 
analyzed escape from XCI. In mouse, the studied cell lines showed a significant overlap, but 
also displayed differences in escaping genes. These differences could be the result of 
differential escape between tissues, but might also be the result of technical differences 
between the studies. In humans, a subset of genes also seems to escape from XCI in a tissue 
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specific manner. Comparing lymphocyte and fibroblast derived cell lines, 35 genes (8.5%) of the 
analyzed 409 genes showed differential escape from XCI (Cotton et al., 2013). This differential 
escape is supported by studies analyzing epigenetic modifications to predict escape status. 
Using DNA methylation to predict XCI status for fetal muscle, kidney, brain and spinal cord 12% 
of the analyzed genes was found to have tissue specific escape (Cotton et al., 2011). This 
indicates that escape is likely tissue specific for a subset of genes. 
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Aim and scope of this thesis 
 
As a result of genetic sex-determination there is a genetic imbalance for X-encoded genes 
between males and females. To compensate for this difference in X chromosomal gene dosage 
one of the two X chromosomes in every female cell is inactivated in a process called X 
chromosome inactivation (XCI). As a result of XCI every female individual is a mosaic of cells 
with an inactive paternal X chromosome or an inactive maternal X chromosome. The aim of 
this these was to further unravel the molecular mechanisms that regulate XCI and extend this 
knowledge to human XCI. 
At the start of this thesis the stochastic model for XCI had only just been formulated. 
The model states that every X chromosome in a nucleus has an intrinsic probability to 
inactivate, which results in random X chromosome inactivation. The existence of an X-encoded 
trans-acting activator of XCI is hypothesized, but Rnf12 has not yet been identified as such. 
In chapter 2 evidence is presented that supports a stochastic model for XCI. We 
describe the generation and analysis of triploid XXY ES cells, that have an X:autosome ratio of 
2:3. The concentration of trans-acting activator only marginally exceeds the threshold for XCI in 
these cells. Computer simulation is used to show that experimental data indeed fit with a 
stochastic model. These simulations confirm that stochastic XCI can be determined by the 
sensitivity of an X chromosome for an activating stimulus and the concentration of XCI 
activator. 
After the identification of Rnf12 as a trans-acting activator of XCI, which further 
validated the stochastic model, the mouse Xic is proposed to contain a cis-acting part and a 
trans-acting part. In chapter 3 XCI is analyzed in a female carrying a heterozygous deletion of 
the XIC region, demonstrating that also the human XIC can be divided in a cis-XIC and a trans-
XIC. We fine-map this deletion to single nucleotide level, and redefine the maximum region 
that is the human cis-XIC. In perspective of previous X-chromosomal aberrations we define the 
region containing the human trans-acting activator to a part of the X chromosome involving 
RNF12. 
In chapter 4 evidence is presented that human RNF12 functions as a trans-acting 
activator of human XCI, in a manner similar to mouse Rnf12. We describe three families 
carrying different mutations in RNF12. In in vitro studies with these RNF12 mutants one proves 
to be a hypermorph, while the other two mutations are hypomorphs. Despite their opposite 
functional effects our results suggest that both gain and loss of RNF12 function results in 
delayed and skewed XCI with preferential inactivation of the mutant allele. Furthermore, our 
results suggest that initiation of XCI is more strictly titrated in human compared to mouse. 
In chapter 5 we analyze the variation of XCI between different tissues. The ratio 
between inactive paternal X chromosomes and inactive maternal X chromosomes can vary 
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considerably between tissues within an individual. These analyses indicate that while blood is 
most often used to determine the X-inactivation ratio, buccal swab is a better alternative. In 
addition, the X-inactivation ratio of ovarian stroma shows a unique association with hair 
follicles. 
In chapter 6 we analyze the potential of the iPS reprogramming technique to produce 
iPS cells with two active X chromosomes. Using standard reprogramming culture conditions, X 
chromosome reactivation is achieved but not maintained, as some cells re-initiate XCI. Using 
naïve human stem cell medium this continuous process of reactivation and re-initiation is 
stabilized, allowing expansion of clones with two active X chromosomes. 
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 Abstract
 
Background 
In female mammalian cells, random X chromosome inactivation (XCI) equalizes the dosage of 
X-encoded gene products to that in male cells. XCI is a stochastic process, in which each X 
chromosome has a probability to be inactivated. To obtain more insight in the factors setting 
up this probability, we studied the role of the X to autosome (X:A) ratio in initiation of XCI, and 
have used the experimental data in a computer simulation model to study the cellular 
population dynamics of XCI.  
 
Methods and results 
To obtain more insight in the role of the X:A ratio in initiation of XCI, we generated triploid 
mouse ES cells by fusion of haploid round spermatids with diploid female and male ES cells. 
These fusion experiments resulted in only XXY triploid ES cells. XYY and XXX ES lines were 
absent, suggesting cell death related either to insufficient X-chromosomal gene dosage (XYY) or 
to inheritance of an epigenetically modified X chromosome (XXX). Analysis of active (Xa) and 
inactive (Xi) X chromosomes in the obtained triploid XXY lines indicated that the initiation 
frequency of XCI is low, resulting in a mixed population of XaXiY and XaXaY cells, in which the 
XaXiY cells have a small proliferative advantage. This result, and findings on XCI in diploid and 
tetraploid ES cell lines with different X:A ratios, provides evidence that the X:A ratio 
determines the probability for a given X chromosome to be inactivated. Furthermore, we 
found that the kinetics of the XCI process can be simulated using a probability for an X 
chromosome to be inactivated that is proportional to the X:A ratio. These simulation studies 
re-emphasize our hypothesis that the probability is a function of the concentration of an X-
encoded activator of XCI, and of X chromosome specific allelic properties determining the 
threshold for this activator. 
 
Conclusions 
The present findings reveal that the probability for an X chromosome to be inactivated is 
proportional to the X:A ratio. This finding supports the presence of an X-encoded activator of 
the XCI process.  
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 Introduction
 
In placental mammals, dosage compensation of X-encoded gene products is achieved by 
inactivation of either of the two X chromosomes in female cells (Lyon, 1961). Random X 
chromosome inactivation (XCI) is initiated early during female embryonic development, and 
results in a transcriptionally inactive X chromosome (Xi). The inactive state of the Xi is clonally 
propagated through many cell divisions. At the onset of XCI the X-linked non-coding Xist gene is 
transcriptionally up-regulated on the future Xi, and Xist RNA coats the Xi in cis (Borsani et al., 
1991; Brockdorff et al., 1992; Brown et al., 1991; Brown et al., 1992). Xist RNA is required for 
XCI and most likely attracts chromatin modifying enzymes involved in the silencing process 
(Marahrens et al., 1997; Penny et al., 1996). The Tsix and Xite genes play a crucial role in the 
early stages of XCI by suppression of Xist transcription and Xist RNA accumulation. Both Tsix 
and Xite also are non-coding genes that overlap with Xist, but are transcribed in anti-sense 
direction (Lee and Lu, 1999; Ogawa and Lee, 2003).  
The first phase of XCI comprises a counting process, followed by initiation of XCI when 
more than one X chromosome is present per diploid nucleus. We have recently shown that 
initiation of XCI is directed by a stochastic mechanism, in which all X chromosomes in a nucleus 
have an independent probability to initiate XCI within a certain time-span (Monkhorst et al., 
2008). We proposed that this probability is proportional to the X to autosome ratio (X:A), and 
most likely depends on at least two factors that act through Xist and Tsix: an X-encoded XCI-
activator that stimulates Xist expression, and itself is transcriptionally inactivated by the XCI 
process, and an autosomally encoded XCI-inhibitor that suppresses Xist by activating Tsix. 
Although the action of Tsix is still not understood, Tsix transcription and chromatin 
modifications in the Xist promoter (possibly mediated by Tsix) provide a threshold that has to 
be overcome by the XCI-activator, allowing accumulation of sufficient Xist molecules to silence 
Tsix and spread in cis. Early in mouse development or upon differentiation of embryonic stem 
(ES) cells, the XCI-activator concentration in a cell will increase, and in female cells this will 
drive the initiation of XCI with a specific probability. This probability is the consequence of 
stochastic transcriptional activation of both Xist and Tsix. In male cells, the XCI-activator 
concentration will be too low;  therefore, these cells induce XCI only sporadically (Monkhorst 
et al., 2008).  
Several findings support the presence of an X-linked XCI-activator. Tetraploid XXXX ES 
cells initiate XCI significantly faster than XXXY cells (Monkhorst et al., 2008). In addition, female 
ES cells with a heterozygous deletion including Xist, Tsix and Xite (ΔXTX), still show initiation of 
XCI on the wild type X chromosome. XCI is not initiated in male cells with one copy of Xist, Tsix 
and Xite indicating a novel trans acting activator, encoded by a gene located outside the 
deleted area (Monkhorst et al., 2008). Also, studies in differentiating ES cell lines with stably 
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integrated Xist promoter transgenes  show significantly more expression of a linked reporter in 
female cells compared to male cells (Sun et al., 2006). The genomic location of the XCI-
activator is unknown so far. However, previous studies which analyzed XCI in male cell lines 
with multi-copy YAC transgenes ranging in size from 320 to 460 kb, encompassing Xist and 
flanking regions, revealed initiation of XCI on the single X chromosome (Heard et al., 1999; Lee 
et al., 1996). Interestingly, a BAC sequence covering a region upstream of Xist, not including 
Xist itself, also induced ectopic XCI in transgenic male and female cells (Augui et al., 2007). 
These studies indicate that the sequence encoding the XCI-activator is likely to be located 
within the sequence covered by these transgenes. Smaller transgenes, only including Xist and 
flanking sequences, have also been reported to induce ectopic XCI in male cells, when present 
as multiple tandemly inserted transgenes (Herzing et al., 1997; Lee et al., 1999). Our finding 
that XCI is still initiated in female cells with a ΔXTX deletion, however, indicates that the 
overlapping region covered by the ΔXTX deletion and these transgenes (Herzing et al., 1997; 
Lee et al., 1999) is not required for the counting process. Some of the reported observations 
may also be attributed to the presence of Tsix transcription, which was not yet discovered, and 
hence not taken into consideration, at the time these studies were performed. 
In diploid and tetraploid cells, one X chromosome will remain active per diploid 
genome. However, in triploid cells this ratio of one active X chromosome per diploid autosomal 
set cannot be achieved. Therefore, triploid cells provide a unique situation for studying the 
mechanism of XCI counting and choice and gene dosage related cell selection. Several studies 
have been conducted with human and mouse XXY and XXX triploid embryos and embryo-
derived cell lines, to try to determine the pattern of X inactivation. In these experiments 
cultured differentiated cells were examined which had completed the XCI process (Gartler et 
al., 2006), and indicated that the majority of cell lines derived from human live born XXX 
triploids predominantly show two active X chromosomes (Hendriksson et al., 1974; Leisti et al., 
1970; Willard and Breg, 1977). In contrast, analysis of 10-day-old XXY and XXX mouse triploid 
embryos showed that most cells had one active X chromosome (Speirs et al., 1990). 
Unfortunately, both studies did not discriminate between primary choice in XCI and the effect 
of cell selection processes on XCI. 
  To explore the mechanism determining the probability of an X chromosome to be 
inactivated, we have generated XXY triploid mouse ES cells. Analysis of XCI in these cells 
allowed us to determine the influence of the X:A ratio on the initiation of XCI, and to 
discriminate between the effects of XCI initiation and cell selection. In addition, we have used 
stochastic and mathematical simulation studies to follow the kinetics of XCI in a population of 
developing or differentiating cells. 
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 Results
 
Generation of triploid ES cells 
Our previous studies with tetraploid XXXX, XXXY and XXYY mouse ES cell lines have indicated 
that the probability for an X chromosome to be inactivated is directly related to the X:A ratio 
(Monkhorst et al., 2008).  To further explore this finding we aimed to generate triploid ES cell 
lines with XYY and XXY karyotypes, having an X:A ratio of 1:3 and 2:3, respectively, for which 
XCI has not been studied before. To generate triploid ES cell lines we decided to fuse 
puromycin resistant female and male ES cells with round spermatids or spermatozoa 
containing a neomycin resistance (neo) gene targeted to either the autosomal Ube2b gene or 
the X-chromosomal Ube2a gene. Both Ube2a and Ube2b encode ubiquitin-conjugating 
enzymes involved in DNA replicative damage bypass (Ulrich, 2005). The encoded proteins have 
at least partially overlapping functions, and two functional alleles of either Ube2a or Ube2b per 
cell are sufficient to generate viable diploid mice. Also, spermatogenesis is not dysregulated in 
Ube2a knockout and Ube2b heterozygous mutant mice (Roest et al., 2004; Roest et al., 1996). 
Therefore, it was expected that loss-of-function of one targeted Ube2a or Ube2b allele, in the 
Ube2b+/- and Ube2ay/- mice, respectively, will not have an effect on the viability of hybrid fusion 
products. In the present study, the targeted mutant alleles serve the function of selection for 
fused cells.  
All PEG mediated fusion experiments were conducted twice. Fusion of the neomycin 
resistant Ube2a-neo round spermatids and spermatozoa with female or male ES cells did not 
result in double resistant colonies (Fig. 1a). In addition, fusions of Ube2b-neo round spermatids 
with male ES cells, and fusions of Ube2b-neo spermatozoa with either female or male ES cells, 
also did not result in double resistant colonies. In contrast, double resistant colonies were 
obtained by fusion of Ube2b-neo round spermatids with female ES cells, and these colonies 
were picked and expanded for further analysis. PCR analysis of genomic DNA indicated the 
presence of the Ube2b-neo allele in all the ES clones picked, confirming the fusion of a round 
spermatid containing the Ube2b-neo allele (Fig. 1b). FACS analysis, using propidium iodide to 
determine the DNA content, indicated that all our cell lines were triploid (Fig. 1c). The small 2n 
population we attribute to contamination of the triploid cells with diploid male feeders that we 
used to grow the ES cells on. Karyotyping also indicated that, in all cell lines, the majority of 
cells had 60 chromosomes, which are stably maintained through many passages (Fig. 1d, and 
data not shown). Interestingly, X and Y chromosome paint analysis showed that all cell lines 
had an XXY 3n karyotype (N=18) although the haploid round spermatids that were used for 
fusion can be expected to contain either an X chromosome or a Y chromosome in a 50/50 ratio 
(Fig. 1e and 1f).   
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Figure 1. 
Generation of triploid ES cells 
a. The different fusion experiments performed; (-) no clones present, (+) clones present which could be 
picked and expanded. Fusion of Y-bearing spermatids and spermatozoa for Ube2a knockout mice was 
not examined, since the neo selection marker localizes to the X (gray boxes). 
b. PCR with genomic DNA detecting the wild type and mutated Ube2b-neo allele. Clone numbers are 
indicated, and control DNA was isolated from wild type, Ube2b-/- and +/- mice. 
c. FACS analysis detecting the DNA content of diploid ES cells, and four different triploid ES cell lines 
analyzed in (B). 
d. Karyotyping of 9 triploid ES cell lines, shown in (B); indicated are chromosome counts of individual 
methaphase spreads. Right panels show representative examples of metaphase spreads. 
e. Y chromosome paint analysis; shown is the number of metaphase spreads with 0, 1, and 2 Y 
chromosomes. Right panels show representative examples of metaphase spreads subjected to DNA 
FISH using a Y paint probe (red, DNA is blue). 
f. X chromosome paint analysis, shown is the number of metaphase spreads with 1, 2, 3, and 4 X 
chromosomes. Right panels show representative examples of metaphase spreads subjected to DNA 
FISH using an X paint probe (Red, DNA is blue). 
 
 
 
 
These results suggest that triploid XYY cells are absent due to an insufficient dosage of 
X-encoded genes. In addition, the lack of XXX 3n karyotypes suggests that introduction of an X 
chromosome through a round spermatid leads to a non-viable triploid ES cell. The absence of 
triploid XXX ES cell lines (X:A ratio of 1) cannot be explained by a dosage problem, but might be 
due to the presence of an epigenetically modified X chromosome present in spermatids. During 
spermatogenesis, the largely unpaired X and Y chromosomes are transcriptionally inactivated, 
forming the XY body or sex body in a process called meiotic sex chromosome inactivation 
(MSCI) (Turner, 2007). Chromatin modifications present on the XY body may be partly 
maintained in post-meiotic round spermatids. Such modifications, particularly relevant for the 
X chromosome with a large gene content, may explain lethality of the triploid XXX ES cells. 
To test whether the spermatid derived X was reactivated after cell fusion, we fused 
round spermatids of males containing an X-linked GFP transgene (Hadjantonakis et al., 2001) 
with male and female ES cells. Analysis of diploid ES cells containing the X-linked GFP transgene 
shows robust GFP expression, indicating that the transgene is properly expressed in ES cells. In 
contrast, after fusion of GFP round spermatids with ES cells, we did not see reactivation of the 
transgene (data not shown). Selection for reactivation of the transgene by applying puromycin 
selection, at days 0, 3 and 5 after fusion, did not result in clones resistant to both selection 
reagents. Therefore, we conclude that ES cells are incapable of reactivating the X from 
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spermatids. This is in contrast to ES fusions with female somatic cells, which lead to 
reactivation of the Xi (Takagi et al., 1983).  
  
XCI in triploid XXY ES cells 
To study XCI in the obtained XXY triploid ES cells, we differentiated 9 of these cell lines into 
embryoid bodies (EB). Cells were fixed and subjected to RNA-FISH after 3, 5, 7, and 10 days of 
differentiation, using an Xist specific probe to stain the Xist coated Xi’s. After a three-day 
differentiation period, we mainly found cells with zero or one Xi, indicating that the triploid XXY 
cells are capable to initiate XCI (Fig. 2a). At this time point only ~2.5% of cells had one Xi (XaXiY) 
and we sporadically (<0.1%) found cells with two Xi’s (XiXiY). During the differentiation process, 
the relative number of cells with one Xi increased, to ~40% at day 10 of differentiation (Fig. 2b). 
To exclude the possibility that our triploid XXY ES cells lost or gained X chromosomes 
over the differentiation process, we performed DNA-FISH with an X chromosome specific BAC 
probe on cells differentiated for seven days. To obtain a reliable measurement, at least 100 
nuclei were scored for every cell line. We found that over 93% of the XXY cells still contained 
two X chromosomes, and only 3% of the cells were found to have three X chromosomes, 
suggesting that the karyotype of these triploid XXY ES cells is stable throughout the 
differentiation period that we assayed (Fig. 2c).  
We further examined whether the increase in time of the percentage of XiXaY cells (Fig. 
2b) might be caused by cell selection. We therefore added BrdU 24 hours prior to cell fixation 
of day 7 differentiated ES cells, and performed immuno/RNA-FISH, detecting BrdU positive cells 
and Xist RNA. Comparison of BrdU positive cells with one or no Xist cloud(s) shows that there 
are significantly more cells with one cloud, indicating that XiXaY cells indeed have a small but 
significant proliferative advantage (p<0.001; Fig. 2d and 2e).  
Previously, we have proposed that the probability for an X chromosome to be 
inactivated is proportional to the X:A ratio (Monkhorst et al., 2008). To further explore this 
finding we compared the percentage of cells that had initiated XCI at day 3 of differentiation 
between cell lines with various X:A ratios, notably  our XXY triploid ES cell lines (with an X:A 
ratio of 0.67) and tetraploid and diploid cells (4n XXXX cells with X:A=1; 4n XXXY cells with 
X:A=0.75; 4n XXYY cells with X:A=0.5; 2n XX cells with X:A=1; and 2n XY cells with X:A=0.5).  ES 
cell lines were differentiated through EB differentiation and subjected to RNA-FISH to detect 
Xist RNA. For each line with a different X:A ratio or a different ploidy number, we performed 
three independent differentiation experiments. 
The results (Fig. 2f) confirm our previous findings (Monkhorst et al., 2008) that, at day 3 
of differentiation, XXXX cells have initiated XCI in significantly more cells (58%) than XXXY cells 
have (20%). Furthermore, tetraploid XXYY and diploid XY cells initiated XCI in less than 0.3% of 
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Figure 2. 
Analysis of XCI in differentiating triploid XXY ES cells 
a. RNA-FISH analysis with an Xist probe (FITC, DNA in blue) on day 3 differentiated triploid ES cells, shows 
cells with no (left panels) or one (right panels) Xist cloud. 
b. The average distribution and standard deviation of cells with different numbers of Xist clouds 
throughout differentiation. 
c. DNA FISH analysis on day 7 differentiated triploid ES cells. Shown is the relative number of cells with 0, 
1, 2 and 3 X chromosomes. 
d. Combined Xist RNA-BrdU detection (Xist in FITC, BrdU in Rhodamine red, DNA in DAPI blue), indicating 
the presence of cells with negative and positive BrdU staining (from left to right). 
e. Quantification of the Xist RNA-BrdU detection, shown are the relative number and standard deviation 
of BrdU positive cells with 0, 1 and 2 Xist clouds. 
f. The relative number and standard deviation of cells that have initiated XCI (at least one Xi), per cell 
line at day 3 of differentiation. 
 
 
 
 
 the cells, whereas diploid XX ES cells initiated XCI in 50% of the cells (Fig. 2f). At day 3, triploid 
XXY cells had initiated XCI in 3-4% of the cells (Fig. 2f). This percentage falls between that found 
for XXXY and XXYY cells. From these results, we conclude that the probability to initiate XCI 
depends on the X:A ratio and that this relationship appears not to be linear (Fig. 2f). 
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Parameters required for computer simulated XCI 
To better understand the kinetics of XCI in a developing female embryo or a differentiating 
population of female ES cells we decided to simulate the XCI process. There are four important 
parameters required to simulate XCI, based on a stochastic model for XCI: 1) the probability for 
an X to initiate XCI, 2) the time window required for one choice round, 3) the rate of cell 
division, and 4) cell selection.  
As indicated by our findings, the probability for an X to initiate XCI is proportional to the 
X:A ratio, and XCI is most likely triggered by a threshold nuclear concentration of an X-encoded 
XCI activator. Although the nuclear concentration of XCI activator will be the same for both X 
chromosomes present in a female cell, specific allelic properties of the individual X 
chromosomes can result in different probabilities because of effects in cis. Previous studies 
with female ES cell lines harboring deletions of either Xist, Tsix or Xite have indicated that the 
probability to initiate XCI positively correlates with the Xist transcription rate and negatively 
with the transcription rate of Tsix and Xite (Lee and Lu, 1999; Marahrens et al., 1997; 
Nesterova et al., 2003; Ogawa and Lee, 2003; Penny et al., 1996). Based on their anti-sense 
nature, transcription initiated by the Tsix and Xite promoters may constitute a threshold for 
Xist to accumulate in cis. Also, Xist promoter related modifications could restrict the action of 
the XCI activator and may therefore be involved in setting up the threshold. Only when 
sufficient XCI activator is present in the nucleus enough Xist transcription is initiated to 
overcome Tsix mediated repression, thereby effectuating a probability to initiate XCI. Xist 
transcription initiation is a stochastic process itself, and depending on the nuclear XCI activator 
concentration, bursts of Xist transcription will generate a continuum of small probabilities to 
initiate XCI in time. This probability will drop after inactivation of an X chromosome with the 
decline in the XCI activator concentration that depends on the nuclear half-life of the XCI 
activator. In our simulations we have used a time window with a specified probability, which 
represents the integrated probability within that time window.  
To test whether XCI is dependent on cell division, we first analyzed the number of cell 
divisions during a 10 day period of embryoid body (EB) differentiation, for ES cells with 
different X:A ratios. To determine the increase in cell number we differentiated 105 cells, and 
isolated DNA before and after differentiation. OD measurements of two independent 
differentiation experiments indicated that the different ES lines divided between 4 and 7 times 
in the 10 day differentiation period (Fig. 3a). Next, female diploid ES cells were EB 
differentiated for one or two days, and then subjected to γ-irradiation-, mimosine- or 
colcemid-mediated cell cycle arrests for one day. Initiation of XCI in treated and untreated cells 
was compared by counting the number of cells with or without an Xi, using RNA-FISH with an 
Xist probe. We found no significant increase or decrease in the number of cells with an Xi after 
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Figure 3 
Initiation of XCI independent of cell division 
a. Determination of the number of cell divisions during a 10 day EB differentiation period. Shown are the 
average and standard deviation of two separate experiments with two different ES lines per X:A ratio 
or ploidy number.  
.b. Analysis of initiation of XCI after a cell cycle block. Diploid female ES cells were EB differentiated for 
one day (left graph) or two days (right graph), and treated with colcemid or mimosine, or cells were 
lethally γ-irradiated, and allowed to differentiate for one more day before fixation. Control samples 
were allowed to differentiate for two or three days. The percentage of cells that initiated XCI was 
determined by Xist RNA FISH, followed by the quantification of the number of cells with Xist clouds.    
 
 
 
 
 cell cycle arrest, although the cells that had been γ-irradiated at day 1 showed a slight 
decrease in cells that initiated XCI (Fig. 3b). This result suggests that cell division is not 
required, or perhaps plays a minor role in the initiation of XCI. Nevertheless, cell division 
characteristics are important in the XCI process, because previous studies have shown that 
cells that inactivate too many X chromosomes stop dividing or slow down the cell division rate, 
which allows the cycling population of cells to outgrow the cells that inactivated too many X 
chromosomes (Monkhorst et al., 2008; Wutz et al., 2002).   
Cell selection also plays an important role in the XCI process, as male cells that 
inactivate their single X chromosome will die. Studies with inducible Xist cDNA transgenes 
integrated on the single X chromosome in male cells showed that Xist mediated silencing 
manifests within 24 hours, and that cell death becomes imminent within three days of Xist 
induction (Wutz et al., 2002). Also, diploid female cells inactivating two X chromosomes or 
incapable of initiating XCI are prone to die (Lee, 2005; Marahrens et al., 1997).  
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Computer simulated XCI    
To comprehend the kinetics of XCI, we have developed a stochastic simulation model to 
determine the populations of cells with a different number of Xa’s and Xi’s. In this approach, 
the distribution of different cell populations is derived using a simulation program with a 
random number generator,  thereby mimicking the choice process. With a small starting 
population of cells, as present in the female mouse embryo around the time XCI is induced, the  
stochasticity resulted in different outcomes of the choice process for every new calculation.  
This phenomenon deviates from what would be obtained in deterministic mathematical 
models, but corresponds to experimental reality. Our stochastic simulation of the XCI process 
used a three-dimensional matrix in which each Z stack represented one choice round (Fig. 4a). 
For our simulations we used a fixed or changing probability per choice round per X 
chromosome, and specific cell cycle characteristics depending on the X:A ratio.  
 
 
 
 different bar-graphs show the relative distribution of the three different cell types (XaXa = yellow, 
XiXa = green, XiXi = gray). Numbers below the bar graphs indicate days of differentiation (1-10), and 
cell division is indicated with a triangle. For time points represented by light gray bars no data is 
available. 
b. Probability curves representing the increase of the probability y in time based on equation [6], with 
m=1, for XX 2n and XXXX 4n cells (purple), and m=0,75 for XXXY 4n cells (orange). The probability at a 
given time point is the integrated probability over a time frame of one day. A negative value for y 
results in a probability of 0, and is represented by a faint line. 
c. Upper left panel shows simulation of XCI in XX diploid cells based on probabilities determined using 
different probabilities in time indicated in the curve, shown in Fig. 4b. Upper middle panel shows the 
experimental percentages of 4n XXXX cells with a different number of Xi’s throughout EB 
differentiation. The upper right panel shows the simulation of XCI using the same parameters as used 
for the XX diploid simulation (XaXaXaXa = yellow, XaXaXaXi = green, XaXaXiXi = grey, XaXiXiXi = red, 
XiXiXiXi, blue).  Bottom left panel shows the experimentally determined percentages of 4n XXXY cells 
with a different number of Xi’s throughout EB differentiation. Bottom right panel shows the XCI 
simulation of 4n XXXY cells using the different probabilities in time indicated in the curve presented in 
(B) (XaXaXaY = yellow, XaXaXiY = green, XaXiXiY = grey, XiXiXiY = red).  
d. Curves representing the probability y in time using equation [6] for cells with a different X:A ratio, 
ranging from 0,5 to 1,5. 
e. Left panel shows the experimentally determined percentages of 3n XXY cells with a different number 
of Xi’s throughout EB differentiation. Middle panel shows the XCI simulation of 3n XXY cells using 
different probabilities indicated in the curve presented in Fig. 4d (XaXaY = yellow, XaXiY = green, XiXiY 
= grey). Right panel shows the simulation of XCI in XXX 2n cells  (XaXaXa = yellow, XaXaXi = green, 
XiXiXa = grey, XiXiXi, red)  
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Figure 4 Computer simulation of XCI 
 a. Left upper panel shows a schematic representation of the stochastic simulation which is executed in a 
three dimensional matrix. Cells (boxes) go through consecutive choice rounds (numbers) interrupted 
by cell divisions (triangle). The three different cell types are represented by XaXa = yellow, XiXa = 
green, XiXi = gray boxes. The dashed lines indicate the origin of progeny of one XiXa and one XiXi cell 
after cell division (not all lines are shown, and note that the XiXi cells do not divide).  The right panels 
show the experimental data from differentiated 2n female XX ES cells (exp.), and the stochastic 
simulation of XCI with a 5%, 10%, 20%, 30%, and 40% fixed probability per X chromosome (sim.). The  
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We started by simulating the XCI process in XX diploid female ES cells throughout  a 10 
day differentiation period, using a fixed probability in time to run the simulations, and 
compared the resulting distributions with experimental data obtained with differentiating XX 
female ES cells. For cells with an X:A ratio ≥ 0.5 we used a cell division rate of once every two 
days, based on our cell division analysis (described above). In addition, the simulation assumed 
that cells with all X chromosomes inactivated stop dividing, which is based on previous studies 
(Wutz and Jaenisch, 2000). To be able to compare the simulations with available experimental 
data, we set the time window to 1 day, representing the integrated probability for cells 
choosing the X to be inactivated over 1 day. In the calculations we have excluded the option 
that, in XaXi cells that just have inactivated an X chromosome, the active second X 
chromosome may still have a probability to be inactivated. We performed the simulations with 
100 cells, which mimics the number of cells present in the female mouse embryo around the 
time XCI is initiated. A number of 5 independent stochastic simulations generated the data for 
statistical analysis of the average and standard deviation. The graphs in the figures only show 
the average value for each time point. Comparison of the simulations, using an increasing 
range of fixed probabilities from 5% to 40% for both X-chromosomes, with previously obtained 
experimental results for differentiated XX female ES cells indicated that a fixed probability 
between 10% and 20% fits our experimental data best (Fig. 4a; Supplemental Fig. 2a, b and c 
and Supplemental Fig. 3a, b and c) (Monkhorst et al., 2008). To validate the simulation results 
we also compared these with data obtained using a mathematical approach were fixed 
probabilities were used to calculate the different XaXa, XaXi and XiXi populations, which 
showed similar population dynamics (Supplemental Text 1 and Supplemental Fig. 1). The 
fluctuation in the percentage of XiXi cells in time is the consequence of applying two choice 
rounds (1 per day) within one cell division (once every two days for XaXa and XaXi cells). 
Because cell division is synchronized in the simulations, XiXi cells are diluted out after every cell 
division. 
From previous experimental data it appears that the probability to initiate XCI is lower 
in the beginning than later during the XCI process, and our experimental findings indicate that 
the probability is dependent on the concentration of XCI activator in the nucleus. In our model, 
the labile XCI activator is produced at a rate (va.synthesis) that is proportional to the number of 
active X chromosomes.  This leads to the following differential equation for the concentration 
of the XCI activator: 
 
[1]  ][)(][ . activatorXCIktvdt
activatorXCId
dsynthesisa −⋅−=
−
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with:  
 
 [2]  Va.synthesis  (t)=ks[mactive(t)] 
 
 
Here, ks is the rate constant for synthesis (in µMolar per second per active promoter), and  
mactive is the number of active X chromosomes per haploid genome, which can be substituted 
by the X:A ratio by renormalizing the rate constant ks. Before XCI, i.e. at the start of the 
simulation, all X chromosomes are active, and whenever the number of active X chromosomes 
remains (approximately) constant in time, the above equation integrates as: 
 
[3]  ( ) ( )( )21/2111),]([ tt
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where: 
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We expect that the decision probability for X inactivation in any very short time period, is 
proportional to the concentration [y] of a number of molecules (or chromosome modifications) 
y that effectuate Xist promoter activation. These molecules are being synthesized through an 
enzymatic activity that depends on the concentration of the allosteric XCI activator through a 
Hill relationship, with Vys and Ka, representing rate at maximum activator concentration and 
activation constants, respectively. Y is degraded by another enzymatic process, depending on 
the concentration y through a Michaelis Menten relationship, with Vyd and KMy and maximum 
rate and Michaelis constants, respectively.  We anticipate that KMy is very small, whereby this 
degradation process of Y effectively always has the same rate.  Also, we expect that y has a 
certain constant lability, through a first order process, with first order rate constant kdy: 
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These molecular processes will reach a quasi-steady state. Equating dy/dt to zero, and 
assuming that KMy is much smaller than any relevant concentration of y, the concentration of y 
is given by: 
 
[6]  
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or y will be zero if this yields a negative number.  At the threshold level, y will be zero, resulting 
in:   
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Above the threshold level its value will increase with an increase in [XCI activator] towards a 
maximum.  By plotting y in time we generated a probability curve, which in the simulations 
represents the integrated probability over a time frame of 1 day. The values for y at different 
days from 0-10 were imported in the simulation program to assign the different Xi’s with a 
specific probability per choice round. After XCI has started on one or more X chromosomes, the 
concentration of the XCI activator will drop fairly quickly, according to the half-life of the XCI 
activator protein (Supplemental Text 1). For cells that started XCI in one choice round, the 
probability will drop according to the m value reached after that choice round.  
Using graded preset values for the parameters, the outcome of simulations using the 
above model, was compared with experimental data sets that were obtained by differentiation 
of diploid XX (m=1) and tetraploid XXXX (m=1) and XXXY (m=0.75) cells (Monkhorst et al., 
2008). This approach enabled us to obtain best-fit values for the parameters (independent 
variables). Probability curves for m=1 (2n XX and 4n XXXX) and m=0.75 (4n XXXY) were derived 
(Supplemental Fig. 4a, b and c, and Fig.  4b) with a Ka of 3.3 µM, equal to the maximum XCI 
activator concentration in diploid XX and tetraploid XXXX cells, and values for ks, kd, kdy, Vys 
and Vyd of 2 µM, 0.6 µM, 1.5 µM, 3 µM and 1.15 µM, respectively. These curves resulted in 
simulated populations with different Xa’s and Xi’s in time that matched our experimental data 
with diploid XX and tetraploid XXXX, XXXY cells (Fig. 4c, and Supplemental Fig. 5a and b and 
Supplemental Fig. 6). In a different approach, we used the same probabilities in time for diploid 
female XX cells in a mathematical model, and obtained distributions of different cell 
populations that supported our findings with the stochastic simulations (Supplemental Text 1, 
and Supplemental Fig. 1b). 
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To validate the findings, we introduced two different m values of 0.67 found in XXY 
triploid cells, and 0.5 found in diploid XY and tetraploid XXYY cells, keeping all other parameter 
values constant. The probability curves obtained with these m values resulted in a negative 
probability (is equal to 0) for diploid XY and tetraploid XXYY cells, as expected (Fig. 4d). For XXY 
cells with an m=0.67 we obtained a positive value for y, predicting initiation of XCI, albeit at an 
even lower level than found in XXXY tetraploid cells (Fig. 4d). Using the probabilities derived 
with m=0.67 we obtained simulated distributions that match well with our experimental data 
(Fig. 4e, and Supplemental Figure 7a). Raising m to 1.5, as found in females with an 47,XXX 
aneuploid karyotype, increases the probability to a maximum of 44% (Supplemental Fig. 4c and 
Fig. 4d). Simulations using this probability curve result in a majority of cells that inactivate two 
X chromosomes (Fig. 4e, and Supplemental Fig. 7b), as reported for 47,XXX human individuals. 
Interestingly, simulation of XXX diploid (aneuploid) cells only resulted in a 26% cell loss. This 
percentage is well below the 50% cell loss obtained for human individuals and viable mice with 
X:autosome translocations (Du Sart et al., 1992; McMahon and Monk, 1983), and does explain 
why mice and humans with one or more additional X chromosomes are viable. Taken together, 
the results show that the XCI process can be simulated using a probability curve representing 
the effective XCI activator concentration in combination with a threshold level required to 
initiate XCI.   
 
Allele specific activation levels for the XCI activator 
A stochastic model implies that different X chromosomes within one nucleus can have different 
probabilities to be inactivated, because X chromosome specific thresholds are determined 
independently. In inbred mice, the X chromosomes are genetically identical and XCI will 
therefore result in two evenly distributed populations of XiXa cells with one of the parental X 
chromosomes inactivated. However, in several F1 hybrid mice, XCI has been reported to be 
skewed towards one of the parental alleles. For mouse, skewing of XCI has been attributed to 
differences in the X controlling element (Xce), a region overlapping and extending 3’ of Xist 
(Cattanach and Isaacson, 1967; Chadwick et al., 2006). In cells where two X chromosomes are 
present with different Xce alleles, a strong Xce is associated with a lower probability to initiate 
XCI compared to the X chromosome harboring the weaker Xce. These reported differences in 
probabilities could be explained as allele specific thresholds for the XCI activator. A more 
sensitive allele (weak Xce) for the XCI activator will result in a higher probability for XCI at a 
certain XCI activator concentration than a less sensitive allele (strong Xce). As a consequence, 
one XCI activator concentration can result in different probabilities for different alleles in the 
same nucleus. Mus musculus castaneus (Cast/Ei ) mice harbor a strong Xce in contrast to Mus 
musculus 129/SV (129/Sv) mice, which harbor a weak Xce, and in somatic tissues of 
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 Figure 5 
Implementing allele specific thresholds 
a,b XCI skewing can be simulated by attributing different probabilities to the two X chromosomes in 
female XX cells. To simulate the 30%:70% skewing of XCI observed in Cast/Ei – 129/Sv F1 mice and 
differentiating F1 ES cells different allele specific probabilities were applied. b. The experimentally 
obtained XCI data (left panel) with differentiating XX Cast/Ei – 129/Sv F1 ES cells does not discriminate 
between inactivation of the Cast/Ei or 129/Sv X chromosome. Right panel shows simulations with 
allele specific probability curves presented in Fig. 5a. 
c. Almost complete skewing of XCI towards the Tsix-stop containing 129/Sv X chromosome was 
simulated using allele specific probabilities for the Cast/Ei and mutated 129/Sv X chromosomes.  
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d. Left panel shows the experimentally obtained XCI data with 2n XX heterozygous Tsix-stop female cells. 
In this experiment no discrimination was made between inactivation of the Cast/Ei and 129/Sv X 
chromosomes. The right panel shows simulated XCI experiments using the probability y presented in 
Fig. 5c.  
e. Predicted probabilities in time for a Tsix-stop X chromosome in male and female ES cells. 
f. Left panel shows simulation experiments with homozygous female Tsix-stop cells. Right panel shows 
initiation of XCI occurring in simulation experiments with Tsix-stop male cells. 
g. Predicted probability curves for Cast/Ei and 129/Sv X chromosomes in 3n XXY ES cells. 
h. Schematic presentation of the Xist locus and the localization of the PCR primers used to determine 
skewing of Xist expression. RT PCR was performed with cDNA of 7 day differentiated 2n XX cells and 
3n XXY cells, with Xist primers spanning intron 6, amplifying a length polymorphism present in exon 7. 
The average percentage, and standard deviation, of Xist emanating from the Cast/Ei X chromosomes 
relative to the total amount of Xist is shown in the right graph.  
 
 
 
 
Cast/Ei -129/Sv F1 female mice and differentiated F1 female ES cells, the 129/Sv X 
chromosome is inactivated in ~70% of the cells (Fig. 5h). Allele specific sequence differences in 
Xist, Tsix, and Xite will lead to different values for Vys and/or Vyd. 
As indicated above, y may represent activated XCI activator molecules or chromatin 
modifications (as targets for activated XCI activator), for which Vys and Vyd reflect the 
composition and breakdown, respectively, of the complex involved in Xist transcriptional 
activation and/or Xist RNA mediated silencing. The values for Vys and Vyd  will depend on allelic 
properties of different X chromosomes, such as SNPs in the Xce region associated with allelic 
threshold levels to initiate XCI. We have investigated both options, using different allele 
specific values for Vys or Vyd.  By training the stochastic simulation program, we found best-fit 
allele specific Vys values for the 129/Sv X and Cast/Ei X alleles of 3.19 and 2.87, respectively, or 
Vyd values for the 129/Sv X and Cast/Ei X alleles of 1.05 and 1.20, respectively (Figure S4D and 
E). Keeping all other variables constant, these obtained values resulted in probability curves 
that, in stochastic simulations of XCI, generated a relative distribution of 129/Sv : Cast/Ei of 
70% : 30% (Fig. 5a and 5b, and Supplemental Fig. 8a).  
Completely skewed XCI has been reported in female mice and ES cells, in which Tsix 
transcription is abrogated by deletion of Tsix regulatory elements or a block of Tsix 
transcription through insertion of poly-adenylation sequences. These mice and ES cells show 
almost completely skewed XCI towards inactivation of the Tsix mutant X chromosome. We 
have recently shown that XCI starts earlier in differentiating Tsix mutant ES cells compared to 
wild type female cells, and that by day one of differentiation already 50% of the mutant cells 
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have initiated XCI, compared to ~10% of the wild type cells. In the stochastic simulation, a raise 
in the probability for the 129/Sv X chromosome harboring the Tsix stop by increasing Vys to 
4.60 µM, results in an outcome that matched the experimental findings (Fig. 5c and 5d, and 
Supplemental Fig. 4f and Supplemental Fig. 8b). This simulation also shows that in this case 
only few cells inactivate both X chromosomes, as we previously reported (Monkhorst et al., 
2008), because early during differentiation the mutant X chromosome is subject to a high 
probability to undergo XCI compared to the wild type X, meaning that the XCI activator level 
will drop well before the second X might become a target. Using the same parameters in a 
simulation of homozygous female Tsix-stop cells we found a very high number of cells 
inactivating both X chromosomes (Fig. 5f and Supplemental Fig. 9a), as was reported for 
differentiating female ES cells with a homozygous mutation of Tsix (Lee, 2005). Interestingly, in 
Tsix-stop male cells with m=0.5 we still find that y can eventually, over a period of time, reach a 
value above zero (Supplemental Fig. 4f), suggesting that the single X in these male cells will still 
have a probability to undergo initiation of XCI upon differentiation or development 
(Supplemental Fig. 9b). Indeed this has been reported in differentiating male ES cells with this 
Tsix-stop mutation and other mutations that abrogate Tsix function (Clerc and Avner, 1998; 
Luikenhuis et al., 2001; Morey et al., 2004; Vigneau et al., 2006). 
Although the thresholds for both Cast/Ei and 129/Sv X chromosomes are similar in F1 2-
1 diploid XX cells and the triploid XXY cells that we generated for this study, the putative X-
encoded XCI activator concentration in the nucleus will be different. In the 3n XXY cells, the XCI 
activator concentration will be lower than in 2n XX cells, related to the larger volume of the 
nucleus of triploid cells as compared to diploid cells. Hence, the allele specific threshold for the 
strong Xce of the Cast/Ei X chromosome in 3n XXY cells may be too high to generate a 
probability to start XCI (Fig. 5g). To test whether this is true, we differentiated 2n XX and 3n 
XXY lines for 7 days (in triplo), and performed RT-PCR analysis with an Xist specific primer set. 
As predicted, we found that skewing of XCI is enhanced towards the weak Xce of the 129/Sv X 
chromosome in the 3n XXY cell lines (Fig. 5h). We conclude that the stochastic simulation 
studies show that our hypothesis that the probability for an X chromosome to undergo 
initiation of XCI is effectuated by an X-encoded activator of XCI, above a nuclear threshold 
level, is feasible, at least when considered in the light of the experimental information. They 
also demonstrated that the probability to initiate XCI may well depend on the number of X 
chromosomes per nucleus, the nuclear volume related to ploidy and different thresholds for 
specific Xce alleles. 
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Discussion 
 
We have analyzed XCI in differentiating triploid mouse ES cells, and found that XXY cells with 
an X:A ratio of 0.67 initiate XCI less frequently compared to cells with a higher X:A ratio. Cells 
that do initiate XCI (XaXiY) proliferate slightly faster than XaXaY cells, and slowly accumulate in 
time. Simulation studies of XCI, based on a stochastic principle, indicate that XCI counting and 
choice can be mimicked when using a probability for an X chromosome to be inactivated, in 
which the probability is dependent on a nuclear XCI activator concentration acting at 
differential threshold levels  for X chromosomes with specific Xce alleles. 
 
Triploid ES cells and the need for speed 
In this study, we have generated triploid mouse ES cells by PEG mediated fusion of diploid ES 
cells with haploid round spermatids. Interestingly, we could only generate triploid ES cells with 
a XXY karyotype, in which the Y chromosome was donated by the round spermatid. The fact 
that we could not generate an ES cell line with the same XXY karyotype by fusion of a male ES 
cell with a round spermatid donating an X chromosome indicates that the presence of a 
spermatid derived X chromosome results in a triploid cell that is not viable. This difference 
could be the consequence of epigenetic interference with transcription of the X chromosome 
from spermatids, which hampered the viability of our triploid cells. However, such an effect 
has never been reported in mice (Kaufman et al., 1989). Epigenetic modification of the X in 
spermatids might be a consequence of meiotic sex chromosome inactivation (MSCI) (Turner, 
2007), that is overcome in normal sperm development and fertilization, but cannot be reversed 
by the ES cell. Indeed, fusion experiments with round spermatids harboring an X-linked GFP 
transgene indicate that the spermatidal X chromosome is not reactivated by the ES cell. In 
contrast, fusion of ES cells with somatic XaXi diploid cells results in proper reactivation of the 
inactive X chromosome (Takagi et al., 1983). Therefore, the apparent absence of spermatidal X 
reactivation in our triploid XXY and XXX ES cells indicates the presence of epigenetic differences 
laid down on an Xi during the MSCI and the XCI processes. The Y chromosome is also subject to 
MSCI, but fusion of XX diploid ES cells with a round spermatid containing a Y chromosome does 
result in viable 3n ES cell lines. This shows that the spermatidal autosomes do not affect the 
viability. The Y chromosome has little gene content, compared to the large X chromosome, 
such that possible epigenetic modification of the Y chromosomes by MSCI may not impact on 
the outcome of the fusion process.  
The absence of triploid XYY ES cells can be attributed to these cells having an X:A ratio 
of 0.33, which is probably lower than required for normal viability and growth for ES cells. 
Lethality due to an elevated level of Y chromosome transcripts is not likely, in view of the 
viability of  47,XYY aneuploid male individuals.  Although XYY triploid embryos have been 
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observed to occur in mouse and human, the observed frequencies are much lower than 
expected (Iliopoulos et al., 2005; Uchida and Freeman, 1985). Interestingly, for differentiating 
mouse triploid XXY ES cells we find many cells with a single Xa, indicating that an X 
chromosome under-dosage problem, of one active X per triploid genome, plays a role in 
particular in undifferentiated ES cells or during early embryonic development. Moreover, after 
10 days of EB differentiation of these  XXY triploid ES cells, we found an increase in the relative 
number of XaXiY cells, making up 41% of the total cell population. This indicates that XaXiY is 
the inactivation pattern that results in a cell with the preferred dosage of X-linked genes. This 
observation is supported by previous in vivo experiments, examining XCI in mouse XXY and XXX 
triploid 10 dpc (days post coitum) embryos, which showed that 83% of the cells were XaXiY, 
and 92% of the cells were XaXiXi, respectively (Speirs et al., 1990). Therefore, we conclude that 
mouse triploid cells preferably keep only one of their X chromosomes active. 
The present observation, that after three days of ES cell differentiation 3-4% of XXY 
triploid ES cells have started XCI, provides additional evidence for the hypothesis that the X:A 
ratio indeed determines the probability to initiate XCI. Our studies also show that the XCI 
initiation rate for the differentiating XXY triploid ES cells is too low to allow all cells to 
inactivate one X chromosome within the time span where XCI can be initiated. These cells 
cannot meet the need for speed. 
 
XCI counting and initiation 
The finding that the probability to initiate XCI is proportional to the X:A ratio suggests the 
presence of an X-linked gene encoding an XCI activator, which itself is transcriptionally 
inactivated during the XCI process. During differentiation or development, the nuclear 
concentration of this XCI activator will increase and reach a threshold level required to 
generate a probability to initiate XCI. In cells with a relatively high X:A ratio, the XCI activator 
concentration will reach the threshold level at an earlier time point and will plateau at a higher 
level, and therefore generate a higher probability, compared to cells with a lower X:A.  
Silencing of one of the XCI activator genes in female cells will lead to a drop in the XCI 
activator level equal to that found in male cells, which is not sufficient to initiate XCI on the 
remaining X. Nevertheless, Xist remains expressed on the Xi because its negative regulator Tsix 
is also silenced in cis, allowing a lower XCI activator concentration to maintain Xist expression. 
Persistent expression of Tsix on the Xa results in silencing of Xist on that chromosome. In 
female mice and cell lines with only one functional copy of Xist, XCI will only be initiated on the 
wild type X chromosome. If Tsix is intact on the other X chromosome the non functional Xist 
gene is silenced in cis (Sado et al., 2006). However, in female cell lines heterozygous for a single 
allelic region containing both a non-functional Xist and Tsix gene, the Xist promoter of the 
mutated allele will not be silenced. This explains the reported persistent expression of non-
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functional Xist from the Xa, and the finding that this mutant Xist promoter adopts the same 
chromatin configuration as found for the wild type Xist promoter on the Xi (Ohhata et al., 
2008).  
A stochastic model for XCI, involving an X-encoded XCI activator, assumes that the 
nuclear volume is directly proportional to the ploidy, which in mice is indeed the case (Henery 
and Kaufman, 1992, 1993). We found that triploid XXY ES cells, and tetraploid XXXY and XXXX 
ES cells showed a significant difference in the number of cells that initiated XCI after three days 
of differentiation, supporting the presence of an XCI activator. Moreover, tetraploid XXXX cells 
have initiated XCI after three days of differentiation more effectively than diploid XX cells, 
despite a similar XCI activator concentration (number of X chromosomes per nuclear volume). 
We attribute this difference to the different number of X chromosomes, that each have a 
probability to initiate XCI. This is supported by our simulations, that also show a faster increase 
of tetraploid XXXX cells with one or more Xi’s than the rate of appearance of diploid XX cells 
with an Xi.  
The counting and initiation phase of XCI has also been explained by the presence of an 
autosomally encoded blocking factor or nuclear entity, of which one dose or one functional 
unit is present in the diploid nucleus, preventing inactivation of one X chromosome. We 
advocate that our current and previous findings do not support a blocking factor model for the 
XCI counting and initiation process. Examination of XCI after a 3-day differentiation period of 
the different tetraploid cell lines showed that XCI counting works properly in XXYY tetraploid 
cells, which only sporadically initiate XCI. Nevertheless, for the XXXY and XXXX tetraploid cell 
lines, we found many cells that initiated XCI on the wrong number of X chromosomes, more 
than one in XXXY and more than two in XXXX tetraploid cells (Monkhorst et al., 2008). A 
blocking factor model cannot explain these results because the two functional units of blocking 
factor (present in tetraploid cells) that properly block XCI on both X chromosomes in XXYY cells 
should have done the same in XXXY and XXXX cells, which is not the case. Nevertheless, the 
actual results could be explained if the blocking factor is assembled out of a limiting amount of 
molecules as predicted by the symmetry-breaking model (Nicodemi and Prisco, 2007), which is 
used up with an increasing number of X chromosomes, but a comparison of our results of 
diploid XX cells with triploid XXY cells argues against this possibility. We found a much lower 
number of triploid XXY cells compared to diploid XX cells that initiated XCI at day 3, despite the 
fact that the concentration of the molecules making up the blocking factor would be the same 
in both cell lines.  
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Cellular population dynamics of XCI 
The present simulation studies of XCI indicate that the XCI counting and initiation process can 
be simulated by inclusion of relatively few variable parameters. First, there is a probability to 
initiate XCI for any individual X chromosome. Second, specific Xce alleles respond to different 
nuclear threshold levels of an XCI activator. This is all that is required to explain the initiation of 
XCI. The simulations only tested whether a stochastic model for XCI could explain the available 
and new experimental data. Other models explaining the initiation phase of XCI, including the 
blocking factor, symmetry breaking, and transvection models, hypothesize that XCI is directed 
by a mutual exclusive choice process (Wutz and Gribnau, 2007). Unfortunately, this situation 
could not be simulated in our program. Nevertheless, the simulations based on a stochastic 
model make predictions, some of which we have thoroughly tested and other predictions that 
await further analysis.  
In the computer simulations, we have used ten XCI choice rounds over a 10 day 
differentiation period. However, in vivo the number of choice rounds may be less than ten, 
resulting in more cells with too many Xa’s, which would be selected against. This is supported 
by observations made in female embryos that show a significant number of cells with two Xa’s 
after completion of the X inactivation process (Speirs et al., 1990; Webb et al., 1992). Our 
simulations also predict less cells with too many Xi’s than we detected in vivo, especially for the 
4n XXXX and XXXY cells. This can be explained, if initiation of XCI on the right number of X 
chromosomes does not result in an immediate drop of the XCI activator level below the 
threshold, so that XCI can still be initiated on additional chromosomes until turnover of the XCI 
activator has resulted in a drop below the threshold level. We have not incorporated this 
possibility in our simulation program.  
With regard to embryo development, it is interesting that simulations with 2n XX ES 
cells indicate that the cell number in female diploid XX embryos will be significantly reduced by 
about 12% when compared to male diploid XY embryos (Figure S5, blue box). This is in the 
range of reported size differences between female and male embryos around the time XCI has 
been completed, and before hormonal cues start to influence growth of the embryo (Burgoyne 
et al., 1995). Therefore, this reported in vivo size difference could be explained by female 
specific cell loss as a by-product of the X inactivation process. Furthermore, for female 
homozygous Tsix-stop cells, our simulation showed that almost all the cells are lost during the 
XCI process. In male ES cells the reduction in expected cell number is 88%. This may explain the 
reported sex-ratio distortion in homozygous ΔCpG Tsix knockout mice (Lee, 2002). However, 
the high loss of cells in our simulations of male and female embryos with a homo/hemizygous 
Tsix-stop mutation indicates that these mice will most likely not be viable. Interestingly, viable 
mice, albeit at a lower mendalian ratio, have been reported with a homo/hemizygous ΔCpG 
Tsix knockout allele suggesting that the probability to initiate XCI for this allele is lower than for 
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the Tsix–stop allele used in our simulations (Lee, 2002). This indicates that the ΔCpG Tsix allele 
is a partial knockout of Tsix, which is supported by in vivo studies showing that a hemizygous 
Tsix-stop allele results in a non-viable phenotype, in contrast to the hemizygous ΔCpG Tsix mice 
that are viable and breed (Lee, 2002; Sado et al., 2001). Also, other mutations of Tsix result in 
activation of Xist in male cells upon ES cell differentiation, in contrast to male cells with a ΔCpG 
Tsix mutation that do not show initiation of XCI (Clerc and Avner, 1998; Luikenhuis et al., 2001; 
Morey et al., 2004; Vigneau et al., 2006).  
The XCI activator has not been identified yet. However, several lines of evidence 
indicate that it acts through Xist, and could be a protein or RNA involved in activation and/or 
stabilization of Xist (Monkhorst et al., 2008). Studies with different Tsix mutant cell lines 
suggest that, in mice, Tsix plays a crucial role in determining the XCI activator level required for 
generating a probability to initiate XCI by suppression of Xist. In addition, chromatin 
modifications of the Xist promoter may also play a role in determining the threshold, which 
might be even more relevant in human were the presence and function of TSIX are still 
speculative. Identification and characterization of the XCI activator, and factors involved in 
setting up the threshold, will be of crucial importance for a better understanding of the 
initiation phase of XCI. 
 
 
 
Materials and Methods 
 
Culture and differentiation of ES cells 
ES cells were cultured in DMEM supplemented with 15% heat inactivated foetal calf serum, 
100 U ml-1 penicillin, 100 mg ml-1 streptomycin, non-essential amino acids, 1000 U/ml 
leukaemia inhibitory factor (LIF) and 0,1 mM β-mercaptoethanol. ES cells were grown on a 
layer of male mouse embryonic fibroblast (MEF) feeder cells. To induce differentiation into EBs, 
ES cells were pre-plated for 60 minutes and non-adherent ES cells were transferred to non-
gelatinized bacterial culture dishes without feeder cells in differentiation medium, IMDM 
Glutamax, 15% heat inactivated foetal calf serum, 50 μg/ml ascorbic acid, 100 U ml-1 penicillin, 
100 mg ml-1 streptomycin, 37.8 μl/l monothioglycerol.  
 
Mice and staput isolation of round spermatids 
All animals were treated in accordance with guidelines of the Erasmus MC, Rotterdam, the 
Netherlands. Testes from two Ube2a homozygous mutant mice and two Ube2b heterozygous 
mutant mice were excised and decapsulated to remove the tunica albuginea. Decapsulated 
testes were pooled in 20 ml PBS (140 mM NaCL, 3 mM KCl, 1.5 mM KH2PO, 8 mM NaH2PO4) / 
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1.1 mM Ca2+/ 0.5 mM Mg2+/ 12 mM lactate (Sigma-Aldrich) of 34ºC, containing 10mg 
hyaluronidase (from ovine testes, Roche-Diagnostics), 20mg trypsin (from bovine pancreas, 
Roche-Diagnostics) and 20 mg collagenase A (Roche-Diagnostics). Testes were shaken for 20 
minutes at 90 rpm with 10 mm amplitude to release seminiferous tubuli from interstitial cells. 
Tubuli were collected by centrifugation for 3 minutes at 2000 rpm and resuspended in 34ºC 
PBS/ 12 mM lactate. After shaking 10 minutes at 120 rpm with 10 mm amplitude to release 
germinal cells from the tubuli, tubuli remnants were removed. Germinal cells were collected by 
centrifugation and resuspended in 34ºC PBS/ 1.1 mM Ca2+/ 0.5 mM Mg2+/ 12 mM lactate. The 
cell suspension was filtrated using a 60 μm filtration cloth. Germinal cells were collected by 
centrifugation and resuspended in 50 ml PBS/ 1.1 mM Ca2+/ 0.5 mM Mg2+/ 12 mM lactate/ 
0.5% w/v BSA. Cells were separated by sedimentation velocity at unit gravity in a 1-4% w/v BSA 
gradient at room temperature. First 20 ml PBS/ 1,1 mM Ca2+/ 0.5 mM Mg2+/ 12 mM lactate was 
bottom-loaded in a chamber, followed by 50 ml cell suspension. A BSA gradient was created by 
loading a total of 500 ml of 1%, 2% and 4% w/v BSA in PBS. Cells were allowed to sediment for 
2 hours. The chamber was emptied in 8 ml fractions using a fraction collector, and fractions 
containing peak amounts of cells were identified using a 340 nm UV light source. Fractions 
containing round spermatids were pooled, collected by centrifugation and resuspended in PBS/ 
1.1 mM Ca2+/ 0.5 mM Mg2+/ 12 mM lactate. Purity of round spermatid preparations derived by 
this procedure were shown to be >90%, as determined by microscopic analysis of an aliquot of 
purified cells fixed in Bouins’ fixative on glass slides (Baarends et al., 2003).  
 
Fusion experiments 
Mus musculus castaneus/ 129/Sv F1 (F1-2 1) female and C57Bl6/ 129/Sv (V6.5) male ES cell-
lines were separated from MEF feeder cells by trypsinizing and preplating for 45 minutes on 
uncoated culture dishes. PEG1500 fusion was performed according to the manufacturer’s 
instructions (Invitrogen). Briefly, 4·106 cells were combined with 4·106 round spermatids in 
DMEM. After centrifugation, cells were resuspended in 300μl 50% v/v PEG1500 and incubated 
for 2 minutes at 37ºC under continuous stirring. The mixture was gradually diluted with serum 
containing medium and plated on drug-resistant MEF feeder cells. After 24 hours medium was 
replaced with medium containing 0.3 μg/ml neomycin and 2 μg/ ml puromycin. After nine 
days, individual ES cell colonies were picked, trypsinized and plated on individual culture dishes 
in neomycin and puromycin containing medium. 
 
Cell cycle block 
ES cells were EB differentiated for one or two days and then blocked in the cell cycle by adding 
0.75 mM mimosine, 12µl/ml colcemid (KaryoMax, Gibco) or 2100centiGray γ-irradiation. Cells 
were fixed one day after applying the cell cycle block. 
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Karyotyping 
ES cells were blocked in metaphase by incubation in medium containing 0.12 μg/ml  colcemid 
for 1 hour. Cells were trypsinized and resuspended in 5 ml 0.075 M KCl at 37ºC, collected and 
resuspended in 0.0625M KCl/ 12.5% methanol/ 4.17% acetic acid. Cells were fixed by washing 
three times in 75% methanol/ 25% acetic acid and stored in 200μl at 4ºC. The fixed cell 
suspension was spotted on ethanol cleaned slides and air dried. For determining the total 
number of chromosomes slides were mounted with 20 μl Dapi vectashield.  
To determine the number of X chromosomes, slides were denatured by a  three minute 
incubation at 80ºC in 100 μl 50% formamide/ 2x SSC/ 10 mM phosphate buffer. Subsequently 
slides were dehydrated, and hybridized overnight at 37ºC with a Cy3 labelled X-paint probe 
(Cambio). After hybridization, slides were washed once with 2xSSC at 45ºC, three times with 
2xSSC/ 50% formamide at 45ºC and two times with PBS. Slides were dehydrated through 
ethanol steps (70%, 90% and 100%) air-dried and mounted with 20 μl dapi vectashield. For 
determining the number of Y chromosomes, Y-chromosome paint (Cambio) was applied, 
following the same protocol as for the X chromosome paint. 
 
RNA-FISH analysis 
One day prior to fixation, non-adherent EBs were trypsinized and differentiated ES cells were 
grown on gelatin-coated cover slips. Cells were rinsed once with PBS and permeabilized by 
successive incubation in cytoskeletal buffer (100 mM NaCl, 300 mM sucrose, 3 μM MgCl2, 10 
mM PIPES pH 6.8 in H2O) for 30 seconds, cytoskeletal buffer containing detergent (0.5% triton 
X-100, 100 mM NaCl, 300 mM sucrose, 3 μM MgCl2, 10 mM PIPES pH 6.8 in H2O) for 2 minutes 
and cytoskeletal buffer for 30 seconds. Cells were fixed in 4% paraformaldehyde/PBS for 10 
minutes, rinsed three times with 70% ethanol and stored in 70% ethanol at 4ºC.  
The Xist probe was a digoxygenin labelled 5.5 kb cDNA sequence (Monkhorst et al., 
2008). To suppress repetitive sequences 25 μg/ml mouse Cot1 DNA was added and probe 
mixture was incubated at 95ºC for 5 minutes and at 37ºC for 45 minutes. After overnight 
hybridization at 37ºC, slides were washed in 2xSSC at 37ºC for 5 minutes, and three times in 
50% formamide/ 2xSSC at 37ºC for 10 minutes. Probe detection was performed at room 
temperature. Detection was with a sheep anti-digoxigenin antibody (Roche diagnosics), 
followed by a FITC labelled rabbit anti-sheep antibody (Jackson labs) and a FITC labelled goat 
anti-rabbit antibody (Jackson labs), each for 30 minutes, in 100 mM Tris pH 7.5/ saline/ Tween, 
BSA. After detection cover slips were dehydrated and mounted on a slide in Vectashield and 
DAPI to counter stain DNA. To determine the number of inactive X chromosomes in a cell, a 
non-overlapped intact nucleus was selected, and the number of Xist clouds were scored.  
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BrdU analysis 
For BrdU analysis, differentiated ES cells of trypsinized non-adherent EBs were grown on 
gelatin-coated cover slips in the presence of 20 µM BrdU, and fixed as described in the RNA-
FISH section. Cover slips were dehydrated, air-dried and denatured in 70% formamid/ 2x SSC/ 
50 mM phosphate for 3 minutes at 85ºC. Coverslips were washed in ice cold 70% ethanol and 
through 70%, 90% and 100% ethanol washes and air dried after which the Xist probe was 
applied. Detection of Xist RNA was as described in the previous section, detection of BrdU was 
performed with a mouse monoclonal BrdU antibody (DAKO), followed by a rhodamin labelled 
donkey anti-mouse antibody (Jackson labs), 30 minutes incubation each. 
To determine the number of BrdU labelled cells for the XaXaY and XaXiY cell 
populations, first a microscope field was selected, containing one or more intact nuclei with an 
Xist cloud. Within this field, the number of cells containing an Xist cloud with negative or 
positive BrdU staining was determined. Subsequently this was also done for all cells without an 
Xist cloud in the same microscopic field. 
 
DNA-FISH analysis 
For DNA-FISH, cells were fixed as for RNA-FISH, and pretreated for 4 min with 0.5% pepsin in 
10mM HCl at 37°C, post fixed for 5 minutes in 4% paraformaldehyde/PBS, washed twice with 
PBS, and dehydrated prior to denaturation. Denaturation of target sequences was as described 
in the BrdU analysis section. Cover slips were incubated with a combination of two biotin-
labelled BACs (CT7-155J2 and CT7-474E4) at 37ºC overnight. BACs were detected using mouse 
anti-biotin (Roche diagnostics) and donkey anti-mouse antibodies (Jackson labs) as described 
for RNA FISH. To determine the number of X chromosomes, non-overlapping nuclei were 
selected and the number of signals per nucleus was determined. 
 
Genotyping and RT PCR analysis 
For genotyping the mutant Ube2b allele was amplified with primers 
CTTTACGGTATCGCCGCTCCCGAT, TTGAAATCCCGCATGAGC, and CGGAGGGAGACGTCATTG. For 
RT-PCR RNA was isolated with Trizol reagent, treated with RNAse free DNAse and reverse 
transcribed (all Invitrogen). Xist RNA was amplified with primers ACTGGGTCTTCAGCGTGA, and 
GGGAATAGGTAAGACACACTG spanning intron 6, which amplify a length polymorphism in exon 
7 (129/Sv fragment is 888 bp, Cast/Ei fragment is 845 bp). 
 
Stochastic simulations 
Stochastic simulations were performed in a SQL based program (the source code can be found 
in Supplemental Text 1), using 10 Z-stacks, and 100 starting cells. The program allows the use 
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of different probabilities in time, a different number of X chromosomes per cell, and a different 
rate of cell division depending on the number of Xi’s. 
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Abstract 
 
Background 
X chromosome inactivation (XCI) is a mechanism specifically initiated in female cells to silence 
one of their X chromosomes, thereby equalizing the dose of X-linked gene products between 
male and female cells. XCI is regulated by a locus on the X chromosome termed the X-
inactivation center (XIC). Located within the XIC is XIST, which acts as a master regulator of XCI. 
During XCI, XIST is up-regulated on the inactive X chromosome and chromosome-wide cis 
spreading of XIST leads to inactivation. In mouse, the Xic comprises Xist and all cis-regulatory 
elements and genes involved in Xist regulation. The activity of the Xic is regulated by trans-
acting factors  located elsewhere in the genome: X-encoded XCI activators positively regulating 
XCI, and autosomally encoded XCI inhibitors providing the threshold for XCI initiation.  
 
Methods and results 
Whether human XCI is regulated through a similar mechanism, involving trans-regulatory 
factors acting on the XIC has remained elusive so far. Here, we describe a female individual 
with ovarian dysgenesis and a small X chromosomal deletion of the XIC. SNP-array and 
Targeted Locus Amplification  (TLA) analyses define the deletion to a 1.28 megabase region, 
including XIST and all elements and genes that perform cis-regulatory functions in mouse XCI. 
Cells carrying this deletion still initiate XCI on the unaffected X chromosome, indicating that XCI 
can be initiated in the absence of two XICs.  
 
Conclusions 
Our results indicate that the trans-acting factors required for XCI initiation are located outside 
the deletion, providing evidence that the regulatory mechanisms of XCI are conserved between 
mouse and human.  
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Introduction 
 
In all XX female somatic cells one X chromosome is inactivated, to balance X-chromosomal 
gene activity to XY males (Lyon, 1961). X chromosome inactivation (XCI) is initiated early during 
embryogenesis, where all cells of the female embryo proper randomly initiate inactivation of 
either the paternal or the maternal X chromosome. After the inactive state is established, the 
inactive X (Xi) is clonally passed on to all daughter cells. As a result, all females are a mosaic of 
cells with an active paternal X chromosome and cells with an active maternal X chromosome. 
Genetic studies identified a region on the X chromosome to be required for XCI. In 
human, this X inactivation center (XIC) has been mapped to a 680-1200 kb region at 
chromosome Xq13 (Allderdice et al., 1978; Lafreniere et al., 1993; Leppig et al., 1993). In 
mouse, the Xic is less well defined and has been mapped to a 10-20 Mb region on the X 
chromosome (Rastan and Robertson, 1985; Russell, 1963). The genes that constitute the 
XIC/Xic are conserved in eutherians, and many of them are long non-coding RNA (lncRNA) 
genes. The lncRNA gene XIST/Xist  is located within the XIC/Xic and plays a key role in XCI in 
human and mouse (Brockdorff et al., 1991; Brown et al., 1991a). Initiation of XCI is 
characterized by XIST/Xist up-regulation on the future Xi, resulting in cis spreading of XIST/Xist 
RNA, which recruits chromatin remodeling complexes that silence the X chromosome 
(Brockdorff et al., 1992). In mouse, several other lncRNA genes located within the Xic are 
involved in the regulation of XCI, through co-activation and -repression mechanisms that 
predominantly act in-cis to regulate Xist (Barakat et al., 2014; Chureau et al., 2011; Lee et al., 
1999; Nora et al., 2012; Tian et al., 2010). Female exclusive initiation of XCI is regulated by X-
encoded trans-acting XCI activators (Monkhorst et al., 2008). To date the only known XCI 
activator is RING finger protein 12 (Rnf12, also known as RING finger LIM domain interacting 
protein Rlim) (Jonkers et al., 2009; Shin et al., 2010). Rnf12 encodes an E3-ubiquitin ligase that 
targets REX1, a repressor of Xist, for proteasomal degradation (Gontan et al., 2012). Only in 
cells with more than one X chromosome present in the nucleus the XCI activator concentration 
is high enough to initiate XCI.  
In human, the regulation of XCI is less clear. Although the XIC has been localized, the 
requirement for trans-regulatory mechanisms has not been studied. To examine whether in 
human XCI is also regulated by trans-regulatory cues acting on the XIC, harboring all the cis-
regulatory information to direct XIST expression, we have identified and studied a female 
carrier with a deletion of the XIC. 
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Results 
 
A 26 year old,  intellectually normal, non-dysmorphic woman presented with primary 
amenorrhea, and was diagnosed with hypergonadotropic ovarian failure due to ovarian 
dysgenesis, also known as premature ovarian insufficiency (POI). Blood examination showed 
increased FSH levels (> 40 IU/l), with decreased estrogen (< 60 pmol/l). Height was between 
the 75th-90th centile and no stigmata of Turner syndrome were evident on examination.  
External genitalia were unambiguously female.  Breast development, pubic and axillary hair 
distribution were normal female at the time of examination following several years on oral 
contraceptive hormone treatment.  On transvaginal ultrasound examination a small uterus was 
visible, measuring 1,9 x 0,9 x 1,4 cm, with hypoplastic endometrium of 0,1 mm thick. No clear 
ovarian tissue was identified, however an area of thickening without antral follicles 0.6cm in 
length was seen in the left ovarian fossa and a similar region 1cm in length, in the right ovarian 
fossa.  Karyotype analysis of blood cells showed a normal 46XX karyotype. DNA was isolated 
from peripheral blood and was used for molecular SNP karyotyping, using the Human 
OmniExpress-24 SNP-array from Illumina. Several copy number changes were identified, with 
the largest being a 1.08-1.24 Mb deletion on chromosome Xq13, encompassing the XIC (Fig. 1a 
and supplemental table 1). The centromeric breakpoint was located in a 148 kb long segment 
between SNPs rs6650032 and rs6650032. This region is characterized by a large inverted 
segmental duplication, including DMRTC1 and DMRTC1b, complicating the precise mapping of 
this breakpoint (Fig. 1b). The location of this breakpoint determines if the duplication is intact 
and present as two copies of DMRTC1 and DMRTC1b, or partially deleted and consequently 
present as a single copy of DMRTC1 on the affected X. The telomeric breakpoint of this region 
was located in a 17 kb region, delineated by SNPs rs12688161 and rs5981589. 
A deletion encompassing the XIC and as small as this, has not been reported before, 
which prompted us to study this deletion in detail. We therefore characterized the breakpoint 
regions by qPCR to determine the copy number at consecutive positions along the breakpoint 
regions. As a control, DNA from a healthy female and a healthy male was used. Primer sets and 
their chromosomal locations are listed in supplemental methods 1. QPCR analysis along the 
inverted duplication of the centromeric breakpoint region, detected two copies centromeric of 
the duplication, and one copy telomeric of DMRTC1. Three qPCR amplicons within the 
duplication all indicated the presence of 1.5 copies, suggesting the breakpoint is located in the 
middle of the duplication (Fig. 1b). Through performing qPCR along the telomeric breakpoint 
region, the deletion was found to extend approximately 40 kb beyond the region identified by 
SNP-array analysis (Fig. 1b). To map the deletion at the single nucleotide level, Targeted Locus 
Amplification (TLA) was performed on frozen lymfoblastoid cells . The TLA technology enables  
results in the sequencing of all sequences that occur in physical proximity to a primer pair used  
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Figure 1. 
 XIC deletion identified by SNP-array and qPCR. 
a. The XIC deletion as identified by CGH. At the top a schematic representation of the X chromosome is 
shown, with the deleted region marked in red. Below, a magnification of chromosome Xq13 and SNP-
array results for this region is shown. In the upper graph the signal intensity of each probe is plotted 
against its chromosomal position. The deleted region is marked in red. The green line depicts the 
average intensity. The lower graph displays B allele frequency for each probe.  
b. Comparison of qPCR results to CGH. A magnification is shown of the regions containing the 
breakpoints. The top panel shows qPCR results along the breakpoint regions, with copy number 
plotted  against chromosomal position. In the map of the chromosomal region below, the inverted 
duplication in the centromeric breakpoint region is marked in blue. The two panels at the bottom 
show the CGH results for the breakpoint regions. 
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 for targeted amplification. Using this technology we found an increase in coverage in the 
center of the inverted duplication, indicating the position of the centromeric breakpoint (Fig. 
2a,b).  
Among the obtained reads the break-spanning read was also identified (Fig. 2c). The 
flanking sequence of the centromeric breakpoint maps to both duplicons of the inverted 
duplication, but the orientation of the sequence corresponds to the telomeric duplicon. This 
maps the deletion to ChrX: 72.080.568-73.367.054 (hg19), a region of 1,28 Mb and among the 
genes involved in the deletion are XIST, TSIX and other cis-regulatory sequences (Supplemental 
table 2).  
The deletion was confirmed by DNA-FISH, using several BACs mapping to different 
regions of the X chromosome. DNA-FISH using BACs containing PHKA2 or RNF12 confirmed the 
presence of two X chromosomes in all nuclei, while DNA-FISH using BACS covering XIST or JPX 
showed the presence of these regions on only one X chromosome in all cells (Fig. 3a). 
 
 
 
 
 
 
Figure 2. 
XIC deletion identified by TLA 
a. TLA coverage is plotted against chromosomal position. Arrow indicates the location of the primer sets. 
Star indicates the increase in coverage on the other side of the deleted region. A genetic map of the 
region is shown below, with the inverted duplication in blue.  
b. Magnification of the centromeric breakpoint region.  
c. The break-spanning read, with sequence centromeric of the breakpoint marked in blue and the 
sequence telomeric of the breakpoint marked in green. 
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Figure 3. 
The X chromosome carrying the deletion is preferentially active 
a.  Shown is a map of the X chromosome with the location of the BAC probes indicated in blue (top). The 
location of the deletion identified by SNP-array and TLA is marked in red. Below, representative 
images of DNA-FISH for regions located inside or outside the deleted region are shown. BACs CTD-
2310H21, CTD-2183M22, RP13-36G14, and CTD 2530H13, cover PHKA2, XIST JPX, and RNF12, 
respectively. At least 30 metaphases were analyzed.  
b. Representative pictures of sequential RNA-DNA-FISH experiments. Two representative nuclei are 
shown with RNA-FISH results for XIST RNA (green), and DNA-FISH results for BAC RP13-36G14 in blue 
and BACs CTD-2310H21 in red. The table shows the percentage of nuclei with overlapping signals of 
XIST RNA and BAC RP13-36G14 DNA. 
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XCI was analyzed by XIST RNA-FISH on cells from a lymfoblastoid cell line of the patient. All 
examined cells contained an XIST RNA cloud, indicating XCI is initiated in with the presence of 
the 1,28 Mb deletion (Fig 3b). Allele specific methylation analysis of FMR, on DNA isolated of 
peripheral blood, showed predominant inactivation of one allele (93:7%), indicating that XCI is 
severely skewed in the patient. To determine which X chromosome was inactivated sequential 
DNA-RNA FISH was performed for XIST RNA and the JPX locus, included in the deletion. XIST 
RNA domains co-localized with the JPX locus of the unaffected X chromosome in most cells, 
indicating the preferential inactivation of the unaffected X chromosome (Fig. 3b).  
 
 
 
Discussion 
 
Our results indicate complete skewing of XCI, with the affected X chromosome remaining 
active. Therefore this deletion could possibly be involved in the ovarian dysgenesis of the 
female individual described here. Prior work has implicated chromosome Xq13, harboring the 
XIC, in amenorrhea, as several cases have been described with a breakpoint in this region and 
primary amenorrhea and various signs of Turner syndrome (Therman and Susman, 1990). Even 
though the XIC deletion was the most likely candidate region, all copy number changes were 
assessed for candidate genes possibly causing the ovarian phenotype. All genes affected by 
copy number changes were screened by Gene Ontology (GO) analysis using the AmiGO 2 
browser. GO terms involved in gonadal functioning or gonadal development, revealed one 
candidate gene: DMRT-like family C1 (DMRTC1), implicated in sex differentiation, and included 
in the 1.28Mb deletion studied here. Little is known about DMRTC1 itself. It is part of the 
Doublesex and Mab-3 Related Transcription factor (DMRT) gene family, involved in sex-
determination in vertebrates. DMRT1, has been extensively studied, and loss of one copy of 
human DMRT1 results in defective testicular development and XY male-to-female sex reversal. 
No studies regarding DMRTC1 functioning in human are published. However, of the three 
mouse homologs of DMRTC1, Dmrt8.3 is expressed in XX germ cells of the embryonic ovary, 
from embryonic day 13,5 onwards, suggesting involvement in meiosis (Chen et al., 2012). 
Taken together, a role for DMRTC1 in ovarian development is likely, and it can be hypothesized 
that the deletion of one of the two copies present on the X chromosome causes ovarian 
dysgenesis in the individual described here. XCI is 100% skewed and as a result cells carrying 
the XIC deletion will contain only one active copy of DMRTC1/DMRTC1b instead of two, which 
might result in a dosage deficiency for DMRTC1/DMRTC1b (Fig. 4), leading to ovarian 
dysgenesis.  
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Our results demonstrate that in the presence of the 1.28Mb deletion, XCI can still occur 
on the unaffected X chromosome. Therefore, the deletion extending from FTX to the first 
duplicon of DMRTC1, does not affect the trans-regulation of XCI, but most likely covers most 
elements and genes involved in cis-regulation of human XCI. The identified deletion, and the 
absence of an X-inactivation phenotype resemble the ΔXTX and Δ(Xite-Dxmit171) deletions 
that were studied in mouse ES cells (Barakat et al., 2014; Monkhorst et al., 2008). The ΔXTX 
deletion involves only Xist, Tsix and Xite, whereas the Δ(Xite-Dxmit171) deletion also includes 
the neighboring regulators Jpx and Ftx. ES cells carrying heterozygous ΔXTX and Δ(Xite-
Dxmit171) deletions, inactivate the wildtype X chromosome, at a rate comparable to wildtype 
ES cells, indicating all trans-acting factors are present. These results and the present human 
deletion indicate that JPX, and other sequences including TSIX, previously implicated in trans-
regulation of XCI, through X-pairing and RNA mediated recruitment mechanisms, are not 
required to properly initiate the human XCI process (Tian et al., 2010; Xu et al., 2006). Whether 
the deletion described here, represents the entire cis-acting XIC remains elusive. This human  
 
 
 
 
 
 
Figure 4. 
In-cis deletion of the cis-XIC and DMRTC1 results in DMRTC1 dose deficiency. 
a. Normal situation: A schematic representation of two X chromosomes after X-inactivation is shown. 
Two copies of DMRTC1 remain active.  
b. In-cis deletion of the XIC and DMRTC1: As a result of the deletion the unaffected X chromosome is 
preferentially inactivated, and only one copy of DMRTC1 remains active. 
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cis-XIC is most likely delineated by the Topologically Associating Domain(s) (TAD) XIST, and its 
regulatory elements are embedded in. TADs were identified by studies examining the higher 
order chromatin structure, which indicated limitation of special interactions in cis domains of 
~1Mb in size (Dixon et al., 2012; Nora et al., 2012). Analysis of available data on TADs in human 
H1 male ES cells and IMR90 female fibroblasts, indicates that the human XIC of H1 ES cells is 
included in a single large TAD, ranging from DMRTC1 to RNF12, not including RNF12 (Dixon et 
al., 2012). In human IMR90 fibroblasts containing an Xi, this putative cis-XIC is divided in two 
smaller TADS with the boundary at the XIST/TSIX locus which now includes RNF12, similar to 
mouse (Fig. 5). This change in higher order topology might be instructive in XCI and considering 
these data, the human XIC might extend beyond the studied deletion from DMRTC1 to FTX, 
and might include RNF12. 
In the female individual described here RNF12 is not included in the deletion and still 
present on both X chromosomes, in support of a role for RNF12 as trans-acting activator of 
human XCI (Fig. 3a). Such a role is  further supported by a recent finding that female carriers of 
a mutation in RNF12, show exclusive XCI of the mutated X (Tonne et al., 2015). These results  
are concordant with mouse studies that show that one functional copy of Rnf12 is required for 
establishment of the inactive X chromosome (Barakat et al., 2014).  
 
 
 
 
 
 
Figure 5. 
Deletions delineating the human XIC 
a. Graph of the chromosomal abnormalities used to define the XIC. Black bars indicate the sequence 
present on the abnormal X chromosome. From top to bottom: the rea(X) of female S.A., the idic(Xp) of 
female A.G., the X;14 translocation chromosome from a 47XXY male, and the cis-XIC deletion reported 
here. Below, a map of the X chromosomal region Xq13.  
b. The topological domains as identified in female IMR90 fibroblasts and male H1 human ES cells. 
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Mouse studies also hinted at the presence of additional XCI activators besides Rnf12, as 
ES cells carrying a heterozygous Rnf12 deletion still initiate XCI, although at a reduced 
frequency (Barakat et al., 2011; Shin et al., 2010). Interestingly, also in humans a hint towards 
the presence and location of multiple human trans-acting factors is provided by previous 
studies involving the identification of the XIC. The human XIC was defined by genetic studies 
involving large X chromosomal abnormalities resulting from truncations and translocations. At 
first the XIC was delineated by an X;14 translocation in an XXY male and the breakpoint of an 
idic(X) (Allderdice et al., 1978; Brown et al., 1991b; Lafreniere et al., 1993). Based on these 
rearrangements the XIC was estimated to measure at least 0.8 Mb in size with a maximum of 
2.89 Mb (Fig. 5). Later the telomeric boundary was redefined by the rea(X), reducing the 
estimated size of the XIC to 0.68-1.2 Mb (Leppig et al., 1993). In all these individuals XCI is still 
initiated, leading to inactivation of the X;14 translocation product, or the mutated idic(X) and 
rea(X) X chromosomes, demonstrating the presence of sufficient levels of XCI activators for 
initiation of XCI. Interestingly, the rea(X) does not contain an intact copy of RNF12. This 
suggests that a single copy of RNF12 is sufficient to initiate XCI, as is found in mouse ES cells, 
and that other human trans-acting activators exist and are located on the proportion of the X 
chromosome not deleted from rea(X).  
In summary, our study indicates that XCI is normally initiated in a female carrier with a 
1.28 Mb deletion of the XIC. Our findings also show that the trans-acting information required 
for female specific initiation of XCI is located outside the reported deletion, and highlight the 
evolutionary conservation of pathways and mechanisms involved in regulation of XCI in 
eutherians.  
 
 
 
Material and Methods 
 
Targeted Locus Amplification 
Cross-linked chromatin,  was fragmented and re-ligated, and two sets of primer pairs were 
designed for the sequence telomeric of the deletion, and used in individual TLA amplifications 
according to (de Vree et al., 2014). PCR products were purified and pooled, prepared for 
sequencing using the Illumina NexteraXT protocol, and sequenced on an Illumina Miseq 
sequencer. Reads were mapped using a BWA-SW algorithm allowing partial mapping. In case of 
a deletion existing interactions with the deleted region are abolished and new interactions with 
the new neighboring sequence are produced.  
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DNA-FISH 
Cells were arrested in metaphase using Colcemid for 2 hours, treated with 0,075M KCl, and 
fixed with methanol/ acetic acid.  Slides were dehydrated, denatured and incubated with probe 
mixture as described in (Jonkers et al., 2009). Probes, indicated in Fig 3a, were detected with a 
FITC conjugated mouse-anti-digoxigenin antibody or Alexa 594 conjugated Streptavidin. 
Metaphase spreads were first identified in DAPI and subsequently the number of red and 
green foci were counted. 
 
DNA-RNA-FISH 
Cytospin preparations were prepared and cells were fixed with 4% PFA, and RNA-FISH was 
performed as described before (Monkhorst et al., 2008). Cells were analyzed for presence of an 
XIST RNA cloud and photographs were taken. Subsequently slides were subject to DNA-FISH. 
Cells were denatured and incubated with probe mixture and detected with a FITC conjugated 
mouse-anti-digoxigenin antibody or Alexa 594 conjugated Streptavidin. Cells analyzed for RNA-
FISH were re-analyzed for a DNA-FISH signal. Pictures from DNA-FISH and RNA-FISH were 
overlaid and scored for co-localization of signals. 
 
RT-PCR 
Quantitative RT-PCR was performed using Platinum Taq DNA polymerase (Life technologies), 
SYBR green (Sigma Aldrich) according to manufacturer’s instructions, using primers listed in the 
Supplemental methods 1. 
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Abstract 
 
Background 
X-linked intellectual disability (XLID) affects 1-2% of the general population, but the genetic 
defect causing XLID is unknown for a large number of families. Several recent publications 
reported the co-segregation of XLID with mutations in RNF12, accompanied by skewed X 
chromosome inactivation (XCI) ratios in carrier females. However, a functional effect of these 
mutations has not been shown yet. RNF12 is a E3 ubiquitin-ligase with several known targets.  
 
Methods and results 
Here, we present three families with mutations in RNF12 that segregate with XLID and skewed 
XCI. The identified mutations lead to altered ubiquitination activities and substrate binding 
capacities. Despite these changes in functional characteristics, changes in protein levels of its 
target REX1 could not be detected. 
 
Conclusions 
Our findings indicate that the three different mutations result in hypomorphic alleles. This 
might explain the observed XLID phenotype and skewed XCI. 
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Introduction 
 
Intellectual disability (ID) is a neurodevelopmental disorder that is characterized by impaired 
intellectual functioning (generally defined as an IQ < 70) and by impaired adaptive behavior. Its 
onset during childhood or adolescence discriminates ID from adult neurodegenerative 
disorders like Alzheimer’s disease. ID is estimated to affect 1-2% of the general population 
(Ellison et al., 2013; Leonard and Wen, 2002). X-linked intellectual disabilities (XLID) are forms 
of intellectual disability , characterized by a pattern of X-linked inheritance and thought to 
account for 10-12% of all male IDs (Ropers and Hamel, 2005). The attention for XLID was 
originally raised by the observations that ID is more prevalent among men than women and by 
reports of large pedigrees showing X-linked inheritance of ID. Over the last decades the 
number of identified X-encoded genes that cause XLID when mutated has grown substantially, 
and momentarily over 100 XLID genes have been identified (Piton et al., 2013). However, the 
potential number of XLID is estimated much higher given that around 40% of the protein-
coding genes of the X chromosome are expressed in brain (Ropers, 2006). Indeed, in a large 
number of XLID families the molecular cause remains unidentified, and to identify new genetic 
causes of XLID a recent study performed exome-sequencing in probands of 405 families with 
unresolved XLID (Hu et al., 2015). In two families mutations in RNF12 were identified, that co-
segregate with XLID. This observation was confirmed by two other studies also describing the 
segregation of RNF12 mutations with an XLID phenotype (Rodriguez Criado, 2012; Tonne et al., 
2015). However, while all studies observed co-segregation of RNF12 mutations with XLID, they 
did not show any functional effect of the observed mutations. 
RNF12 is an E3 ubiquitin ligase, targeting other proteins for proteasomal degradation 
through poly-ubiquitination. The function of Rnf12 has been thoroughly studied in mice, and 
was originally identified as a negative regulator of the LIM-homeodomain transcription factors, 
as it was shown to target co-factors LDB1 and LDB2 for proteasomal degradation (Bach et al., 
1999; Ostendorff et al., 2002). Later studies implicated a role for RNF12 in many other 
processes, including telomere length homeostasis, through the ubiquitination-mediated 
degradation of TRF1, and cell proliferation through the targeted degradation of Stathmin (Chen 
et al., 2014; Her and Chung, 2009). RNF12 also affects TGF-β family signaling by targeting 
SMAD7 and SMURF2 for proteasomal degradation. Furthermore, RNF12 affects expression of 
Estrogen responsive genes through the ubiquitination of Estrogen Receptor alpha (ERα) (Huang 
et al., 2011; Johnsen et al., 2009; Zhang et al., 2012). In addition, RNF12 has been identified as 
an important activator of X chromosome inactivation (XCI) in mouse (Gontan et al., 2012; 
Jonkers et al., 2009). 
XCI is an epigenetic process that compensates the genetic imbalance between XX 
females and XY males by inactivation of one X chromosome in every female cell (Lyon, 1961). 
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XCI is initiated around gastrulation in the early female embryo, and is random with respect to 
the parental origin of the X chromosomes. After the inactive X chromosome (Xi) is established, 
this inactive state is clonally passed on to all daughter cells. As a result of XCI, every female 
individual is a mosaic of two cell populations that carry either an inactive paternal X 
chromosome or an inactive maternal X chromosome (Beutler et al., 1962). In most females the 
ratio between cells with an inactive paternal X chromosome and an inactive maternal X 
chromosome is 50:50, but skewed XCI where more than 80% of the cells have inactivated the 
same X chromosome is common (Amos-Landgraf et al., 2006). It is thought that skewed XCI can 
ameliorate disease phenotypes in female carriers of X-encoded mutations by preferentially 
inactivating the X chromosome carrying the affected allele (Archer et al., 2007; Martorell et al., 
2011). 
RNF12 was identified as an activator of XCI in mouse, with most studies of the genetic 
elements involved in XCI being performed in mice and mouse embryonic stem cells. In mouse, 
XCI is regulated from a locus on the X chromosome termed the X-inactivation center (Xic) 
(Rastan, 1983; Rastan and Robertson, 1985). The mouse Xic can be divided in a cis-acting part 
required for cis inactivation of the X chromosome, and a trans-acting part that ensures 
inactivation of the correct number of X chromosomes in a cell (Gribnau and Grootegoed, 2012). 
The cis-Xic harbors the two antisense non-coding genes Xist and Tsix. Xist produces a non-
coding RNA that accumulates on the future Xi in-cis and is required for inactivation, while Tsix 
acts as a repressor of Xist (Brockdorff et al., 1992; Lee et al., 1999; Lee and Lu, 1999; Penny et 
al., 1996). The trans-Xic contains inhibitors of XCI and trans-acting activators that ensure 
proper counting of the number of X chromosomes in relation to the ploidy of a cell and the 
inactivation of the correct amount of X chromosomes. To date, RNF12 is the only trans-acting 
activator that has been identified (Jonkers et al., 2009). RNF12 activates XCI by targeting the 
XCI inhibitor REX1 for proteasomal degradation via poly-ubiquitination, resulting in the 
upregulation of Xist (Gontan et al., 2012). Intact Rnf12 is essential for counting the number of 
active X chromosomes as the introduction of additional copies of Rnf12 coding sequences in 
mouse ES cells results in ectopic XCI (Jonkers et al., 2009). In addition, Rnf12 provides feedback 
of XCI via its own inactivation, which lowers the concentration of RNF12 and prevents 
inactivation of the second X chromosome (Gontan et al., 2012). One allele of Rnf12 needs to 
remain active to establish the Xi (Barakat et al., 2014). 
The elements of the mouse Xic, including Xist, Tsix and Rnf12 are conserved from 
mouse to human, and human XIST has been shown to function in a similar way to mouse Xist. 
In addition, extra copies of human RNF12 coding sequence also lead to ectopic XCI in 
transgenic male and female mouse cells. However, whether RNF12 also functions as an XCI 
activator in human has not been shown. In a previous report we have shown that like the 
mouse Xic, the human XIC can be divided in a cis-acting part and a trans-acting part. Cells 
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carrying a deletion of the cis-Xic  are still able to inactivate the unaffected X chromosome, 
indicating that a trans-acting activator is located outside the deletion (Chapter 3 of this thesis). 
Other X-chromosomal truncations and translocations limit the region where this trans-acting 
activator is located to a region telomeric of the cis-XIC, encompassing RNF12 (Allderdice et al., 
1978; Brown et al., 1991; Lafreniere and Willard, 1993). Interestingly, another rearrangement 
involving the X chromosome suggests the presence of additional trans-acting activators 
centromeric of the cis-XIC (Leppig et al., 1993). 
Here, we report three families where mutations in RNF12 are accompanied by XLID in 
males and skewed XCI in carrier females. Two of these mutations have recently been reported 
as newly identified associations with XLID (Hu et al., 2015). However, neither effect on RNF12 
functions have been shown yet for these mutations, nor for the other mutations that have 
been reported in RNF12. Therefore, we investigated the effect of three different mutations on 
the interaction of RNF12 with REX1 and the subsequent ubiquitination and degradation of 
REX1. As the XLID phenotype segregating with the different RNF12 mutations has been 
described elsewhere, we will not focus on the XLID phenotype. Finally, we hypothesize that 
functional effects of RNF12 mutations induce skewed XCI through altered REX1 degradation. 
 
 
 
Results  
 
RNF12 has recently been associated with XLID in a large study performing exome sequencing in 
405 families with unresolved XLID (Hu et al., 2015). In two of the analyzed families mutations in 
RNF12 were identified, and subsequently a third family with XLID was also diagnosed with a 
mutation in RNF12. In all three families the mutation in RNF12 segregates with XLID, with 
males being exclusively affected, while females carrying the mutation appear unaffected (Fig 1. 
a,b,c). Affected males show mild to profound ID, with variable behavior problems. As no other 
mutations segregating with the ID phenotype were identified in these families the identified 
RNF12 mutations are likely to cause the phenotype. Furthermore, the three identified 
mutations are located in functional domains of the RNF12 protein. All three mutations are 
missense mutations resulting in amino-acid substitutions. The c.1093C>T mutation identified in 
family 1 results in a p.Arg365Cys substitution and is located in the central region of the RNF12 
protein. This region has not been functionally characterized for human RNF12, but is highly 
conserved to the homologous region in mouse RNF12, which is essential for the interaction 
with its target proteins LDB1 and LDB2 (Fig. 1d) (Ostendorff et al., 2002). The other two 
mutations, c.1795C>T resulting in a p.Arg599Cys in family 2 and c.1760C>G resulting in an 
p.Arg578Cys in family 3, are located in the RING domain of RNF12, which is essential for  
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Figure 1. 
Three families in which different mutations in RNF12 co-segregate with skewed XCI. 
Pedigrees of the three families carrying different mutations in RNF12, all segregating with XLID. The 
pedigrees of families 2 and 3 have been published in Hu, et al. 2015. 
a. Pedigree of family 1with the amino-acid substitution Arg 365Cys. Subjects 1, 3 and 4 experience color 
blindness. Individuals 2, 3 and 4 suffer from POI. 
b. Pedigree of family 2 with the amino-acid substitution Arg 599Cys. 
c. Pedigree of family 3 with the amino-acid substitution Pro587Arg. 
d. Comparison of mouse and human RNF12 protein, with the relevant functional domains and identified 
mutations indicated. 
e. Methylation-based analysis of X-inactivation ratio in skin fibroblasts from individuals 3 and 4 of family 
1.  Top panels show analysis for the AR locus, without methyl-sensitive HpaII digestion and with HpaII 
digestion. Bottom panels show analysis for the PCSK1N locus, which was informative only in individual 
4, without and with HpaII digestion. Table indicates XIR. 
f. Expression analysis of skin fibroblasts from subjects 3 and 4 of family 1. Sequences are shown for DNA 
and cDNA. Note that for HUWE1 cDNA was sequenced in the opposite direction. 
 
 
 
 
ubiquitination of its substrate. HOPE analysis predicts all three mutations to be damaging as 
they are located in functional domains or highly conserved regions (Venselaar et al., 2010).  
In all three families females carrying a mutated RNF12 allele appeared unaffected and 
analysis of X chromosome Inactivation Ratio’s (XIR) of peripheral blood leukocytes using 
methylation-based analyses of the Androgen Receptor (AR) and Fragile X Mental Retardation 1 
(FMR1) loci revealed highly skewed XCI in all carrier females. Considering that females carrying 
the mutation appear unaffected it is likely that the X chromosome harboring the mutant RNF12 
allele is exclusively inactivated. Further evidence hereto was provided by a phenotype of color 
vision deficiency occurring alongside the RNF12 mutation in two female individuals from family 
1 (Fig. 1b). These two female individuals inherited color vision deficiency through their father, 
and inherited the mutated RNF12 allele through their mother, indicating the maternal X 
chromosome carrying the RNF12 mutation is inactive while the paternal X chromosome 
responsible for color vision deficiency is active. To confirm that the RNF12 mutation was 
located on the Xi detailed analysis of skin fibroblasts from individuals 3 and 4 was performed. 
Methylation based XIR analyses confirmed skewed XCI in their fibroblasts (75,1% and 84,1%), 
although this was less extreme than the XIR observed in peripheral blood leukocytes (91% and 
100%)(Fig. 1e). This difference is likely caused by acquired changes in methylation patterns in 
fibroblasts during culture, as transcriptional analysis for the X-encoded genes G6PD, HUWE1 
and NAP1L3 confirmed that XCI in skin fibroblasts was highly skewed, corresponding to the XIR 
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observed in peripheral blood leukocytes(Fig. 1f). Transcriptional analysis of RNF12 revealed 
that the mutated allele was indeed silenced in the majority of skin fibroblasts (Fig. 1f). 
To test whether the identified mutations altered RNF12 functioning, the effect of the 
different mutants was tested in vitro on REX1, the single known target of RNF12 during XCI. 
First, the proteasomal-dependent degradation of human REX1 was tested in HEK293 by co-
transfecting constructs expressing FLAG-RNF12 and V5-REX1 in HEK293 cells. A clear increase in 
V5-tagged REX1 was observed upon proteasomal inhibition with mg132, indicating human 
REX1 is degraded by the ubiquitin proteasome, like mouse REX1 (fig. 2a). When testing 
different ratios of REX1: RNF12, the amount of nuclear REX1 is most completely degraded in a 
ratio of 3:1 to 1:3 (fig. 2a). To test the effect of the identified mutations in RNF12 on 
ubiquitination of REX1, HEK293 cells were co-transfected with FLAG-RNF12 and V5-REX 
expressing constructs.  After proteasomal inhibition to allow accumulation of ubiquitinated 
REX1, immunoprecipitation for V5-REX1 was performed. A clear difference in REX 1  
 
 
 
 
Figure 2. 
RNF12 mutations result in different ubiquitination efficiencies, but not in altered target protein levels 
a. Immunoblot of nuclear protein extracts from HEK293 cells co-transfected with different ratios of 
FLAG-RNF12 and  V5-REX1 expressing constructs. HEK293 cells were treated with proteasome 
inhibitor mg132 for 3 hours prior to protein isolation. REX1 was detected using a V5 antibody. RNF12 
was detected using an RNF12 antibody. 
b. Immunoblot of immunoprecipitates for V5-tagged human REX1 from nuclear protein extracts of 
HEK293 cells that were transfected with human wt RNF12 or mutant RNF12 alone, or in combination 
with V5-tagged human REX1. HEK293 cells were treated with proteasome inhibitor mg132 for 3 hours 
prior to protein isolation. Immunoprecipitates were generated from nuclear extracts shown below in 
figure 2c. 
c.  Immunoblot analysis of nuclear protein extracts from co-transfections using human REX1 and human 
wildtype or mutant RNF12. Left panels shows nuclear protein extracts of HEK293 cells not treated with 
mg132. Right panels show nuclear protein extracts of HEK293 cells cultured in the presence of mg132 
for 3 hours. 
d. FACS analysis of hREX1 levels in HEK293 cells co-transfected with constructs expressing hREX1-GFP 
and hRNF12-Cherry. Top panel shows representative images of HEK293 cells co-transfected with 
different combinations of hREX1-GFP and wildtype or mutant hRNF12-Cherry. The left plot shows the 
GFP intensity plotted against the number of cells for cells transfected with hREX1 alone, and hREX1 
co-transfected with wildtype or mutant hRNF12. Only cells expressing hRNF12-Cherry were included. 
The right plot shows the Cherry intensity plotted against the number of cells for wildtype and mutant 
hRNF12. 
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ubiquitination was observed between wildtype RNF12 and all three RNF12 mutants (Fig. 2b). 
Interestingly, RNF12 mutant 1 with a mutation in the putative interaction domain showed 
increased REX1 ubiquitination, while RNF12 mutants 2 and 3 containing a mutation in the RING 
domain showed decreased REX1 ubiquitination. In addition,  the amount of RNF12 that co-
immunoprecipitated with REX1, was slightly increased for mutant 1, while it was decreased for 
mutant 2 and 3, arguing that the three mutants have altered binding affinities. 
Despite the change in REX1 ubiquitination, no obvious differences in REX1 protein levels were 
observed between wildtype and mutant Rnf12 when nuclear extracts were analyzed by 
immunoblot (Fig. 2b). Also, when HEK293 cells were co-transfected with GFP-tagged REX1 and 
Cherry-tagged RNF12 and REX1 levels were measured by flow cytometry for GFP, no difference 
in REX1 levels could be detected. When co-transfected cells were treated with the proteasome 
inhibitor mg132 an increased level of REX1 was observed in nuclear extracts, indicating REX1 is 
subject to proteasomal degradation (Fig. 2b). However, no difference in REX1 accumulation 
was apparent between wildtype and mutant RNF12 upon proteasomal inhibition.  
RNF12 levels did not differ between wildtype and mutants, whether they were 
transfected alone or co-transfected with REX1 (Fig. 2b). Interestingly, an upper band 
representing phosphorylated RNF12 and possibly auto-ubiquitinated RNF12, was present and 
stronger in wildtype and mutant 1 compared to mutant 2 and 3, further confirming a functional 
effect of the three mutations. When Cherry-tagged RNF12 was transfected alone and levels 
were analyzed by flow cytometry, a slight decrease in RNF12 levels was detected for mutants 2 
and 3, which is consistent with immunoblot results (Fig. 2c). In summary, the identified 
mutations in RNF12 result in altered phosphorylation susceptibilities, and different capacities 
to ubiquitinate REX1, but do not lead to changes in REX1 protein levels in co-transfection 
experiments. 
To test if differences in ubiquitination of REX1 resulted in an altered half-life of REX1 
protein, the decay of REX1 was measured in co-transfected HEK293 cells after translational 
inhibition with cycloheximide.  In the presence of RNF12 REX1 has a half-life of 1,7-2,0 hours. 
Small differences in REX1 decay were observed after two hours of cyclohexamide treatment, 
which shifted the half-life in the expected direction for the relative ubiquitination capacities of 
the three RNF12 mutants, with a shorter REX1 half-life correlating with increased 
ubiquitination by RNF12 mutant 1, and a longer REX1 half-life correlating with decreased 
ubiquitination by RNF12 mutants 2 and 3 (Fig. 3). However, these differences are not 
significant, as there is a large variation between experiments. Although the obtained results 
show that the identified mutations affect RNF12 binding and ubiquitination capacities, RNF12 
functioning is not completely abolished. To confirm that the identified mutations result in 
hypomorphic proteins, their ability to degrade mouse REX1 was compared to mouse wildtype 
RNF12 and an inactive RNF12 mutant. The catalytic inactive mutant of mouse RNF12 carries  
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Figure 3. 
hREX1 degradation is not affected by RNF12 mutation 
Half-life analysis of hREX1 and hRNF12 in HEK293 cells co-transfected with constructs expressing V5-hREX1 
and wildtype or mutant hRNF12. HEK293 cells were treated with  to block protein synthesis for 0,2,4 and 6 
hours.  
a. Human V5-REX1 was detected using a V5 antibody. REX1 decay curves are based on three separate 
Western Blots 
b. Human FLAG-RNF12 was detected using a FLAG antibody. RNF12 decay curves are based on one 
Western Blot. Decay curves were plotted using the 0 hour measurement as reference.  
146 |  Chapter 4 
 
 
two mutations in the RING domain (H569A, C572A) that completely abolish its capacity to 
ubiquitinate REX1. Where both mouse and human wildtype RNF12 completely degrade REX1, 
the catalytic inactive version of mouse RNF12 is unable to degrade REX1. In comparison, the 
identified RNF12 mutants are able to degrade mouse REX1 to an extend almost comparable to 
wildtype RNF12. These results suggest that the identified mutants in RNF12  indeed result in 
hypomorphic alleles. 
 
 
 
Discussion 
 
We present three families with different mutations in RNF12 segregating with XLID in males 
and skewed XCI in females. The identified mutations in RNF12 are most likely causing the XLID 
phenotype, as XLID phenotype segregates with the XLID phenotype in all three families. Using 
exome sequencing, no other mutations segregating with the XLID phenotype were identified. 
The association of RNF12 mutations with XLID is further supported by two other recently 
published families where other mutations in RNF12 co- segregate with a XLID phenotype, 
similar to that described here (Rodriguez Criado, 2012; Tonne et al., 2015). While the 
association of XLID with mutations in RNF12 has been described before, none of these reports 
have shown a functional effect of the identified mutations on RNF12 functioning. Here, we 
show that the identified mutations affect the ubiquitination capacity and substrate binding 
capacity of RNF12. The mutation of family 1, located in the putative substrate binding domain, 
results in increased substrate ubiquitination and increased binding affinity. In contrast, the 
mutations identified in families 2 and 3 which are located in the RING domain of RNF12result in 
a reduced ubiquitination capacity. 
Interestingly, while our results showed a clear effect of the identified mutations on the 
ubiquitination capacity of RNF12, our results did not reveal a change in REX1 protein levels or 
REX1 half-life. Although this might be a consequence of the used experimental setup involving 
transient expression of RNF12 and its substrate REX1 in HEK293 cells, it could also be that 
ubiquitination of human REX1 might not result in targeted degradation, but instead in altered 
cellular localization or different DNA-binding capacities. However, this contrasts with the 
observed proteasomal degradation that is suggested by the accumulation of ubiquitinated 
REX1 upon proteasomal inhibition (Fig. 2a). This discrepancy in results could be a consequence 
of transient overexpression of REX1 and RNF12. In addition, the used co-transfection assay 
might not be sensitive enough to detect changes in REX1 protein levels. 
Regardless of an effect of the identified RNF12 mutations on REX1 protein levels, it is 
unlikely that the XLID phenotype is caused by altered REX1 levels. REX1 is not expressed in 
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brain, the tissue that would be expected to be primarily affected in XLID. Instead, REX1 is a 
pluripotency marker, that is expressed in stem cells and which expression is lost upon 
differentiation. Therefore, it seems more likely that mutations in RNF12 result in XLID by 
altering protein levels of a substrate other than REX1. Several substrates have been identified 
and have been shown to be degraded after poly-ubiquitination by RNF12 (Bach et al., 1999; 
Chen et al., 2014; Her and Chung, 2009; Huang et al., 2011; Ostendorff et al., 2002; Zhang et 
al., 2012). Of these substrates, several are involved in signaling cascades involved in embryonic 
development, and can therefore be considered interesting candidates as intermediates in 
causing the XLID phenotype. 
In all three families reported here, females carrying the mutation exhibit skewed XCI in 
which the X chromosome carrying the mutant RNF12 allele is inactivated. This skewed XIR 
could be the result of primary skewed XCI, in which the cells of the early female embryo 
undergoing XCI all inactivate the X chromosome carrying the mutation, or post-XCI secondary 
cell selection, where a selective pressure favors cells carrying an active wildtype X 
chromosome. Given the function of mouse Rnf12 as a trans-acting activator of XCI, it is not 
unlikely that the identified mutations in human RNF12 result in primary skewed XCI. However, 
the involvement of human RNF12 and REX1 in XCI has not been demonstrated yet. As the 
identified RNF12 mutations clearly affect REX1 ubiquitination, a functional effect of REX1 
protein levels on XIST expression should be demonstrated to confirm that human RNF12 also 
functions as a trans-acting activator of XCI. Although a function as a trans-acting activator has 
not been shown yet for human RNF12, observations from individuals carrying X-chromosomal 
aberrations make RNF12 a likely candidate for this function.  
Although a human trans-acting activator of XCI has not been identified yet, 
observations from individuals carrying X-chromosomal aberrations make RNF12 a likely 
candidate for this function. In a previous report we described a female individual carrying a 
1,28 Mb deletion encompassing XIST and TSIX, but leaving RNF12 intact (De Hoon et al, 
unpublished). As XCI was still present in cells heterozygous for this deletion a trans-acting 
activator must be located outside this deletion. Other X chromosomal truncations and 
translocations limit the region where this trans-acting activator is located to a region telomeric 
of the cis-XIC, encompassing RNF12 (Allderdice et al., 1978; Brown et al., 1991; Lafreniere and 
Willard, 1993). It is interesting to note that one X-chromosomal rearrangement lacking RNF12 
suggests the presence of additional trans–acting activators centromeric of the cis-XIC (Leppig 
et al., 1993). In addition, a strong conservation of RNF12 between mouse and human, with 89% 
protein sequence similarity, suggests that RNF12 performs a comparable function in humans 
and mice (Ostendorff et al., 2000).  It should also be noted that in mouse, Rnf12 is the only 
trans-acting activator of XCI identified to date, and that in human no alternative trans-acting 
activator has been identified. 
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If indeed, human RNF12 functions as a trans-acting activator of XCI, it can be 
hypothesized that the observed mutations in RNF12 result in primary skewed XCI, as mouse 
cells carrying a heterozygous deletion of Rnf12 show primary skewed XCI in which the mutant X 
chromosome is preferentially inactivated (Barakat et al., 2014; Jonkers et al., 2009; Shin et al., 
2010). This hypothesis is supported by the observation that two female carriers of family 1 
show skewed XCI in multiple tissues of different embryonic origin.   
In summary, we present three families with XLID segregating with different mutations in 
RNF12. We provide evidence that the identified mutations alter the capacity of RNF12 to bind 
and ubiquitinate target proteins. A function of RNF12 as a trans-acting activator of XCI can be 
hypothesized based on other studies involving chromosomal deletions, and on the skewed XIR 
that is observed in multiple tissues of two carrier females of family 1, and therefore is likely to 
be primary. To demonstrate that RNF12 acts as a trans-acting activator of human XCI, it should 
be shown that its target REX1 regulates XIST expression. 
 
 
 
Methods 
 
Skewing analysis 
Genomic DNA was isolated using phenol/chloroform extraction and subjected to digestion with 
and EcoRI and methylation sensitive HpaII, or EcoRI alone over night at 37°C. Restriction 
enzymes were inactivated by incubating at 80°C for 25 minutes. The CAG repeat of the 
Androgen Receptor gene was amplified using primers TGCAGTTAGGGCTGGGAAGG and 
CTGTGGGGCCTCTACGATGG. The AC repeat in the SLITRK4 gene was amplified using primers 
GCACACAAGCAGTCCTTCCT and TGGCTTCTTGGTTGCTCTCT. The tandem CA and AG repeat of 
PCSK1N was amplified using primers ATGCGAAGACCATTCCCTCT and 
GTGCGTGTGATGTGAGGAGA. The amplified products were analyzed separately on an ABI3130 
genetic analyzer. 
 
Expression analysis 
The presence of informative SNPs was analyzed on genomic DNA using primers 
TCCGTGACTCTGCCCTTTCC and GCTGCCAGTGGTGAATCTACAGG for RNF12, 
GCTGGGTAGAATTAAAGCTCTGC and GGGCAAATACACAACACATAGAAAACG for HUWE1, primers 
TGCAGAGTTGGTGGGACAGG and CCCTCGCTGCTGCTACTACCC for G6PDX, and primers 
TCAGGGGTTGCCTCCATACAG and CAGCAGTGATGAGGAGGTGCA for HUWE1. PCR products 
were analyzed using Sanger sequencing. CDNA was generated using Superscript®  II First Strand 
Synthesis kit and DNAse I from Life Technologies, according to the manufacturer’s instructions. 
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Expression of RNF12 mutation was analyzed by PCR using primers 
CCGATTGGATCGAGAAGAAGC and TTCTACGAATGGGAATTCTGATGG. Expression of SNPs was 
analyzed for G6PDX using primers CCGTGTACACCAAGATGATGACC and 
CCAGGAATGTGCAGCTGAGG, for HUWE1 using primers TGCTACCCGTGAAGTCCTTGG and 
CTTGGGGGAGGAGCAGTGG, and for NAP1L3 using primers 
AAGAAGAATGTGAATGGAATTCAGAGG and CAATCAGCCAATAGTCAGGAATGC. 
 
Generation of RNF12 and REX1 encoding constructs 
The coding sequences from human RNF12 and REX1 were amplified from human cDNA and 
cloned into the TOPO Blunt II vector from Invitrogen. Mutations in RNF12 were generated 
using site-directed mutagenesis. RNF12 coding sequences were subcloned in pCAG-Flag, a CAG-
driven expression vector containing a Flag-tag (gift from D. van den Berg) and a modified 
pCherry-C1 vector (gift from H. Lans). REX1 coding sequence was cloned into pCAG-Flag–V5 
(gift from H. Lans) and pEGFP-N3 (Clontech). 
 
Cell culture and transfection 
HEK 293 cells were cultured under standard conditions with 50% DMEM/ 50% Ham’s F10, 
supplemented with 15% heat inactivated fetal calf serum, 100 U ml-1 penicillin, 100 mg ml-1 
streptomycin, non-essential amino acids. Cells were transiently transfected using 
polyethylenimine (Polysciences) for 48 h with 2 μg wild-type or mutant Rnf12 expression 
vectors, in the absence or presence of 2 μg V5-tagged Rex1 expression vector. Where 
indicated, cells were treated with 15µM proteasome inhibitor MG132 for 3 h (Sigma). For half-
life analysis cells were incubated with 50µg/ml Cyclohexamid, 24 hours after being transfected. 
 
Nuclear extract preparation 
Cells were collected by scraping in ice-cold PBS. To isolate nuclear extracts cells were incubated 
with 400µl buffer containing 10 mM Hepes, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, protease 
inhibitor, and 15 uM MG132 for 10 minutes on ice. After vortexing briefly, nuclei were 
resuspended in buffer containing 20 mM Hepes, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 
0.2 mM EDTA, 0.5 mM DTT, protease inhibitor and 15 uM MG132 and incubated for 20 
minutes, on ice. After centrifugation, the supernatant was used as nuclear extract. For 
immunoblotting 20µg of nuclear extract was used and detected with antibodies against REX1, 
RNF12, V5-tag, and actin was used as a loading control. 
To recover V5-tagged REX1 15 μl of V5 antibody-agarose beads (Sigma) were added to 
nuclear extracts and the mixture was centrifugated for 10 minutes at 4 °C. Beads were washed 
with buffer containing 20 mM Hepes, 10% glycerol, 150 mM KCl, 1.5 mM MgCl2, 0.2 mM EDTA, 
0.02% NP40, 0.5 mM DTT, protease inhibitors and 15µm mg132. Bound proteins were eluted 
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with sample buffer and visualized by immunoblotting. Co-immunoprecipitated RNF12 was 
detected with RNF12 antibody, and poly-ubiquitinated REX1 with a V5 antibody. 
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Abstract 
 
Background 
As a result of the epigenetic phenomenon of X chromosome inactivation (XCI) every 
woman is a mosaic of cells with either an inactive paternal X chromosome or an inactive 
maternal X chromosome. The ratio between inactive paternal and maternal X 
chromosomes is different for every female individual, and can influence an X-encoded 
trait or disease. A multitude of X linked conditions is known, and for many of them it is 
recognised that the phenotype in affected female carriers of the causative mutation is 
modulated by the XCI ratio. To predict disease severity an XCI ratio is usually determined 
in peripheral blood samples. However, the correlation between XCI ratios in peripheral 
blood and disease affected tissues, that are often inaccessible, is poorly understood. Here, 
we tested several tissues obtained from autopsies of 12 female individuals for patch size 
and XCI ratio. 
 
Methods and results 
XCI ratios were analysed using methyl-sensitive PCR-based assays for the AR, PCSK1N and 
SLITRK4 loci. XCI patch size was analysed by testing the XCI ratio of tissue samples with 
decreasing size. XCI patch size was analysed for liver, muscle, ovary and brain samples and 
was found too small to confound testing for XCI ratio in these tissues. XCI ratios were 
determined in the easily accessible tissues, blood, buccal epithelium and hair follicle, and 
compared with ratios in several inaccessible tissues. 
 
Conclusions 
Buccal epithelium is preferable over peripheral blood for predicting XCI ratios of 
inaccessible tissues. Ovary is the only inaccessible tissue showing a poor correlation to 
blood and buccal epithelium, but has a good correlation to hair follicle instead. 
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Introduction 
 
Female XX mammals equalize their X-chromosomal gene dosage to XY males by inactivating 
one of their two X chromosomes in a process called X chromosome inactivation (XCI)(Lyon, 
1961) . XCI is initiated early during embryonic development, and once the inactive X 
chromosome (Xi) is established the Xi is propagated through a near infinite number of cell 
divisions. As a result every female is a mosaic of cells with an inactive paternal X chromosome 
(Xp) and cells with an inactive maternal X chromosome (Xm)(Beutler et al., 1962). XCI 
mosaicism will be organized in clones of cells that have the same inactive X chromosome. The 
size of these clones, or XCI patches, might differ between tissues and depends on the number 
of cells present at the moment of XCI, and the extent of cell migration. To assess XCI mosaicism 
most studies use the ratio between cells with a different active X chromosome in a population 
of cells largely exceeding the patch size. This X-inactivation ratio (XIR) will be approximately 
50:50 in most women, but deviations from this 50:50 XIR are common. When 80% of cells has 
the same inactive X chromosome this is termed skewed XCI, while for extremely skewed XCI 
over 90% of cells should have the same inactive X chromosome (Amos-Landgraf et al., 2006; El 
Kassar et al., 1998). 
A skewed XIR can be caused by conditions that influence the XCI process itself, resulting 
in primary skewed XCI, or as a result of secondary cell selection. Primary skewed XCI occurs 
around gastrulation of the early embryo, when XCI is initiated. Initiation of XCI is a stochastic 
process, resulting in a cell autonomous random choice of which X chromosome will be 
inactivated. After establishing an inactive X chromosome, the silent state of this X chromosome 
will be clonally passed on to all daughter cells. The random nature of this choice makes most 
female embryos end up with a ratio of 50:50. By coincidence, the majority of cells can 
inactivate the same X chromosome, resulting in primary skewed XCI. The chance of this 
happening increases if the cell population undergoing XCI is smaller in size (Sandovici et al., 
2004; Tan et al., 1993). Primary skewed XCI can also be caused genetically driven by mutations 
or variations in the genes involved in the inactivating process (Plenge et al., 1997; Pugacheva et 
al., 2005). Secondary skewed XCI is the result of post-inactivation cell selection that occurs 
when there is a selective pressure for a heterozygous X-linked gene. Such a selection can occur 
at any age, in all tissues or might be tissue specific. Secondary skewed XCI might also be the 
result of a decreasing stem cell pool during life, increasing the chance that most stem cells 
have the same inactive X chromosome (Holstege et al., 2014a). 
A skewed XIR is clinically important whenever an X-chromosomally encoded trait or 
disease is involved. By inactivating predominantly the healthy or the mutated allele, skewing of 
XCI can modulate the severity of an X-linked disease . This has been established for Fragile X 
syndrome, where the full mutation does not affect cell viability, but only cell functioning. 
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Conversely, an X-encoded mutation can also induce secondary skewed XCI. This can be clearly 
seen in Incontinentia Pigmenti, where cells with an active IKBKG mutation are more prone to 
undergo apoptosis. For some conditions females carrying the mutation might even appear to 
be unaffected, because they display completely skewed XCI. Despite the correlation between 
disease severity and skewed XCI, the mechanism through which this selection is achieved 
remains unclear for some diseases (Archer et al., 2007; Knudsen et al., 2006; Orstavik et al., 
1998). Currently, clinical analysis of the XIR is widely used to explain disease severity in female 
carriers of X-linked diseases, or to predict disease severity in females with a heterozygous X-
linked recessive disease, like Fragile X syndrome, Barth syndrome  or Rett syndrome.  
Interestingly, there are also several clinical conditions for which no causative X-linked 
locus has been identified, but that have been associated with skewed XCI. This association has 
for example been shown for autoimmune thyroiditis, where it is thought that female 
individuals with extremely skewed XIR can develop autoimmunity to self-antigens encoded by 
the X chromosome that is inactive in the majority of cells (Ozcelik et al., 2006; Simmonds et al., 
2014). Also for polycystic ovary syndrome (PCOS) skewed XCI is thought to play a role in its 
etiology, by preferentially inactivating the less sensitive androgen receptor gene and thereby 
contribution to the hyperandrogenaemic phenotype. However, both these associations are still 
under discussion. 
When analyzing the XIR to assess or predict the severity of an X-linked disease, the 
tissue being tested should have a high degree of correlation with the affected tissue. A 
complicating factor is that secondary skewed XCI might occur mainly in the disease affected 
tissue without affecting other tissues. Peripheral blood is most commonly used for testing the 
XIR, but its correspondence to other tissues has been investigated only infrequently. Other 
easily accessible tissues, such as buccal epithelium and hair follicles have scarcely been 
evaluated. One previous study performed an elaborate comparison between several tissues 
using autopsy samples. However, a direct comparison to blood was not performed, because 
blood samples were only available in a limited number of individuals, and instead XCI patterns 
from spleen were also used to represent blood (Bittel et al., 2008). In the present study, we 
test the correlation between the easily accessible tissues, blood, buccal swab and hair follicles, 
and a number of inaccessible tissues (thyroid, heart, liver, kidney, muscle and ovary), using 
samples collected during autopsy of 12 female individuals.  
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Results 
 
Before testing the XIR of several tissues, we verified that our analysis is not confounded by the 
XCI patch size. If a sample taken for XIR analysis consists  largely of a single clone, or patch, the 
observed XIR does not represent the XIR of that tissue, but rather the contribution of the patch 
to the analyzed sample. To exclude an influence of patch size on XIR analysis, we attempted to 
identify the patch size for different tissues by determining the XIR for tissue samples with 
decreasing size. A sample composed entirely of a single patch will have the same X 
chromosome inactive in all cells, instead of a mixture of both X chromosomes. Liver and muscle 
were used first to determine patch size, because these organs have a homogeneous structure. 
Liver is mainly comprised of hepatocytes and muscle mainly of myocytes, and both tissues have 
relatively little contamination of other cell types that could possibly affect the XIR. An organ 
specific XIR, to which the test samples could be compared, was determined by taking the 
average of three samples of approximately 6mm3 from different sites of each tissue fragment. 
Liver samples used to determine patch size were obtained from four individuals and were 
0.008mm3 to 0.064mm3 in size, containing 17,000 to 100,000 cells. Sensitivity tests of the 
Human Androgen Receptor Assay (HumARA) on samples of equal size, using male DNA and 
female DNA with a known XIR of 10%, confirmed that the assay provides a reliable XIR in this 
range of cell number (data not shown). When using the threshold for extremely skewed XCI 
(below 10% and above 90%) to identify an XCI patch, no sample encompassing a patch could be 
detected (Fig. 1a). Muscle samples contained a lower number of cells, ranging from 700 to 
46,000 cells.  Since striated muscle consists of multinucleated cells, the calculated cell number 
does not represent the actual number of cells, but instead represents the number of nuclei in a 
sample. The amount of nuclei reflects the number of cells that have fused to one or more 
multinucleated cells. Although the term “nuclei” might be more appropriate, for convenience 
we will use the term “cells” instead. Although no was observed, several samples showed a 
clear deviation from the tissue specific XIR in one individual. This deviation occurred in the 
range of 4,000 up to 6,000 cells (Fig. 1b), possibly indicating that these samples approach the 
patch size in muscle.  
Next, patch size analysis was performed for brain and ovary, because of the clinical 
relevance of these tissues. The X chromosome inactivation patterns in brain are of particular 
clinical relevance, because the X chromosome is relatively enriched for genes involved in 
neuronal functioning (Graves et al., 2002). Samples obtained from cerebral cortex contained 
3,000 to 100,000 cells, but did not display an extremely skewed XIR, nor a clear deviation from 
the tissue-specific XIR (Fig. 1c). Ovarian patch size is of clinical importance for ovarian 
phenotypes involving hyperandrogensim, such as PCOS. Ovarian samples for patch size analysis 
were isolated from the cortical region using laser microdissection to ensure they did not 
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Figure 1. 
X-inactivation ratios compared to 
number of cells 
Patch size analysis for: 
a.  liver of four different individuals. 
b. muscles from three individuals. 
c. brain samples of three individuals. 
d. ovary from three individuals.  
The left part of the graph shows the X-
inactivation ratio plotted against the 
number of cells. Different symbols 
represent different individuals. The right 
part of the graph shows the tissue-
specific X-inactivation ratio determined 
for each individual, as determined from 
three larger samples. Error bars show 2 
standard deviations from the tissue 
specific average. 
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contain any follicles or vascular structures with possible oligoclonal expansion. The obtained 
samples were 0.001mm3 to 0.002mm3 in size and contained 7,000 to 75,000 cells. No skewed 
XCI was observed in these samples, indicating that the patch size in ovarian cortex is less than 
7,000 cells (Fig. 1d). These results show that the patch sizes for liver, muscle, brain and ovary 
are smaller than 17,000, 6,000, 3,000, and 7,000 cells respectively. A sample of 1mm3 will 
therefore be large enough to measure XIR, without being biased by patch size. 
After validating that patch size does not affect skewing analyses, we compared XIR’s 
between different human tissues. We obtained tissues from 12 female individuals, with a 
median age of 58 (table 1). Cause of death varied from blood loss, to infection or sepsis and 
complications of an organ transplantation. Of the 12 individuals for which tissue samples were 
collected, 9 were informative for the Androgen Receptor (AR) locus. To analyze XCI in all 12 
individuals we used the assays designed by Bertelsen and colleagues, that are based on a 
technique similar to the AR assay, but use a methyl-sensitive HpaII site in proximity of a 
dinucleotide repeat in the PCSK1N and SLITRK4 genes (Bertelsen et al., 2011). The PCSK1N and 
SLITRK4 assays were informative in 7 of 12 and 8 of 12 individuals, respectively, which is a 
slightly lower frequency of heterozygosity than the 75% and 80% observed by Bertelsen and 
colleagues (Bertelsen et al., 2011). After performing the three assays on all informative tissue 
samples, we tested the correlation between the three assays in our samples. For the AR and 
PCSK1N assays we found a Pearson correlation coefficient of 0,80, for the AR and SLITRK4 
assays 0,64, and for the PCSK1N and SLITRK4 assays 0,81, indicating a good correlation 
between the three assays (Fig. 2).  
For testing the XIR between different tissue samples, we used the average XIR from all 
informative assays. When comparing XIR’s between tissues of an individual they cluster 
together, although there is considerable variation between tissues (Fig.  3). The largest 
observed difference between two tissues of the same individual was 58.8% between blood and 
thyroid of individual 4. The average difference between all tissues within one individual ranged 
from 6.9% in individual 7 to 17.2% in individual 4. Information regarding infection and blood 
transfusion was documented, because theoretically these conditions could be accompanied by 
proliferation of a subpopulation of lymphocytes, possibly resulting in a secondary skewed XCI 
in blood. Also occurrence of monoclonal diseases and administration of cytostatic drugs was 
documented, since also these conditions could theoretically result in the selective increase of a 
subpopulation of cells in any tissue. No clear pattern was observed between these conditions 
and the occurrence of skewed XCI >90% in a single or multiple tissues. 
The correlation of the easily accessible tissues to the inaccessible tissues was tested 
using Pearson’s correlation coefficient. Using blood as easily accessible tissue, a good 
correlation was found with liver (r=0.58, p=0.078), kidney (r=0.50, p=0.097) and buccal 
epithelium (r=0.70, p=0.016) (Table 2 and Supplemental Fig. 1). When buccal epithelium was 
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 used as easily accessible tissue a much stronger correlation (r>0.68) was found with all tissues, 
except for ovary and hair, and for several tissues this correlation was significant. Surprisingly, 
blood and buccal epithelium both have a weak correlation with the ovarian XIR (r= 0.18 and r= 
0.23 respectively). Instead, hair follicles show a strong correlation to ovarian XIR (r=0.77, 
p=0.005), while for all other inaccessible tissue there is a weak correlation (r< 0.40) with hair 
follicles.  
 
 
 
 
 
 
Figure 2. 
Correlation between the three assays used for analyzing XCI: AR, PCSK1N and SLITRK4 
a. Plot showing the correlation between the XIR obtained by analyzing the AR and PCSK1N loci for each 
tissue of all informative individuals using a Pearson correlation coefficient. 
b. Plot showing the correlation between the XIR obtained by analyzing the AR and SLITRK4 loci for each 
tissue of all informative individuals using a Pearson correlation coefficient. 
c. Plot showing the correlation between the XIR obtained by analyzing the PCSK1N and SLITRK4 loci for 
each tissue of all informative individuals using a Pearson correlation coefficient. 
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Figure 3. 
X inactivation ratio (XIR) analysis in all accessible and inaccessible tissues of female individuals.  
Each data point represents the average XIR value from the assays informative in an individual. For every 
assay PCRs were performed in triplicate. Error bars represent the SD from the assays that were used. 
Different tissues are represented by different symbols. The table below shows which assays were 
informative for each individual 
 
 
 
 
Since long it has been described that there is an age-related increase of skewing in blood, 
occurring above the age of 60 (Amos-Landgraf et al., 2006; Busque et al., 1996; Sharp et al., 
2000). This has been attributed to oligoclonal expansion from a limited number of stem cells, 
an effect that might be increased by a possible decrease of the number of stem cells in older 
women (Amos-Landgraf et al., 2006; Holstege et al., 2014a). If this is true, it can be expected 
that within a female individual the XIR’s of different tissues initially cluster together around the 
same value, but diverge at later ages. To test if tissue specific XIR’s within an individual diverge 
with increasing age, the average XIR difference was calculated from the XIR differences for 
every tissue combination within an individual. The average XIR difference is the smallest in the 
youngest individual and the largest in the oldest individual and showed a significant correlation 
with age (r=0.72, p=0.008) (Supplemental Fig. 2). These data suggest that XIR’s of different 
tissues within an individual diverge with increasing age, although a larger number of individuals 
will be required to confirm this hypothesis.  
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Discussion 
 
We performed a XIR-based patch size analysis for several inaccessible tissues, to avoid XIR 
analyses being confounded by XCI patch size. The obtained results show that the patch size for 
liver, muscle, brain and ovary is smaller than 17,000, 6,000, 3,000, and 7,000 cells respectively. 
These results are consistent with results from previous studies, that have all been performed 
on epithelial layers. Most of these studies used a mutation in the glucose-6-phosphate 
dehydrogenase (G6PD) gene, to stain tissue sections for the presence of G6PD activity. These 
studies estimated the patch size of endothelium in the arterial wall to be 50 cells, of the 
epidermis to be smaller than 30mm2, and smaller than 1 mm2 in hair follicles (Benditt and 
Gown, 1980; Gartler et al., 1971; Linder and Gartler, 1965).  Another study employed the 
HumARA to assess patch size in bladder urothelium and estimated the patch size to be 120mm2 
(Tsai et al., 1995). Unlike in some of the abovementioned studies we did not identify a XCI 
patch in our samples, although our sample sizes were in the same range or smaller. A possible 
explanation is that epithelium has a larger patch size, compared to tissues that contain a 
mixture of parenchyma and stromal cells, as parenchyma and stromal cells might already 
originate from different embryonic germ layers with different XIR’s. 
While the HumARA assay is probably the most widely used assay to determine the XIR, the AR 
locus is not informative for every individual. To analyze the XIR in all individuals, we used 
recently published assays for the SLITRK4 and PCSK1N loci alongside the HumARA. Like the 
HumARA, these assays determine XCI by assessing the methylation status of a locus 
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neighboring a polymorphic repeat. A methylation sensitive restriction enzyme is used to digest 
unmethylated DNA, leaving methylated templates intact, which are  subsequently amplified by 
PCR. The amplified polymorphic repeat is used to discriminate between the two alleles. 
Although a strong correlation was found between all three assays, the three assays do not 
always perfectly agree. The average difference between two assays was 6.4% for the AR and 
PCSK1N assays, 6.2% for AR and SLITRK4 and 4.8% for PCSK1N and SLITRK4. The largest 
observed difference comparing all three assays was 27.1%, in blood of patient 2. This 
difference in XIR between the assays might be explained by the low number of methylation 
sites that are analyzed. When using only one (PCSK1N and SLITRK4) or two (AR) methylation 
sites, this might not always reflect the methylation status of the complete locus. Indeed, it was 
shown for the HumARA that DNA methylation not always corresponds to relative expression of 
the two alleles (Swierczek et al., 2012). Expression of the PCSK1N and SLITRK4 loci has not been 
compared to methylation status, but instead to AR methylation (Bertelsen et al., 2011). 
Theoretically, the three assays may also differ because of tissue specific gene silencing, 
independent of X-inactivation status. Altogether, this difference shows that analyzing a single 
methylation site might not be representative for the inactive status of an entire X 
chromosome, and using three loci increases reliability. 
The tissues that were used in this study were collected during autopsies of females that 
died of various causes, and theoretically several clinical conditions might affect the XIR of 
different tissues. In case of cancer or cytostatic therapy the XIR of all analyzed tissues could 
theoretically be affected. Any tissue could be affected by cancer, altering the XIR through 
monoclonal expansion of the primary tumor or metastases. In addition, cytostatic therapy 
could also affect any tissue by dramatically reducing the number of stem cells, resulting in 
oligoclonal expansion and a secondary skewed XIR. In both conditions the expected result 
would be a shift of the XIR towards extremely skewed XCI, which was not observed. In several 
other individuals, the T-lymphocyte composition in peripheral blood, that was used to assess 
XIR, could have been altered. First, the occurrence of infection and sepsis is likely to alter T 
lymphocyte composition in the peripheral blood samples analyzed. However, this is not likely 
to skew the XIR, as this would require an oligoclonal expansion of thymocytes and during an 
immune response a larger number of thymocytes will be activated. Therefore, it can be 
considered unlikely that infection or sepsis will affect the XIR. Secondly, after major blood loss 
the peripheral T-lymphocyte population is largely lost and needs to be replaced. However, as 
the peripheral T-lymphocyte population is a reflection of the stem cell population, it is not 
likely that the population of newly circulating T-lymphocytes will have a different XIR. An 
erythrocyte transfusion will not affect the XIR of a peripheral blood sample, as erythrocytes are 
enucleated cells. In none of the individuals suffering from any of the conditions that could alter 
the peripheral T-lymphocyte population extremely skewed XCI was observed. Although this 
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argues against an oligoclonal expansion, we cannot exclude that these conditions have affected 
the XIR of peripheral blood in a small degree. 
The comparison of tissue-specific XIR’s yielded an interesting correlation pattern for 
hair follicle, as hair follicles display a weak correlation with all inaccessible tissues, except  
ovary. Contradictory to our results, a previous study analyzed XIR in hair follicles of 21 
individuals and found a significant correlation to blood XIR (r=0.67; p=0.009) (Kaupert et al., 
2010). One possible explanation for this difference is the number of hair follicles used to assay 
XCI. We used 20 hair follicles, where Kaupert and colleagues used 3-4 follicles to assay XCI. Hair 
follicles originate from a small number of precursor cells, and the chance that a hair follicle is 
monoclonal regarding XCI status has been estimated around 50% (Goldstein et al., 1971). 
Consequently, using a smaller number of hair follicles, increases the chance that patch size 
confounds XIR analysis. Given the strong correlation between hair follicles and ovary, we 
conclude that when interested in the XIR of an ovary, of use in for instance PCOS patients, 
testing XCI in hair follicles should be preferred over testing peripheral blood samples or buccal 
swabs.  
The comparison of XIR’s between easily accessible tissues blood and buccal swap and 
inaccessible tissues demonstrated that buccal epithelium has a better correlation to 
inaccessible tissues compared to blood. To date most studies analyzing skewing of XCI in single 
patients or patient populations use peripheral blood samples for analysis. A good correlation 
between XCI in blood and buccal epithelium has been reported before by two studies, and is 
confirmed by our results (Bolduc et al., 2008; Sharp et al., 2000). However, given the stronger 
correlation of buccal epithelium to all examined tissues we conclude that when testing for XCI 
skewing, buccal swab should be the method of choice. 
Many studies have reported an age-related increase of skewing in blood, occurring 
above the age of 60, which has been attributed to a decreasing number of stem cells in older 
women (Amos-Landgraf et al., 2006; Busque et al., 1996; Holstege et al., 2014b; Sharp et al., 
2000). Given the small number of individuals we were unable to test for an age-related 
increase in skewed XCI. However, the obtained XIR’s from different tissues presented an 
unique opportunity to test if an age-related increase in skewed XCI might be caused by a 
decreasing stem cell number. Indeed we find that tissue specific XIR’s within an individual 
diverge, although a larger number of individuals will be required to confirm this hypothesis. 
In conclusion, we show that the patch size of XCI in liver, muscle, brain and ovary is 
small enough not to confound XIR analysis of 1mm3 biopsies. When comparing blood, buccal 
epithelium and hair follicle as easily accessible tissues for assaying XIR, hair follicles show the 
best correlation with ovary. For all other inaccessible tissues buccal epithelium shows  the best 
correlation. Moreover, buccal swap is non-invasive, and should therefore be considered the 
best and most convenient method for determining XIR. 
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Materials and Methods 
 
All samples used in this study were obtained from the Erasmus MC Tissue Bank, in accordance 
with the Dutch Law on Medical Research and  autopsy materials were only used for research 
after permission was obtained through signed informed consent from the next of kin. This 
research was approved by the local medical ethical committee (MEC-2011-145). Tissue samples 
for comparison of tissue specific XIR were collected during autopsies performed in the Erasmus 
Medical Centre in Rotterdam, between June 2012 and August 2014. Tissue samples were snap 
frozen and DNA was extracted using phenol-chloroform purification. Blood samples could not 
be extracted by peripheral vein puncture and were therefore obtained through cardiac 
puncture. Ovarian samples for XIR analysis were cut by hand from the ovarian cortex, only 
selecting regions that did not contain any visible follicles. 
Samples for patch size analysis were obtained by cutting cryosections of 8µm thick, 
from which final samples were cut by hand measuring 1mm2 to 8mm2. DNA was isolated using 
phenol-chloroform extraction. The number of cells in each sample was calculated back from 
the total amount of DNA present, assuming a single cell contains 6pg DNA. Ovarian samples for 
patch size analysis were obtained during autopsies of three female individuals of 
premenopausal age.  Samples were 0.10mm² to 0.16mm² were isolated from 14µm 
cryosections using a PALM laser dissection. 
XIRs were analyzed using the Human Androgen Receptor Assay (HumARA). DNA 
samples were digested with the methyl-sensitive restriction enzyme HpaII and EcoRI, or EcoRI 
alone for 24 hours at 37°C. After inactivating the enzyme by incubating at 80°C for 25 minutes, 
the Androgen Receptor locus was amplified using primers TGCAGTTAGGGCTGGGAAGG and 
CTGTGGGGCCTCTACGATGG. The AC repeat in the SLITRK4 gene was amplified using primers 
GCACACAAGCAGTCCTTCCT and TGGCTTCTTGGTTGCTCTCT. The tandem CA and AG repeat of 
PCSK1N was amplified using primers ATGCGAAGACCATTCCCTCT and 
GTGCGTGTGATGTGAGGAGA. The amplified products were analyzed separately on an ABI3130 
genetic analyzer. Correlations of XIRs between different tissues were calculated using 
Pearson’s correlation coefficient. All individuals were pooled in a single group, regardless of 
their age and menopausal status.  
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Abstract 
 
Background 
In placental mammals balanced expression of X-linked genes is accomplished by X 
chromosome inactivation (XCI) in female cells. In human rXCI is initiated early during 
embryonic development. To investigate whether reprogramming of female human fibroblasts 
into induced pluripotent stem cells (iPSCs) leads to reactivation of the inactive X chromosome 
(Xi), we have generated iPSC lines from fibroblasts heterozygous for large X-chromosomal 
deletions. 
 
Methods and results 
 These fibroblasts show completely skewed XCI of the mutated X chromosome, enabling 
monitoring of X chromosome reactivation (XCR) and XCI using allele-specific single cell 
expression analysis.  
 
Conclusions 
This approach revealed that XCR is robust under standard culture conditions, but does not 
prevent re-initiation of XCI, resulting in a mixed population of cells with either two active X 
chromosomes (Xa’s) or one Xa and one Xi. This mixed population of XaXa and XaXi cells is 
stabilized in naïve human stem cell medium allowing expansion of clones with two Xa’s.   
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Introduction 
 
Inactivation of one of the two X chromosomes in eutherian female cells by XCI is an epigenetic 
process, which compensates for potential dosage differences of X-linked genes between 
female XX and male XY cells (Lyon, 1961). Mechanistic and regulatory aspects of XCI have been 
extensively studied during mouse development and for mouse embryonic stem cells (mESCs). 
These mESCs are derived from the inner cell mass (ICM) of the blastocyst and contain two 
active X chromosomes (Xa), but will undergo XCI upon in vitro differentiation. The non-coding 
Xist RNA is crucial for XCI and becomes up-regulated upon differentiation of mESCs. Xist coats 
the future Xi, attracting chromatin remodelling enzymes which infer the transcriptional 
shutdown of the Xi (reviewed in:(Barakat and Gribnau, 2012; Pollex and Heard, 2012)). Several 
components of the regulatory network driving XCI are conserved between mouse and man, but 
many questions regarding human XCI remain unanswered. Contrary to undifferentiated mESCs, 
most human ESC lines (hESCs) are in a post-XCI state, and are prone to epigenetic fluidity (Silva 
et al., 2008). This variation in regulation and stability of the XCI state between these eutherian 
species might reflect suboptimal culture conditions for the human cells, resulting in a gradual 
progression towards a more differentiated state, including initiation of XCI. Alternatively, the 
XCI process itself may have reached a more advanced state in the human ICM compared to the 
mouse, so that XCI in the hESCs derived from the ICM has occurred already prior to or during 
ESC derivation .  
The derivation of human induced pluripotent stem cells (hiPSCs) from fibroblasts 
(Takahashi et al., 2007) offers an opportunity to study XCI in human cells. For mouse 
fibroblasts, it has been shown that the Xi becomes reactivated during the reprogramming 
process, followed by random XCI (rXCI) upon differentiation of these miPSCs (Maherali et al., 
2007; Stadtfeld et al., 2008). Similar to studies involving hESC lines, previous studies of XCI in 
hiPSCs have provided varying results. Systematic analysis of multiple female hiPSC lines derived 
from several fibroblast populations under different reprogramming strategies indicated that all 
hiPSC lines retained the Xi inherited from the starting fibroblasts (Amenduni et al., 2011; 
Ananiev et al., 2011; Cheung et al., 2011; Tchieu et al., 2010). In another study it was found 
that in all hiPSC lines derived from one fibroblast population with established rXCI, one and the 
same X chromosome had become the Xi in all lines, indicating involvement of cell selection 
processes (Pomp et al., 2011). In contrast, other studies showed reactivation of the Xi, an 
apparent reversal of XCI which is herein referred to as X chromosome reactivation (XCR), in all 
or a limited number of hiPSC lines, but XCI was reinitiated upon differentiation of these hiPSC 
lines (Bruck and Benvenisty, 2011; Kim et al., 2011; Marchetto et al., 2010). XCR followed by 
reinitiation of XCI and stable establishment of the Xi upon hiPSC differentiation, are crucial 
steps that need to take place for hiPSCs to be applied for various purposes. If hiPSC lines do not  
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pass through this series of events, they show signs of stochastic reactivation of the Xi inherited 
from the founder fibroblasts (Mekhoubad et al., 2012). This erosion of XCI is detrimental for 
studies involving cell types generated from female hiPSC, as it can be expected that many of 
these cell types will be prone to gene dosage inequalities. Therefore the availability of such 
hiPSC lines with stable XCR, having two active X chromosomes as in mESCs, would greatly 
advance research on modelling of X-linked human diseases and studies on regulatory 
mechanisms of human XCI. 
The varying results regarding XCR and XCI obtained for hiPSCs may be explained by 
different reprogramming techniques and the growth conditions in which hiPSCs are generated 
and maintained. In a recent study it was found that growth of hESCs and hiPSCs in defined 
conditions (naïve human stem cell medium; NHSM) results in more naïve iPSCs, and leads to 
efficient loss of Xi specific markers including XIST RNA and Xi specific histone modifications, 
which are re-established upon differentiation (Gafni et al., 2013). Although these NHSM-
cultured hESCs and hiPSCs resemble mESCs and miPSCs in several aspects, it is unclear if the 
described loss of Xi specific markers under these growth conditions has resulted in XCR, as 
expression of X-linked loci was not assessed (Gafni et al., 2013).    
Skewed rXCI is obtained in cells which carry a large X chromosomal deletion on either 
one of the two X chromosomes outside the X inactivation center (XIC), based on selection 
against cells which inactivate the intact X chromosome. Here, we have generated and analysed 
hiPSC lines derived from female carriers with such heterozygous large X chromosomal 
deletions, which were expanded under different growth conditions (standard versus NHSM). 
These hiPSCs provide a powerful model system to study XCR and XCI, facilitated by allele 
specific expression analysis. Single cell expression analysis of these hiPSC lines, when generated 
under standard culture conditions, revealed robust XCR, which was followed by XCI. Hence, the 
presence of two active X chromosomes in these hiPSCs is not a stable condition, as it is in 
undifferentiated mESCs. However, growth of the present hiPSC lines in NHSM conditions did 
stabilize the equilibrium between XCR and XCI over several passages, and allowed rapid 
expansion of hiPSC clones with two active X chromosomes. 
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Results 
 
Cell lines with non-rXCI for hiPSC formation 
To generate novel hiPSC lines to investigate XCR and XCI during reprogramming at a single cell 
level, we screened cell repositories for female cell lines harbouring large deletions on one of 
the X chromosomes. Due to secondary selection, an X chromosome with a large deletion is 
preferentially inactivated in female carriers providing a sensitive assay to identify hiPSC lines 
which have reactivated the Xi inherited form the founder fibroblasts, because this results in bi-
allelic expression of polymorphic informative genes.   
Cell lines were collected through different sources, and the gene content was further 
characterized by MLPA, SNP array, and DNA-FISH analysis (Fig. 1a,b, Supplemental Table I, 
Supplemental Fig. 1). The fibroblast lines X12, X14, and X15 containing informative large 
deletions of Xq, were selected for further studies examining XCR and XCI. The respective 
deletions concern regions outside the XIC. Deletions including the XIC would block XCI of the X 
chromosome carrying the deletion, whereas large deletions which do not include the XIC will 
lead to clonal selection of the cells which have inactivated the mutant X chromosome, keeping 
the intact X chromosome as the Xa. In addition, 46,XX fibroblasts not carrying an X-
chromosomal deletion, and 47,XXX fibroblasts derived from a patient with triple X syndrome, 
were included as controls (Brosens et al., 2014). RNA-FISH analysis indicated that in fibroblast 
cell lines X12, X14, and X15, 99% of the cells showed one XIST cloud per nucleus (Fig. 1c, n=200 
cells analysed per cell line). In the 47,XXX fibroblasts, two XIST clouds marking two inactive X 
chromosomes were found in almost every cell (Fig. 1c), in agreement with the rule that all but 
one X chromosome becomes inactivated per diploid genome (Harnden, 1961). HUMARA 
analysis amplifies a polymorphic region in the androgen receptor (Ar) gene after digestion with 
a methylation sensitive enzyme, and is used to detect the methylated Ar allele marking the Xi 
(Allen et al., 1994). This analysis indicated that rXCI is completely skewed towards inactivation 
of one of the two X chromosomes, for all three X12, X14, and X15 fibroblast cell lines 
(Supplemental Table 1). Both in the 46,XX and the 47,XXX fibroblast cell lines, rXCI without such 
skewing was observed (Supplemental Table 1) (Brosens et al., 2014). Preferential inactivation 
of one specific X chromosome in fibroblast line X12 was confirmed by RFLP RT-PCR analysis of a 
SNP in XIST (Fig. 1d). Although no informative SNPs were available for XIST in the X14 and X15 
fibroblast cell lines, analysis of X-linked genes showed completely skewed XCI in both cell lines 
(Supplemental Fig. 1d). We conclude that the X12, X14, and X15 fibroblast cell lines show highly 
skewed rXCI, most likely silencing the X carrying the deletion.  
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Figure 1. 
Fibroblast cell lines with skewed rXCI  
a. Schematic representation of the human X chromosome. Location of genes analyzed in this study is 
indicated. The dashed lines indicate the deletions in the X12, X14, and X15 fibroblast cell lines. Also 
DNA-FISH probes are indicated. 
b. DNA-FISH on metaphase chromosomes of X12 and X15 fibroblasts, using probes 1, 2, 3, and 4. 
Magnification of X chromosomes is shown in the insets. 
c. RNA-FISH detecting XIST RNA (FITC) in X12, X14, X15, and 47,XXX fibroblasts. DNA is counterstained 
with DAPI (blue, bar=10µm). D) PCR and RT-PCR analysis with DNA and cDNA from X12, X14, and X15 
fibroblast cell lines, amplifying an RFLP in XIST. PCR products were digested with MfeI, to discriminate 
between both alleles. 
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Figure 2. 
Generation of hiPSC lines from fibroblasts 
a. Schematic overview of the lentiviral reprogramming cassette (Warlich et al., 2011), and the procedure 
at 10 and 22 days post-transduction, to establish the present hiPSC lines.  
b. Transduced fibroblasts express dTomato (left panel), which is silenced upon proper reprogramming 
(right panel, bar=100µm). 
c. Representative picture of a hiPSC colony (p3 denotes passage 3) from iPSC line X12-2 (left panel, 
bar=100µm), and karyogram of iPSC X12-2, revealing a 46,XX karyotype (right panel). 
d. Representative picture of EBs derived from iPSC line X12-2 after 8 days of differentiation 
(bar=100µm).  
e. qRT-PCR analysis of pluripotency factors in X12 hiPSC lines (1-6). Expression of the same factors in an 
hESC line (H9) served as a control, and was set at 100%. 
f. qRT-PCR analysis of differentiation associated markers in day 8 (d8) EBs from X12 hiPSC lines. Gene 
expression was normalized to a differentiated hESC line H9.   
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Generation of hiPSC lines  
To generate hiPSC lines, X12, X14, X15, 46,XX, and 47,XXX fibroblasts were transduced with a 
polycistronic lentiviral vector expressing OCT4, SOX2, KLF4, and MYC, and a dTomato reporter, 
under the control of a retroviral promoter (SFFV) that is rapidly silenced during the 
reprogramming process (Warlich et al., 2011) (Fig. 2a, b). These fibroblasts were plated on 
MEFs, and cultured in the presence of standard human ESC medium. After approximately 10 
days, small clusters of cells appeared which started to develop a human ESC cell morphology. 
These clusters gradually lost the expression of the dTomato reporter (Fig. 2b and Supplemental 
Fig. 2a), which indicated proper silencing of the lentiviral transgene, required to establish fully 
reprogrammed hiPSCs. For each one of the different genotypes, we obtained several iPSC lines, 
of which the X12, X15, 46,XX, and 47,XXX iPSC lines were subjected to further analysis. All these 
iPSC lines showed morphology resembling hESCs, with a stable 46,XX karyotype (or 47,XXX in 
case of lines derived from the 47,XXX fibroblasts) and expression of key endogenous 
pluripotency factors including NANOG and REX1, at different passages (p) after establishment 
(Fig. 2c, d, e, Supplementary Fig. 2c, d, and data not shown). Also, SNP arrays of various hiPSC 
lines confirmed an identical genome content compared to the founder fibroblasts 
(Supplementary Fig. 2d). Upon embryoid body (EB) differentiation, qPCR analysis indicated that 
most hiPSC lines showed  expression of endodermal (FLK1, AFP), mesodermal (GATA2), and 
ectodermal (PAX6) marker genes (Fig. 2g, only X12 clones are shown). This was confirmed by 
immunocytochemistry analysis on EB differentiated iPSCs plated on slides, revealing GFAP 
(ectoderm), Vimentin (mesoderm) and AFP positive cells for all iPSC lines, which supports our 
conclusion that all iPSC clones were completely reprogrammed and acquired full differentiation 
potential (Supplementary Fig. 2b, results of one representative X12 clone is shown). 
 
Early passage female hiPSCs show reactivation of the Xi   
The X12, X15, and 47,XXX iPSCs were subjected to immuno-RNA-FISH analysis at passages 3-5, 
to investigate the XCI status of these cell lines. This analysis showed that in several iPSC lines 
generated from the X12 and X15 fibroblasts only 30% of the nuclei displayed XIST-coated X 
chromosomes (Fig. 3a, d). In hiPSC lines generated from the 47,XXX fibroblasts, many cells did 
not show Xi markers, or showed signs of only one Xi (Fig. 3a,e). In all cell lines, analysis of 
heterochromatin markers associated with the Xi, including enrichment of H3K27me3, indicated 
variable staining, with many cells not displaying all characteristic Xi features (Fig. 3a and data 
not shown). Also, Barr bodies (e.g. DAPI-dense, heterochromatic regions covering the Xi) were 
detected in a minority of cells. Strikingly, in many colonies, cells with all Xi hallmarks, including 
depletion of H3K9ac, were most often found at the edges or in the centre of the colonies, 
where most of the differentiated cells are found. In contrast, cells without XIST and associated 
Xi markers were found in a donut shaped region surrounding the middle of the colonies (Fig.  
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3b,c).These results could be explained by: 1) loss of X chromosome(s), 2) loss of XIST expression 
and Xi markers during hiPSC cell culture and colony formation, similar to findings for hESC lines 
(Bruck and Benvenisty, 2011), or 3) XCR in a pluripotent subpopulation of hiPSCs, possibly 
followed by XCI. Option 1 was excluded, as karyotyping and SNP array analysis did not reveal a 
significant population of cells with X chromosome aneuploidies at different passages after 
establishment of the iPSC lines. To distinguish between options 2 and 3, we first analysed the 
methylation pattern of the Xi by HUMARA analysis, focussing on the hiPSC lines derived from 
the X12 and X15 fibroblasts. If the Xi in the hiPSCs is the same X chromosome as the Xi 
inherited from the founder fibroblasts, HUMARA analysis will detect completely skewed 
methylation of the Ar gene. Furthermore, using this analysis, XCR in all cells would lead to an 
absence of methylation at the Ar gene, whereas XCR followed by rXCI which might also involve 
the intact X chromosome would result in methylation of the previously unmethylated Ar allele. 
HUMARA analysis for genomic DNA of undifferentiated X15 hiPSC lines showed the initial 100:0 
skewing ratio (Fig. 3f), which was also observed for the founder fibroblast cell line, compatible 
with either an absence of XCR, or XCR in a small subpopulation of cells which cannot be 
detected by this method. In undifferentiated X12 p3 hiPSC lines, we observed methylation, in 
some clones up to 12%, also of the second Ar allele located on the intact X chromosome (Fig. 
3f). This finding indicates that XCR in the X12 p3 hiPSCs is unstable, and that these cells have 
started rXCI also on the intact X chromosome in a subpopulation of cells. We next performed 
allele specific expression analysis of XIST using RFLP RT-PCR analysis on RNA from X12 hiPSCs, 
the only hiPSC line with an informative XIST SNP. On the whole cell population level we 
detected XIST expression from both X chromosomes (Fig. 3g). This supported the findings with 
the HUMARA analysis, indicating that XIST upregulation and initiation of XCI have occurred 
following XCR, in X12 hiPSC lines. In the day 8 differentiated progeny of X12 hiPSC lines, we 
detected mono-allelic XIST expression (Fig. 3h), comparable to that in the original X12 
fibroblasts. This is explained by survival, at later passages, of cells which have silenced the 
mutant X chromosome and loss of cells which have initiated XCI on the intact X chromosome  
 
Bi-allelic expression of X-linked loci, and reversal of XIST expression  
The observed presence of XIST negative cells within colonies at early passages of the X12 hiPSC 
lines is in agreement with the present findings for the whole cell populations with the 
HUMARA assay and XIST expression analysis. Taken together, the results provide evidence that 
the hiPSCs, cultured under the above standard conditions, engage in both XCR and subsequent 
initiation of XCI.  
To precisely evaluate the dynamics of XCR we performed allele specific single cell RT-
PCR analysis, amplifying RFLPs in the X-linked genes XIST, SUVAR39H1, and G6PD at different 
time points after reprogramming. X12 iPSC and 47,XXX iPSC lines were FACS sorted in 96-well 
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Figure 3. 
XCI analysis of hiPSCs  
a. Immuno-RNA-FISH analysis on hiPSC lines X12-2, X15-2, and 47,XXX-3 (all cells in a-e and g, passage 3), 
detecting XIST (Rhodamine Red) and H3K27me3 (FITC). In the upper panels, the nuclei are 
counterstained with DAPI  (bar=10µm). 
b. Example of an X12-1 hiPSC clone, at lower magnification. Center part and edge of colony are indicated 
with D, the undifferentiated middle part of the colony with an U (bar=100µm). 
c. Immuno-RNA-FISH detecting XIST (Rhodamine Red) and H3K9ac (FITC, top panels), and detecting XIST 
(Rhodamine Red) and H3K27me3 (FITC, bottom panels) on cells found in U (left panels) and in d (right 
panels) (bar=10µm). 
d. Quantification of immuno-RNA-FISH analysis of representative hiPSC lines X12 (1-4) and X15-2. 
Percentages of cells with both an XIST cloud and H3K27me3 accumulation, only an XIST cloud, or only 
H3K27me3 accumulation are shown (mean±SD, n=3 experiments, >100 cells were counted per 
experiment). 
e. Quantification of immuno-RNA-FISH analysis of representative hiPSC lines 47,XXX (2-4). Percentage of 
cells with either one or two XIST clouds is plotted (mean±SD, n=3 experiments, >100 cells were 
counted per experiment). 
f. Quantification of all HUMARA analyses performed with different fibroblast and hiPSC lines, passages 3 
and 5 (p3 and p5). 
g. Allele-specific RT-PCR analysis of XIST. PCR products were digested using MfeI to distinguish between 
both parental alleles. The hiPSC lines X12-2 and X12-4 show bi-allelic XIST expression, which was not 
found in the original fibroblast line (compare to Fig. 1d). 
h As for Fig. 3g, but here day 8 differentiated X12 hiPSC lines are assessed. 
 
 
 
plates, using antibodies against the pluripotency associated surface markers SSEA4 and Tra1-
81, at p0, p3/4 and p25 after establishment. All sorted cells were tdTomato negative. Passage 0 
cells were isolated 20 days after the start of the reprogramming procedure, prior to picking. 
For all time points, the SSEA4 and Tra1-81double positive fraction represented more than 40% 
of the total viable cell fraction (Fig. 4a, and data not shown), and qPCR analysis showed 
increased expression of the pluripotency markers in pooled double positive SSEA4+/Tra1-81+ 
and GCTM2+/CD9+ sorted cells (Fig. 4b). SSEA4+/Tra1-81+ double positive (tdTomato negative) 
cells were sorted in lysis buffer, and single cell nested RT-PCR was performed, followed by 
restriction digestion to distinguish between expression from the different alleles. Analysis of 
XIST in X12 hiPSCs revealed a high percentage of cells not expressing XIST, and cells displaying 
expression of XIST emanating from the Xa (allele B) at all stages after reprogramming (Fig 4d,e). 
Also, allele specific expression analysis of X-linked SUVAR39H1 revealed a high percentage of 
cells displaying expression of the previously inactive allele B (Supplemental Fig. 3). 
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Figure 4 
Single cell RT-PCR analysis of sorted hiPSCs 
a. FACS analysis of hiPSCs stained for the pluripotency associated surface markers SSEA4 and 
TRA1-81 (gate used to sort hiPSCs is shown). 
b. qRT-PCR analysis of NANOG in living sorted H9 ESCs, and X12-2 and 47,XXX-4 hiPSCs, 
comparing: unsorted cells (U), SSEA4-/TRA1-81- double negative cells, CD9+/GCTM2+ 
double positive cells, and SSEA4+/TRA1-81+ double positive cells. Results are normalized 
for GAPDH. NANOG expression in unsorted H9, the positive control, was set at 100. 
c. Allele specific expression analysis of SUVAR39H1 on gDNA and cDNA isolated from X12 
fibroblasts.  
d. Single cell RT-PCR analysis of SSEA1+/TRA1-81+ sorted cells from hiPSC line X12-2 (passage 
25, p25). Shown are the cells numbered 49-60. Allele-specific expression of XIST and 
SUVAR39H1 was assessed by digestion with MfeI and MspI, distinguishing the parental 
alleles (indicated with A and B). 
e. Quantification of (Fig. 4d) for XIST (left graph) and SUVAR39H1 (middle graph) on X12 iPSC 
lines (X12-2 up to X12-24, and the pooled lines) at different passages (p0 up to p25) after 
reprogramming. The right graph shows the quantification of allele specific expression 
analysis of G6PD on SSEA4+/Tra1-81+ sorted 47,XXX iPSCs (for all experiments N=96 cells 
per cell line) 
f. Dome shaped morphology of NHSM cultured hiPSCs (bar=100µm).  
g-k TRA1-81 (Fig . 4g), ID3 (Fig. 4h) and STAT3 (Fig. 4i) expression is increased, and DNMT3A 
(Fig. 4j) and DNMT3B (Fig. 4k) expression is decreased in NHSM cultured iPSC lines. Shown 
is mean intensity of TRA1-81 determined by FACS analysis. For ID3, STAT3, DNMT3A and 
DNMT3B expression per iPSC line is shown relative to H9 hESCs cultured in human ES 
medium.  
l. XIST expression analysis as in (Fig. 4h-k). 
m. XIST RNA-FISH analysis on X12-23 iPSCs grown in NHSM, passage 6 (>100 cells were 
counted per experiment, bar=10µm).  
n. Quantification of cells with XIST-coated X chromosomes in different X12 iPSC lines (p6). 
o. Allele specific expression analysis of XIST and SUVAR39H1 at different passages (p0 – p4) of 
X12 hiPSC lines growing in NHSM (alleles A and B, as in Fig. 4d).  
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Interestingly, only a small percentage of cells displayed XIST and SUVAR39H1 expression both 
exclusively from the alleles A, as was found for the founder fibroblasts used to generate the 
iPSCs (Fig. 4c, d, e, and Supplemental Fig. 3). In addition, the percentage of cells expressing 
only the XIST and SUVAR39H1 alleles A did not markedly drop after establishment of the iPSC 
line. Similar results were obtained with iPSCs generated from 47,XXX fibroblasts analysed at p0 
and p25, revealing a considerable amount of cells which showed bi-allelic expression of G6PD, 
indicating reactivation of the Xi (Fig 4e). These results indicate robust reactivation of the Xi 
during the early stages of the reprogramming process. In addition, the results of the RNA-FISH 
analysis on iPSC clones X12-2 and X12-4 suggest that in most cells expressing XIST, this RNA is 
detected only at very low levels (Fig. 3d and Fig. 4e). To test whether XCR involved multiple 
genes on the X chromosome we performed allele specific expression analysis of three 
additional informative genes located at different positions on the X. RNA was isolated from 
pooled cells of different X12 clones. In two out of the three tested iPSC clones (X12-23 and 
X12-24) we found bi-allelic expression of HUWE1, ATP7A and NROB1, whereas in iPS clone X12-
19 only NROB1 expression was bi-allelic (Supplemental Fig. 4, indicating that the robustness of 
XCR is variable between clones.  
Recently, hESCs and hiPSCs have been generated with more naïve characteristics closely 
resembling the mouse mESCs (Gafni et al., 2013). Naïve hiPSC lines were established by 
reprogramming human fibroblasts in NHSM medium, but could also be generated by culturing 
hiPSCs established in standard hESC medium in NHSM. To test whether NHSM medium would 
enhance XCR in our iPSCs, we passaged (p3/4) five different hiPSC lines in NHSM medium, 
which already at passage one resulted in morphologically mouse-like hiPSCs that could be 
passaged through trypsinization (Fig. 4f). FACS and quantitative RT-PCR analysis indicated that 
expression of TRA1-81, ID3 and STAT3 was up-regulated, and that expression of DNMT3A and 
DNMT3B was down-regulated, in NHSM culture conditions as described (Gafni et al., 2013) 
(Fig. 4g, h, I, j, k). Other tested markers, including TEAD4 and DUSP10, did not show consistent 
changes. XIST RNA-FISH and quantitative-RT-PCR analysis on these hiPSC lines, fixed after six 
passages in NHSM, indicated a near loss of XIST clouds and XIST expression in most lines (Fig. 
4l, m, n), consistent with reported findings (Gafni et al., 2013). Allele specific RT-PCR analysis 
indicated no change in the allelic expression ratio of XIST after culturing the hiPSCs in NHSM, 
with different clones showing either bi- or mono-allelic expression of XIST (Figure 4O). For most 
clones, the allele specific expression ratio of SUVAR39H1 was stable throughout several 
passages in NHSM. Also, allele specific expression analysis of HUWE1, ATP7A and NROB1, on 
three different X12 iPSC lines, indicated no change in the expression status before and after 
transfer to NHSM.   These findings indicate that culture of the hiPSC lines in NHSM does not 
have an effect on XCR, but reduces XIST expression. This indicates that indeed a further shift 
towards stable XCR in hiPSCs can be obtained by culturing iPSCs in NHSM.   
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Discussion 
 
Here, we have investigated the dynamics of X chromosome inactivation in hiPSCs derived from 
human female fibroblast cultures with completely skewed rXCI. This approach allowed us to 
include analysis of X chromosome reactivation (XCR) and X chromosome inactivation (XCI) at 
the single cell level. The present results show that, at the single cell level, reprogramming of 
human cells into hiPSCs results in XCR, even at early passages. Bi-allelic expression of different 
X-linked loci indicates that the Xi is reactivated in a large part of the cell population of our 
hiPSC lines, but is variable between iPSC lines. In several hiPSC lines we also detected XIST 
expression and expression of several X-linked genes from the allele which was not active in the 
starting fibroblast culture. Human iPSC lines share a clonal origin, and therefore this switch in 
expression from one allele to the other, or bi-allelic expression, indicates that during the 
reprogramming process XCR must have occurred in a high proportion of cells.  Differentiation 
of hiPSCs was found to result in completely skewed rXCI, similar to that of the starting 
fibroblast population, indicating a high selective pressure against cells which have inactivated 
the intact X chromosome. 
 A recent study indicated that XIST expression can be lost upon prolonged passaging of 
female hiPSCs, referred to as “erosion of XCI” (Mekhoubad et al., 2012). This epigenetic erosion 
was found to be irreversible, and correlated with a loss of differentiation characteristics, and is 
very relevant for disease modelling procedures. Erosion of XCI in hiPSC lines can be effectively 
prevented by XCR followed by XCI upon differentiation. Several studies have been published 
assessing XCR during the reprogramming process. Derepression attributed to XCR of genes 
located on the Xi has been observed in hESC lines (Lengner et al., 2010), and has been reported 
in studies involving gene expression profile comparison of multiple female hESC and hiPSC lines 
(Bruck and Benvenisty, 2011). Very recently, XCR was shown to happen efficiently early during 
reprogramming of human cells, but that this was quickly followed by initiation of XCI upon 
generation of nascent hiPSC lines, leading to XaXi cells only (Kim et al., 2014). These authors 
concluded that XCR was the result of over-expression of the exogenous reprogramming 
factors, and that shut-down of the reprogramming cassette leads to XCI initiation. In contrast, 
our study indicates that in the present reprogramming and culture conditions hiPSCs maintain 
the XaXa state in a high percentage of cells in the absence of ectopic expression of the 
reprogramming factors. The present single cell allele specific expression analysis revealed 
expression of the SUVAR39H1, HUWE1, ATP7A, NROB1 and G6PD alleles located at different 
positions on the X chromosome that was the Xi in the starting fibroblasts, in a high (>50%) 
proportion of cells of X12 and 47,XXX hiPSC lines. This effect was already present 20 days post-
transduction, arguing against erosion of XCI in our hiPSC lines, and favouring XCR of the 
silenced Xi upon reprogramming. Our studies also showed that XaXa cells represent the major 
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population of cells at all stages after reprogramming, indicating that the present experimental 
conditions prevented robust precocious initiation of XCI, but allowed cells to maintain either 
the XaXa or the XaXi situation. Our findings would be in agreement with the suggestion that 
culturing hiPSCs in naïve growth conditions facilitates XCR, which was not addressed in this 
initial report (Gafni et al., 2013). Indeed, our studies indicate that NHSM growth conditions 
effectuate a reduction in the percentage of cells with XIST-coated X chromosomes. However, 
this does not lead to changes in the allele specific expression ratio of SUVAR39H1, HUWE1, 
ATP7A and NROB1 in most hiPSC lines, and although we only analysed our cells at an early 
stage after changing to the NHSM condition (passage 4), these findings suggest that XCR and 
XCI characteristics are hiPSC line specific and established during reprogramming, and cannot be 
changed afterwards. Recently, two other protocols have been described to revert primed into 
naïve hESCs (Takashima et al., 2014; Theunissen et al., 2014). Surprisingly, one study reports 
initiation of XCI after induction of the naïve state (Theunissen et al., 2014), whereas another 
study indicates loss of XIST and H3K27me3 accumulation after a reset of primed to naïve ESCs 
(Takashima et al., 2014). These findings emphasize that knowledge about the transcriptional 
status of the X chromosomes in the ICM of the female pre-implantation human embryo will be 
crucial to conclude which of these conditions result in hESCs that resemble ICM cells most.  
The results presented herein strongly suggest that XCR of the Xi is an important first 
step in reprogramming of human female fibroblasts, and demonstrate that rXCI is often de 
novo initiated during the culture of the generated hiPSC lines, most likely triggered by partial 
differentiation of the hiPSCs. In addition we found that XCR appears to occur remarkably 
efficient under standard reprogramming conditions, and that subsequent NHSM culture 
conditions stabilize this XaXa state. This facilitates rapid expansion and genetic manipulation of 
established female hiPSC lines with two active X chromosomes, to be used for various 
applications, in particular disease modelling, offering differentiated cell types that have newly 
established an Xi, thereby avoiding effects related to erosion of XCI. Furthermore, this provides 
us with a powerful model system to study human XCI, allowing us to examine the effects of a 
wide spectrum of X-linked mutations and deletions on XCI.  
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Experimental Procedures 
 
Cell lines 
GM07148 (X12), GM03923 (X14) and GM03827 (X15) fibroblast were obtained from the Corriel 
cell repository, and 47,XXX fibroblasts established from a skin biopsy of a triple X patient 
(Brosens et al., 2014). All fibroblast were cultured in standard fibroblast medium.  
 
hiPS cell generation and culture 
To generate iPSC, human fibroblasts from lines X12 (p12), X15 (p4), and 47,XXX (p14) were 
reprogrammed according to Warlich et al., with minor modifications (Warlich et al., 2011). 
NHSM medium and culture conditions were as described by Gafni et al., 2013. Detailed 
information is provided in the supplementary experimental procedures. 
 
Immuno-RNA-FISH analysis 
Detailed protocols and probes for RNA-FISH and immuno-RNA-FISH have been described 
(Barakat and Gribnau, 2014; Barakat et al., 2011; Jonkers et al., 2009). For immunostainings, 
the following antibodies were used: anti-Nanog (1:100, Abcam), anti-KLF4 (1:250, Abcam), anti-
H3K27me3 (1:500, Diagenode), anti-H3K4me3 (1:1000, Upstate), anti-H3K9ac (1:1000, Sigma), 
anti-CD9 (Invitrogen), anti-GCTM2 (BD), anti-SSEA4 (BD) and anti-TRA1-80 (BD).   
 
RT-PCR and single cell RT-PCR 
All primers used are described in Supplementary Table 2. For single cell RT-PCR, SSEA1+/TRA1-
81+ double positive cells were FACS sorted in 96-well plates containing 9 μl lysis buffer using a 
BD FACSAria apparatus. Lysis buffer consisted of 8 μl 2xReaction mix (SuperScript One-Step RT-
PCR kit, Invitrogen), 10U RNAseOut (Invitrogen), and 0.15% IGEPAL CA-630 (Sigma). cDNA was 
prepared with gene specific outer primers, and further processed as described in the 
supplementary experimental procedures. PCR products were precipitated, and digested with 
the indicated restriction enzymes (New England Biolabs) to distinguish expression from the 
different alleles. RFLPs in XIST, SUVAR39H1, G6PD, and SNPs in HUWE1, NROB1 and ATP7A 
were identified by PCR amplification and Sanger sequencing, followed by allele specific 
expression analysis using cDNA specific primer sets described in Supplementary Table 2.       
 
SNP array and HUMARA analysis 
To map the deletions in our fibroblast cell lines, SNP array was performed using Human CYTO 
SNP 12 version 1 arrays (Illumina®, San Diego, CA, USA), aligned to human genome build 18. A 
detailed description of the HUMARA assay applied to determine skewing of XCI is provided in 
the supplementary experimental procedures.  
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DNA-FISH analysis 
To visualize the deletion in cell lines, DNA-FISH was performed according to standard 
procedures. Probes used were BAC CTD-3076O23 (BAC1FITC, Xq23, 108,9 Mb, HG19), RP11-
799O20 (BAC2, A595, Xq25, 123 Mb) RP11-75N13 (BAC3, FITC, Xq21.1,  84,5 Mb), and RP1-
279N11 (BAC4, A595, Xq13.3, 75,8 Mb).   
 
Statistics qRT-PCR analysis 
For qRT-PCR expression analysis the average and standard deviation of three biological 
replicates is shown. 
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Human iPS cells as a model system for XCI 
 
At this moment there is no efficient model system at hand for studying the mechanisms of 
human XCI. In addition, studying human XCI as it occurs during female embryonic development 
would require the study of human embryos, which is difficult and ethically objectionable. With 
the generation of human iPS cells, a model system for studying human XCI may be within 
reach. Human iPS cells were first generated by S. Yamanaka’s lab in 2007 (Takahashi et al., 
2007). By introducing four pluripotency-associated transcription factors in adult somatic cells 
they were able to reprogram these cells into pluripotent stem cells. This technology 
circumvents the need for human embryos in generating pluripotent stem cells, and holds great 
promise for the field of regenerative medicine. In addition, human iPS cell technology has been 
very useful to model human disease and to study human embryonic development. 
Furthermore, as iPS cells can be maintained indefinitely, and hold the potential to maintain 
two Xa’s, they also seem a promising model system for studying the mechanisms of XCI. 
However, several studies that analyzed the status of X chromosomes in iPS cells have reported 
contradictory outcomes regarding reactivation of the Xi (Amenduni et al., 2011; Ananiev et al., 
2011; Cheung et al., 2011; Kim et al., 2011; Marchetto et al., 2010; Pomp et al., 2011; Tchieu et 
al., 2010).  
In chapter 6 we studied reactivation of the Xi during reprogramming of human 
fibroblasts towards iPS cells, using fibroblasts that are 100% skewed. Using fibroblasts with 
100% skewed XCI will increase the sensitivity to detect expression form the Xi.  We found 
that only one of the three fibroblast lines that were used, had reactivated the Xi during iPSC 
reprogramming. The inability to generate iPSC clones with two Xa’s from the other two cell 
lines, illustrates the inefficiency of the reactivation process during the reprogramming from 
adult somatic cells towards iPS cells. In addition, it is also possible that we obtained iPSC clones 
with two Xa’s for only one of the three cell lines purely by chance. The reprogramming process 
is highly variable, and only a few iPSC clones reach a state that is naïve enough to facilitate 
reactivation of the Xi. Therefore, the large variability in reprogramming efficiency will probably 
result in a stochastic outcome of the Xi reactivation process. The outcome of only one of the 
three cell lines managing to reach a state with two reactivated X chromosomes, might also be 
subject to coincidence during the analysis. As only six iPSC clones were analyzed per cell line, 
clones with an Xi could by coincidence have been selected. Although unlikely, this option 
cannot be ruled out. Another, intriguing, hypothesis explaining why only one of the three cell 
lines yielded iPSC clones with two Xa’s is that the X chromosome aberration of this cell line is 
implicated in the reactivation process of the Xi. The fibroblast cell line for which we could 
generate iPSC clones with two Xa’s carries an abnormal X chromosome, involving a truncation 
of the long arm of the Xi. Loss of genetic material from the Xi might facilitate its reactivation 
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during reprogramming. One explanation how loss of genetic material might facilitate 
reactivation, is if the region involved in the truncation contains a trans-acting activator of XCI. 
Genetic loss of a trans-acting activator is likely to result in a larger probability for reactivation 
of the Xi. This hypothesis is contradicted by the observation that one of the other fibroblast cell 
lines that was used in this experiment did not show any Xi reactivation, while it carried an Xi 
with a deletion involving the same region that is deleted in the X12 fibroblasts. This line, X15, 
carries an Xi with a larger truncation of the long arm, encompassing the truncation of the X12 
line. Therefore, involvement of the deleted region of the X12 fibroblast line in successful Xi 
reactivation, should be considered with caution. 
The reactivation of the Xi which was observed, was found to be instable. Instead of a 
stable reactivation, the Xi seems to be subject to a continuous process of reactivation and 
inactivation in conventional culture medium. When cultured in naïve medium, expansion of 
clones containing two Xa’s is possible. This observation illustrates the difficulties in obtaining 
and maintaining iPSC clones carrying two Xa’s, and indicates that Xi reactivation in iPS cells 
should be considered with care.  
Another argument to consider Xi reactivation in iPS cells with caution is provided by a 
rather unusual reactivation pattern that was observed in an iPSC clone generated from 
fibroblasts of a female carrying an RNF12 mutation on the Xi (unpublished results). This female 
carried the RNF12 hypermorph mutation of family 1, described in chapter 4. Two fibroblast cell 
lines were obtained from siblings that are carriers of this mutation, and were subjected to iPSC 
reprogramming. Six iPSC clones were obtained in total, with only one of these clones showing 
Xi reactivation. Transcriptional analysis of the Xi showed reactivation of the X-encoded genes 
G6PD, HUWE1 and NAP1L3 in this iPSC clone. However, the mutant RNF12 allele was not 
expressed in these iPS cells, suggesting that most of the X chromosome, if not all, was 
reactivated except for RNF12. This observation might be explained by the RNF12 mutation 
itself, although we consider this option unlikely, as the point mutation of the mutant allele 
would have to result in either complete transcriptional inhibition or transcript instability. This is 
something we did not observe in HEK293 cells or mouse ES cells transfected with this mutant 
allele. A more likely explanation would be that while most of the X chromosome is reactivated, 
a small region surrounding the XIC is not, and Xist is still expressed from the reactivated Xi. The 
continued expression of Xist after reactivation of the Xi, provides an explanation why the 
region surrounding the Xic is not reactivated, as Xist RNA still accumulates locally in the Xic 
region. Furthermore, this hypothesis might explain why human iPS cells preferentially 
inactivate the reactivated Xi upon iPSC differentiation, as Xist might already have locally 
accumulated on this chromosome prior to differentiation. Lastly, the continued expression of 
Xist from the reactivated X might explain why the Xi of iPS cells in conventional medium seems 
to be subject to continuous reactivation and inactivation. Unfortunately, the described 
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reactivation pattern of reactivation along the X chromosome, except for a region surrounding 
the Xic, was observed only in a single iPSC clone. So far we could not confirm these results for 
other iPSC clones, as allele specific RNF12 expression analysis could only been performed for 
one other iPSC line. 
In conclusion, it seems possible to obtain iPSC clones that contain two active X 
chromosomes, at a low efficiency and with questionable stability. In addition, it could be that 
reactivation does not involve the entire X chromosome, and  XIST continues to be expressed 
from the partially reactivated X chromosome. Altogether, it appears unlikely that iPSC 
technology will be suitable as a standard model for studying the mechanisms of human XCI at 
this moment. Perhaps that with the inclusion of additional reprogramming factors, new culture 
media and increasing knowledge of the reprogramming process, iPSC reprogramming will be 
more efficient and can be accompanied by stable reactivation of the Xi. Future experiments 
should be aimed at understanding the difference between human and mouse ES and iPS cells, 
as  mouse ES and iPSC cells are characterized by two Xa’s, where human ES cells and iPS cells 
mostly carry an Xi. The differences between mouse and human systems might be explained by 
the developmental stage represented by these cells. In addition, studies with human embryos 
will be crucial to understand how XCI precedes during normal human peri-implantation 
development, providing a benchmark what to expect with respect to human iPS cells.   
 
 
 
The stochastic model for counting and choice 
 
In chapter 2 we provided additional evidence that XCI in mouse ES cells is stochastic, with both 
X chromosomes having an individual probability to inactivate. The previously postulated 
models are deterministic in nature and propose that prior to actual inactivation, a cell 
determines which X chromosome will be inactivated. However, a deterministic model cannot 
explain the observation of diploid female cells that have initiated XCI on both X chromosomes.  
In a stochastic model initiation of XCI on both X chromosomes is possible, as both X 
chromosomes have an intrinsic probability to inactivate, independent of each other.  
Although a stochastic model of XCI is most fitting with in vitro and in vivo observations, 
debate has continued on whether a stochastic model should be supplemented or replaced by 
the transvection model. In the transvection model, inactivation of one of the two X 
chromosomes present in female cells is accomplished by a transient co-localization of the two 
X chromosomes, before initiation of XCI. Co-localization of the Xic’s of the two X-chromosomes 
regulates monoallelic Xist upregulation, resulting in the inactivation of only one X chromosome 
(Augui et al., 2007; Bacher et al., 2006; Donohoe et al., 2009; Masui et al., 2011; Xu et al., 
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2006).  Indeed, in a recent publication it is argued that the frequency at which biallelic Xist 
upregulation is observed is too low to be explained by stochastic gene expression alone, and 
other mechanisms need to exist to ensure monoallelic expression (Masui et al., 2011). 
Therefore, the authors propose the transvection model as an alternative model to stochastic 
initiation of XCI. The hypothesis of transvection in XCI is based on the observations that the 
two Xic’s co-localize for 45 minutes during initiation of XCI, and that during co-localization Tsix 
expression is often monoallelic. The observed monoallelic expression of Tsix is proposed to be 
the consequence of an asymmetric distribution of regulatory factors, and will result in 
monoallelic Xist expression. Although Tsix expression is restored to biallelic expression after 
one hour, Xist continues to be monoallelic expressed, resulting in XCI .  
Although transvection is an intriguing hypothesis, the observed frequency of Xic-Xic 
pairing is too low to explain in vitro observations, with XCI initiating at a much higher 
frequency. Instead, the observed Xic-Xic pairing could also be explained by a more general 
mechanism of transcriptional regulation. Gene transcription occurs at nuclear foci enriched for 
RNA pol II, termed transcription factories. Genes are transcribed in bursts, separated by pauses 
of gene silence. During their transcriptional bursts genes tend to co-localize in transcription 
factories, and multiple genes, located in-cis or in-trans can therefore share the same 
transcription factory (Osborne et al., 2007). Given these observations, it seems more likely that 
the co-localization of the two Xic’s during initiation of XCI is a reflection of their change from 
transcriptional silence to transcriptional activity, during which they will co-localize with 
increased frequency at the same transcription factory. 
In addition, several in vitro experiments suggest that transvection of the two X 
chromosomes is not required for proper initiation of XCI. The elements that were proposed to 
be required for transvection are the Xite, Tsix and Xpr regions. However, studies with mouse ES 
cells carrying deletions of these genetic elements, separately or together, showed proper 
initiation of XCI in absence of these elements (Barakat et al., 2014). This indicates that 
transvection is not required for initiation of XCI, or can still occur in absence of these elements.  
In addition, transvection seems relatively easy when two X chromosomes are involved, 
but can be envisioned as highly problematic when more than two X chromosomes are present. 
If in such a situation the co-localization of more than two X chromosomes occurs sequentially 
or parallel was never specified. Nevertheless, XCI takes place in situations where more than 
two X chromosomes are present. In human female 47XXX individuals two of the X 
chromosomes are inactivated (Grumbach et al., 1963). Also in mouse tetraploid XXXX and XXXY 
embryos and ES cells, XCI occurs and the majority of cells maintains two Xa’s (Webb et al., 
1992).  Although co-localization of more than two X chromosomes would be a complicated 
process none of these experiments measured co-localization of the two X chromosomes during 
XCI, and can therefore conclude that it does not occur. Therefore, the most convincing 
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evidence that transvection is not required for proper initiation of XCI comes from experiments 
where XX and XY ES cells where fused to form XX-XY heterokaryons. Upon differentiation, 
these cells still initiate XCI on the single X chromosome present in the male nucleus, a situation 
that is incompatible with transvection. Taken together, these results indicate that X-pairing or 
transvection is not required for determining the number of X chromosomes and proper 
initiation of XCI. Therefore, we conclude that a stochastic model for XCI counting and choice is 
the only model compatible with all observed outcomes of the XCI process.  
 
 
 
Trans-acting activators of XCI 
 
Rnf12 is likely not the only trans-acting activator of XCI in mouse 
Correct regulation of XCI is probably subject to a sensitive titration between XCI activators and 
XCI inhibitors. The XCI activators are responsible for counting the number of X chromosomes in 
a nucleus and together with autosomal XCI inhibitors determine how many X chromosomes 
will be inactivated. The major representative of the XCI activators in the mouse is Rnf12, as it is 
the only XCI activator identified to date (Gontan et al., 2012; Jonkers et al., 2009). Despite 
being the only identified trans-acting activator of XCI, the involvement of other XCI activators 
in mouse is indicated  by experiments with female Rnf12+/- ES cells. Such ES cells should with 
regard to XCI, be similar to male ES cells that have only one allele of Rnf12. However, where 
male ES cells do not initiate XCI, female Rnf12+/- ES cells can initiate XCI, although at a lower 
rate compared to wildtype cells (Barakat et al., 2014). 
When speculating on the genomic location of other XCI activators, one should consider 
the evidence that hinted at the genomic location of Rnf12. Rnf12 was identified as an activator 
of XCI by screening transgenic ES lines carrying BACs covering two regions of 5 Mb, located 
centromeric and telomeric of the Xic. The presence of an XCI activator in these regions was 
indicated by experiments analyzing XCI in mice carrying the HD3 truncation and the T(16;X) 
Searle’s translocation (Fig 1). Cells carrying an X chromosome with the HD3 truncation were 
still able to inactivate both the wildtype X chromosome and the X chromosome with the HD3 
truncation, indicating the presence of an XCI activator on this X chromosome. On the other 
hand, cells carrying the X16 product of Searle’s translocation never showed inactivation of the 
X16 product, indicating the XCI activator is missing from this chromosome. In addition, deletion 
of the Xic from one of the X chromosomes in female ES cells did not result in an XCI phenotype, 
indicating that this region not contains an XCI activator (Monkhorst et al., 2008). From these 
observations it followed that an XCI activator had to be located in between the breakpoints of 
these two X-chromosomal aberrations, leading to the identification of Rnf12.  
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Figure 1. 
Mouse X chromosome abnormalities defining the region harboring a trans-acting activator 
a. Ideogram of a mouse X chromosome depicting the chromosome bands  
b. The HD3 truncation has its breakpoint in the middle of chromosome band D. 
c. Searle’s translocation involves the exchange of genetic material between the X chromosome and 
chromosome 16. The X-chromosomal breakpoint is located in chromosome band B. 
 
 
 
 
 
As Rnf12 is the first XCI activator identified in the region delineated by the HD3 
truncation and Searle’s translocation, it is likely to be the most important. The location of other 
XCI activators can also be hypothesized between the breakpoints of the HD3 truncation and 
Searle’s translocation (Rastan, 1983; Rastan and Robertson, 1985; Takagi, 1980). However, the 
presence of XCI activators outside this region should certainly not be excluded. The 
breakpoints delineating this region were described and examined in the early 80’s. The 
breakpoint of the HD3 truncation, was mapped to the middle of the X-D band using 
karyotyping (Robertson et al., 1983). However, a later study examined hybrid cell lines from 
the HD3 ES cell line, and found 7 classes of HD3 breakpoints. Only one of these breakpoints 
retained an Xist allele, as is compatible with the observed XCI from this truncated X 
chromosome. Using PCR this breakpoint was not mapped to the X-D band, but instead to the 
interval between DXMit4 and Plp1 in band X-F1 (Arnaud et al., 1993). Based on this study the 
telomeric interval harboring the XCI activators is not 5 Mb but 36 Mb instead. Given that these 
early studies analyzed XCI using chromosome staining techniques (like the Kanda method) to 
identify the inactive X chromosome, it is not unlikely that they were unable to detect early 
initiation of XCI in the analyzed cells and embryos (Kanda, 1973). As Rnf12 is the major XCI 
202 |  Chapter 7 
 
 
activator, the effect of less important activators might have been missed using these less 
sensitive methods. Taken together, the location of the breakpoints delineating the region 
harboring the XCI activators can be questioned, as well as the sensitivity of XCI analysis. 
Therefore the location of additional XCI activators with less potential than Rnf12 should best be 
approached in an unbiased, hypothesis-free way. 
 
Human RNF12 as a trans-acting activator of XCI 
While Rnf12 is identified as an activator of murine XCI, it is uncertain whether RNF12 also acts 
as an activator for human XCI. In chapter 3 and 4 several observations suggest that RNF12 
might act as an activator of human XCI as well, although definite proof still needs to be 
provided. In chapter 3 genetic evidence is provided that RNF12 might act as a trans-acting 
activator of human XCI. We describe a female individual, with a 1.2 Mb deletion of the Xic, 
involving XIST, TSIX and their cis-regulatory elements, but not RNF12. Cells heterozygous for 
this deletion are able to undergo XCI, which is in agreement with our observations in the 
mouse, and indicate that also in human the XCI activator(s) is located outside the deleted 
region. Comparing this deletion to other X-chromosomal aberrations narrows down the 
location of a trans-acting activator to a region telomeric of the cis-XIC, encompassing RNF12 
(Allderdice et al., 1978; Brown et al., 1991; Lafreniere and Willard, 1993).  
Other lines of genetic evidence suggesting that RNF12 might act as a trans-acting 
activator of XCI are provided by ring X chromosomes. Ring X chromosomes are truncated X 
chromosomes that retain a centromere and are fused at their truncated telomeres, resulting in 
a ring-shaped chromosome. They can be detected in Turner syndrome patients, that show 
mosaicism  with the majority of their cells having a 45X0 karyotype and a small proportion 
containing an additional ring X chromosome. The active state of these ring X chromosomes is 
associated with a more severe phenotype. Some of these ring X chromosomes contain 
different regions of the XIC and adjacent regions and could provide a clue to the location of 
trans-acting activators. Quite a number of X chromosomes contain a breakpoint nearby RNF12, 
but unfortunately they are not characterized with enough precision to assess involvement of 
RNF12. Therefore, more precise characterization of the breakpoints of these ring X 
chromosomes is mandatory before conclusions can be made with respect to involvement of 
RNF12 in XCI. Nevertheless, XCI phenotypes of cell lines containing ring X chromosomes need 
to be interpreted with caution, as the ring X chromosome could have arisen after XCI had 
occurred and the trans-acting activator might have been deleted after onset of XCI. An 
example of an abnormal X chromosome not undergoing XCI because it had arisen after XCI is  
described in a female individual with Turner syndrome and chromosomal mosaicism involving 
three abnormal cell lines (Migeon et al., 1996). One of these cell lines retained a truncated X 
chromosome involving a deletion of the long arm, but leaving the cis-XIC and RNF12 intact. 
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Despite the presence of two copies of RNF12 and two XIC’s this cell line did not show XCI. The 
relative proportions of the three cell lines in this individual, and the absence of XCI in the cell 
line containing the truncated X chromosome led the researchers to believe that the truncated 
X chromosome had been formed through duplication of  a monosomic X chromosome and 
subsequent degeneration of the duplicated X chromosome. This report illustrates that the XCI 
phenotype might not always be related to the observed X chromosomal abnormalities found in 
Turner syndrome patients. However, when iPS cell reprogramming can reliably generate cells 
with two active X chromosomes, iPS cells generated from cell lines containing well 
characterized ring X chromosomes will be very interesting for genetic dissection of the human 
XCI machinery. Alternatively, human XCI activators could be identified by introducing large 
deletions in the X chromosome of human iPSC lines using the CRISPR/Cas9 targeting system. 
Upon deletion of an XCI activator these cell lines will initiate XCI at a lower rate when they are 
induced to differentiate. 
Several studies have described individuals carrying X-chromosomal aberrations that 
indicate that a human trans-acting activator is located in the region containing RNF12 
(Allderdice et al., 1978; Brown et al., 1991; Lafreniere and Willard, 1993; Leppig et al., 1993). 
However, one study describes an abnormal X chromosome that lacks RNF12 but still displays 
XCI, indicating that other trans-acting activator genes might exist besides RNF12 (Leppig et al., 
1993). These alternative trans-acting activators must be located in the region centromeric of 
the cis-XIC, or on the short arm of the X chromosome.  
In addition to genetic observations suggesting that RNF12 might function as a trans-
acting activator of XCI, several lines of biochemical evidence also support this. Firstly, human 
and mouse RNF12/Rnf12 transgenes induce ectopic XCI equally well in male transgenic ES cells 
(Jonkers et al., 2009). This shows that human RNF12 functions in a murine cellular 
environment, and suggests that human RNF12 is able to target mouse REX1 for proteasomal 
degradation, leading to XCI in male cells, analogous to how mouse Rnf12 operates (Gontan et 
al., 2012; Jonkers et al., 2009). The experiments described in chapter 4 show that in HEK293 
cells human RNF12 ubiquitinates human REX1, thereby targeting the latter for proteasomal 
degradation. Despite this analogy in RNF12-induced degradation of REX1 between mouse and 
human, we have not been able to show that the human RNF12/REX1 axis also regulates human 
XCI. Human iPS cells generated from female carriers of mutations in RNF12 did not contain a 
reactivated X chromosome, and could therefore not be used to demonstrate an effect of the 
identified RNF12 mutation of XCI. 
Indirect evidence that RNF12 is involved in XCI is provided by the families described in 
chapter 4. Although these families carry different mutations in RNF12, that affect different 
functional domains, all three families show completely skewed XCI in females carrying the 
mutated allele. Skewed XCI affects blood cells, skin fibroblasts and cone cells of the retina. We 
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consider it unlikely that this skewed XCI is the result of secondary cell selection against cells 
that have inactivated the X chromosome carrying the unaffected RNF12 allele. In fact, males 
inheriting this mutation are viable and display diverse phenotypes, demonstrating that cell 
viability is unaffected or mildly affected. Instead it seems more likely that cell functioning is 
affected by RNF12 mutations, which could possibly lead to secondary cell selection. However, 
we consider it unlikely that such a secondary cell selection would lead to completely skewed 
XCI, and that this would affect all tissues analyzed. Therefore, we hypothesize that the 
identified mutations affect RNF12 protein functioning, and result in primary non-random 
skewing of XCI. This hypothesis is supported by the observation that XCI in Rnf12+/- mice is also 
primary skewed towards inactivation of the mutant X chromosome. 
Taken together, the experiments described in chapter 4 indicate that human REX1 is 
targeted for proteasomal degradation by RNF12. However, to finally prove that RNF12 acts as a 
trans-acting activator of XCI, a repressive effect of REX1 on XIST expression should be 
demonstrated. To date, involvement of REX1 as a repressor of XIST has to our knowledge not 
been investigated yet. Demonstrating this function of REX1 is crucial to demonstrate that 
human RNF12 functions as a trans-acting activator of XCI, analogous to mouse Rnf12. 
Unfortunately, human iPS cells do not seem suitable for this purpose. A promising experiment 
would be to mutate REX1 human ES cells containing two active X chromosomes, using CRISPR 
technology to analyze the effect on XCI. 
Although the results presented here provide evidence that RNF12 might act  as a trans-
activator of XCI, they do not allow us to conclude this with any certainty. Instead, it should still 
be considered that RNF12 might not be involved in human XCI, as several arguments support 
this as well. First, REX1 protein levels did not differ between wildtype and mutant RNF12 in co-
transfection experiments. Also, endogenous REX1 levels in iPS cells reprogrammed from skin 
fibroblasts of an affected male from family 3 did  not show any differences from unaffected iPS 
cells (quantified immunostainings, data not shown). Second, XCI might proceed differently in 
humans compared to mouse. When XCI is initiated in mouse embryos Xist accumulates on one 
X chromosome, which results in the inactivation of the Xist coated X chromosome. Although a 
small percentage of cells can be observed with two Xist coated X chromosomes, these cells are 
thought to have faulty inactivated both X chromosomes (Monkhorst et al., 2008). In human 
embryos, the onset of XCI in early blastocysts has been studied by few studies. Two of these 
studies observed two XIST domains in the majority of cells, without accompanying 
characteristics of gene silencing (Okamoto et al., 2011; Teklenburg et al., 2012). Although these 
observations are contradicted by a third study, they provide an interesting hypothesis in light 
of our results. If indeed, during human XCI XIST RNA accumulates on both X chromosomes 
before gene silencing is induced, a function of RNF12 as a trans-acting activator might have 
become obsolete. Instead, such a system would require a trans-acting inhibitor that prevents 
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inactivation of both X chromosomes when actual silencing is initiated. Hypothetically RNF12 
could still perform this feedback function via inhibition of XIST transcription through REX1. 
 
RNF12:REX1 titration 
From previous experiments, and the experiments described in chapter 4 it can be hypothesized 
that correct regulation of XCI is subject to a sensitive titration  between XCI activators and XCI 
inhibitors, which is mostly reflected by the balance between REX1 and RNF12. Previous studies 
performed in mouse showed that degradation of REX1 by RNF12 is dose dependent, indicating 
that expression of Rnf12 and Rex1 is well balanced during mouse XCI (Gontan et al., 2012). It 
can be hypothesized that also for human XCI titration between XCI activators and XCI inhibitors 
needs to be well balanced to correctly regulate XCI. The experiments described in chapter 4 
show that degradation of human REX1 is dependent on the dose of RNF12, and that titration of 
these levels is very important with respect to the outcome of the experiment. In co-
transfection experiments with a human RNF12:REX1 ratio of 1:16, RNF12 expression seems not 
to affect REX1 expression, indicating that REX1 is not significantly degraded when present in 
excess. In contrast, at a ratio of 3:1 RNF12 completely degrades REX1, and REX1 is no longer 
detectable. The importance of RNF12:REX1 titration, and well titrated expression of other 
putative XCI activators and -inhibitors, is further illustrated by the experiments with XXY 
triploid ES cells described in chapter 2. In these cells the gene dosage between RNF12 and REX1 
is 2:3, whereas in normal diploid cells this ratio is 2:2. Compared to diploid cells XXY triploid 
cells have a very low rate of XCI initiation, indicating that the relative level of RNF12 and other 
putative XCI activators in these cells only marginally exceeds the threshold required for XCI (fig. 
2). Furthermore, when these cells are compared to tetraploid XXXY cells with a RNF12:REX1 
ratio of 3:4, it becomes obvious that the rate of XCI depends on the genic ratio of RNF12:REX1, 
with large differences in the rate of XCI initiation occurring as a result of small changes in the 
XCI activators: XCI inhibitors ratio. Taken together, these results suggest that the balance 
between XCI activators and XCI inhibitors, which is likely reflected by RNF12 and REX1 needs to 
be titrated precisely to ensure a well-executed XCI process. 
The importance of correct titration of RNF12 and REX1 is further illustrated by the 
observations described in chapter 4, where mutations in RNF12 with both a gain-of-function 
and a loss-of-function result in exclusive inactivation of the X chromosome carrying the mutant 
allele. This observation suggests that cells do not tolerate an overdose, nor a deficit in 
functional RNf12. Here, we present a model explaining the observation that both a 
hypermorphic RNF12 allele and a hypomorphic RNF12 allele result in primary non-random XCI 
of the mutant X chromosome. (Fig. 3). In mouse, before XCI is initiated there is a relatively high 
concentration of REX1, with a low concentration of RNF12. Upon differentiation RNF12 is 
upregulated leading to targeted degradation of REX1. When the concentration of REX is  
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Figure 2. 
XCI initiation differs by X:ploidy ratio 
The percentage of cells that initiated XCI at d3 of ES cells differentiation is plotted against the X:ploidy 
ratio. XCI initiation is shown for XY and XX diploid cells, XXY triploid cells and XXYY, XXXY, and XXXX 
tetraploid cells. 
 
 
 
 
reduced below a threshold where REX1 is no longer able to repress Xist, XCI is initiated. This 
results in Xist upregulation on both X chromosomes. The X chromosome where Xist silences its 
antisense inhibitor Tsix will be completely inactivated, and will be the future Xi. On this X 
chromosome Xist will also silence Rnf12 in-cis, leading to a reduction in the concentration of 
RNF12, which prevents inactivation of the second X chromosome by halting further 
degradation of REX1 (Fig. 3a). We hypothesize that in cells carrying a hypermorph or a 
hypomorph RNF12 allele, the only possible outcome of XCI is inactivation of the mutant X 
chromosome, because inactivation of the wildtype RNF12 allele will result in re-activation of 
the Xi in both situations. After reactivation the XCI process starts over again, repeating itself 
until the mutant RNF12 allele is inactivated.  
When considering cells heterozygous for a hypomorph RNF12 allele, these cells are 
presented with the choice to inactivate the X chromosome carrying the mutant RNF12 allele, or   
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Figure 3. 
Models of XCI in the presence of a 
hypermorph or hypomorph RNF12 
allele 
a.   Wildtype situation: Graph 
representing the relative 
concentrations of functional 
RNF12 and REX1 plotted against 
time from differentiation. In 
pluripotent cells REX1 
concentrations are high, whereas 
RNF12 concentrations are low. 
Upon differentiation RNF12 is 
upregulated and targets REX1 for 
degradation, lowering the REX1 
concentration. When REX1 
concentrations drop below the XCI 
threshold Xist is upregulated and 
XCI starts on both X 
chromosomes. After the first X 
chromosome has silenced its copy 
of RNF12 the concentration of 
RNF12 decreases, which prevents 
a further decrease in REX1 and 
inactivation of the second X 
chromosome. 
b.  Hypomorph situation: If the X 
chromosome carrying the 
wildtype allele of RNF12 is 
inactivated the effective 
concentration of RNF12 from the 
mutant allele is insufficient to 
keep REX1 concentrations below 
the XCI threshold. Note that the 
 total amount of functional RNF12  is lower, and that upon inactivation of the wildtype allele, the 
functional dose of RNF12 is insufficient to keep REX1 below the XCI-threshold. 
 c.  Hypermorph situation: If the X chromosome carrying the wildtype allele of RNF12 is inactivated an 
excessive amount of functional RNF12 remains. This excess of functional RNF12 degrades REX1 levels 
to below the threshold for inactivation of the second X chromosome. When both copies of RNF12 are 
silenced, REX1 levels increase again resulting in the reactivation of one or both X chromosomes. Note 
that the total amount of functional RNF12 is increased.  
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the X chromosome carrying the wildtype RNF12 allele. When inactivation of the mutant X 
chromosome occurs, the wildtype allele will remain active, resulting in a wildtype situation. 
However, inactivation of the wildtype allele, means that the hypomorph allele remains active, 
resulting in a functional level of RNF12 that is insufficient to keep REX1 levels below the 
threshold required for XCI. This results in reactivation of the wildtype X chromosome, which 
allows the choice process to start over again until it results in inactivation of the mutant allele 
(Fig. 3b). When cells heterozygous for a hypermorph RNF12, inactivate the wildtype X 
chromosome an excess of functional RNF12 remains, which results in inactivation of the 
second X chromosome. When both alleles of RNF12 are silenced the concentration of REX1 
raises in the absence of RNF12, which results in reactivation of one or two X chromosomes (Fig 
3c.). Both scenarios are characterized by an extended time period during which cells inactivate 
and reactivate, which eventually results in skewed XCI. 
 
 
 
Skewing of XCI 
 
The clinical relevance of skewed XCI is clearly demonstrated by female carriers of X-linked 
diseases like Rett syndrome and Fragile X syndrome, as disease severity in these females is 
correlated to the degree of skewed XCI (Archer et al., 2007; Knudsen et al., 2006). In chapter 5 
we examined the correlation of different tissues within a female individual with regard to their 
XIR, and despite the good correlation between tissues, we observed considerable variation 
within individuals. This result is not only of relevance for clinical interpretation of XIR’s 
determined in peripheral blood and their correlation to inaccessible disease affected tissues, 
but will also be important for the interpretation of X-linked variants in GWA studies. Until now, 
X-chromosomal data in GWA studies have been relatively neglected, due to their complexity in 
analysis. However, attention in this field is focused on developing new methods to properly 
analyze X-chromosomal data, and the first analyses dedicated to X-chromosomal variants are 
published (Chang et al., 2014; Wise et al., 2013). An increase in identified X-linked variants can 
be expected, and for the correct interpretation of these X-linked variants their relative 
expression will be of importance. For this reason the correlation of XIR’s between tissues 
deserves future attention , and should preferably be aimed at identifying X chromosome wide 
expression profiles for multiple tissues, to detect tissue specific silencing and escape from XCI. 
One phenomenon that will possibly hamper these analyses is that XIR’s appear to 
diverge with age. An association of XCI skewing with increasing age has frequently been 
reported. Extrapolating from these observations we reasoned that different tissues might skew 
in opposite directions. The results presented in chapter 5 seem to confirm this hypothesis, 
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although a larger number of samples will be needed to confirm this. This divergence of tissue 
specific XIR’s within individuals can imply that the correlation between different tissues is 
different in younger females compared to elderly females. When performing X chromosome-
wide analysis of methylation or transcription with the intention to extrapolate to different 
tissues this should be taken into account. 
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Summary 
 
The difference in sex-chromosome constitution between XY males and XX females results in an 
imbalance for X-encoded genes, with females having a double amount of X-encoded gene 
products compared to males. To compensate this difference in X-chromosomal dosage, one of 
the X chromosomes in every female cell is inactivated in a process called X chromosome 
inactivation (XCI). XCI is initiated during early female embryogenesis, and seems to differ 
between mouse and human. In mouse two successive forms of XCI take place, with imprinted 
XCI (iXCI) occurring in cells of the extraembryonic tissues, and random XCI (rXCI) in cells of the 
embryo proper. Imprinted XCI precedes random XCI , and results in the exclusive inactivation of 
the paternal X chromosome (Xp) in all cells of the morula stage embryo. Later, the cells that 
will comprise the embryo proper reactivate their inactive Xp to undergo rXCI, in which all cells 
will make an individual choice which X chromosome is inactivated.  After a cell has inactivated 
one of its X chromosomes, this inactive state will passed on to all daughter cells. In humans, 
both extra-embryonic and embryonic tissues undergo r XCI. While human rXCI is of clinical 
importance when a X-linked disease or trait is involved, rXCI has been most extensively studied 
in the mouse. In this thesis we studied the mechanism behind rXCI in mouse, and the genetic 
elements involved in human rXCI. In addition, we studied the correlation of XCI between 
different human tissues and examined the reactivation of the Xi during reprogramming of 
human somatic cells.  
For mouse rXCI, several models explain how cells count the number of X chromosomes 
that are present, and determine which X chromosome is inactivated. The most fitting model is 
the recently postulated stochastic model, where every X chromosome is proposed to have an 
intrinsic chance to inactivate. This model was proposed after the observation that tetraploid 
XXXX cells undergo XCI at a higher rate compared to XXXY cells. Chapter 2 describes 
experiments that support the stochastic model of XCI. The dynamics of XCI in triploid XXY 
embryonic stem (ES) cells were analyzed and demonstrate that the probability for an X 
chromosome to inactivate depends on the X:autosome ratio. In addition, it is shown that XCI is 
independent of cell division. Since XCI is severely delayed in triploid XXY cells, the 
concentration of a hypothetical trans-acting activator only slightly exceeds the required 
threshold for XCI. Computer simulation is used to show that observational experimental data 
of XCI match a stochastic model, where XCI is determined by the concentration of a trans-
acting activator of XCI and an X chromosome specific threshold for XCI. Simulated data predict 
that the probability for an X chromosome to inactivate is not static, but changes during 
differentiation. 
Where in the mouse the genetic locus and diffusible factors required for proper 
initiation of XCI have been well defined, their involvement in human XCI is less well 
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understood. In mouse, the genetic locus required for XCI to take place is the X-inactivation 
center (Xic). The mouse Xic can be divided in a cis-acting part and a trans-acting part. The cis-
acting part is required for inactivation of the X chromosome in-cis, and the non-coding genes 
Xist and Tsix are crucial for its functioning. Xist produces a non-coding RNA that associates 
exclusively with the inactive X-chromosome (Xi). Tsix is located antisense to Xist and acts as a 
negative regulator of Xist. The trans-Xic is responsible for counting the number of X 
chromosomes in a cell and ensures that all X chromosomes but one are inactivated per diploid 
genome. To date, the only identified trans-acting activator of the trans-Xic is the E3 ubiquitin 
ligase Rnf12. Rnf12 activates Xist by targeting the XCI-repressor REX1 for degradation.  These 
central elements of the mouse cis- and trans-Xic are conserved from mouse to human to 
various degrees. Human XIST is moderately conserved, but functions analogous to mouse Xist 
as its RNA also associates with the Xi in-cis. TSIX is poorly conserved and seems no longer 
functional. RNF12 is strongly conserved, but its involvement in human XCI has not yet been 
shown. Moreover, whether the human XIC contains a cis-acting region and a trans-acting 
region, like the mouse Xic, has not been shown. In chapter 3 evidence is provided that also the 
human XIC can be divided in a cis-acting part and a trans-acting part. We describe a female 
individual with a deletion encompassing the cis-XIC. This deletion is mapped to the single 
nucleotide level, using a chromatin conformation capture based technique, and defines the cis-
XIC. The location of a human trans-acting activator is defined to a small region telomeric of the 
cis-XIC, and contains RNF12. In addition, the described individual presented with 
hypergonadotrophic hypogonadism and we propose that a dosage reduction of DMRT1C by 
50%  causes this phenotype.  
Chapter 4 describes three families with missense mutations in different functional 
domains of RNF12. These different mutations all segregate with intellectual disability in males 
and result in exclusive XCI of the affected X chromosome in females. In vitro experiments show 
that a mutation in the interaction domain of RNF12 results in a gain of function, as 
ubiquitinated levels of its substrate REX1 increase. Two mutations in the RING domain of the 
protein result in a loss of function, with a decreased ubiquitination capacity. Although exclusive 
inactivation of the X chromosome carrying the RNF12 mutant allele suggests that human 
RNF12 acts as a trans-acting activator of XCI, analogous to mouse Rnf12, additional 
experiments are required to definitively confirm this. 
As a result of XCI every female individual consists of two cell populations that have a 
different active X chromosome (Xa). In most females the ratio between cells with an inactive 
paternal X chromosome and an inactive maternal X chromosome will be around 50:50. 
Deviations from this 50:50 X-inactivation ratio (XIR) are common, and a situation where over 
80% of all cells carry the same Xi is termed skewed XCI. In a healthy female population the XIR 
follows a normal distribution. The proportion of females that display skewed XCI increases with 
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age, probably already from neonatal life onwards. The XIR is of clinical relevance when an X-
encoded trait or X-linked disease is involved. For several diseases like Rett syndrome and 
Fragile X syndrome it has been shown that female heterozygote carriers of the causative 
mutation the disease phenotype is modulated by XIR. Also several clinical conditions, for which 
no causative X-linked locus has been identified, are nonetheless associated with an increased 
prevalence of skewed XCI. Clinical testing of the XIR is often done in peripheral blood samples, 
which is not necessarily the disease-affected tissue. To investigate the correlation between the 
XIR of easily accessible tissues like blood, buccal epithelium and hair follicle, and often 
inaccessible disease-affected tissues we compared the XIRs of different tissues. These results 
are reported in chapter 5, where we find that there is a good correlation between tissue-
specific XIR’s within an individual, although a substantial variation between tissues is present. 
Of the easily accessible tissues blood, hair follicles, and buccal epithelium the best correlation 
to inaccessible tissues was observed for buccal swab.  The only inaccessible tissue with a poor 
correlation to buccal epithelium is ovary, which has a poor correlation to blood as well, but has 
a good correlation to hair follicles instead. 
Despite the clinical implications of XCI, a good model system for studying human XCI is 
not available yet. With the generation of induced pluripotent stem (iPS) cells, such a model 
system seemed at hand, as these new pluripotent cells might contain two active X 
chromosomes. However, reprogramming cells to a naïve state that is associated with two 
active X chromosomes is difficult, and many studies have reported different outcomes 
regarding the activity of the X chromosomes. In chapter 6 the reactivation of the Xi is analyzed 
when cells are being reprogrammed from skin fibroblasts to iPS cells. Although the Xi seems to 
be reactivated during the early stages of the reprogramming process, the reactivated state is 
unstable, resulting in re-inactivation. As a result a cell population is a mixture of cells that have 
two Xa’s and cells with one Xi and one Xa. Culturing these cells in naïve medium seems to 
stabilize the reactivation-inactivation process and allows expansion of clones with two Xa’s. 
These results show that although very inefficient human iPS cells might provide a model 
system for studying XCI. 
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Samenvatting 
 
Door het verschil in geslachtschromosomen tussen XY mannen en XX vrouwen hebben 
vrouwen een dubbele hoeveelheid van X-chromosomale genproducten in vergelijking met 
mannen. Om te compenseren voor deze relatieve overdosering van het X chromosoom in 
vrouwen wordt in iedere vrouwelijke cel een X chromosoom geïnactiveerd in een proces 
genaamd X chromosoom inactivatie (XCI). XCI vind plaats tijdens de vroege embryongenese en 
is waarschijnlijk verschillend tussen mens en muis. In de muis treden er twee opeenvolgende 
vormen van XCI op, waarbij de cellen van de extra-embryonale weefsels een geïmprinte vorm 
van XCI (iXCI) ondergaan, terwijl de cellen van het embryo random XCI (rXCI) ondergaan. 
Geïmprinte XCI treedt als eerste op en resulteert in de inactivatie van uitsluitend het paternale 
X chromosoom in alle cellen van het morula-stadium embryo. Later tijdens de embryonale 
ontwikkeling reactiveren de cellen van het embryo proper hun inactieve paternale X 
chromosoom, om vervolgens rXCI te kunnen ondergaan, waarbij iedere cel een individuele 
keuze maakt welk X chromosoom geïnactiveerd wordt. Nadat een cel één van zijn X 
chromosomen geïnactiveerd heeft, wordt deze inactieve status doorgegeven aan alle dochter-
cellen. In de mens treedt in zowel de embryonale weefsels als de extra-embryonale weefsels 
rXCI op. Ondanks dat humaan rXCI van klinisch belang is, wanneer er sprake is van een X-
chromosomale aandoening of eigenschap, is rXCI het meest uitvoerig bestudeerd in de muis. In 
dit proefschrift hebben we het mechanisme achter rXCI in de muis en de genetische elementen 
die betrokken zijn bij humane rXCI bestudeerd. Daarnaast hebben we de correlatie van XCI 
tussen verschillende humane weefsels onderzocht en hebben we de reactivatie van het 
inactieve X chromosoom tijdens de reprogrammering van humane somatische cellen 
geanalyseerd. 
Er bestaan verschillende modellen die voor rXCI in de muis verklaren hoe een cel 
bepaald hoeveel X chromosomen er aanwezig zijn en hoe bepaald wordt welk X chromosoom 
geïnactiveerd wordt. Het meest plausibele model is het recent gepostuleerde stochastische 
model, waarin voorgesteld werd dat ieder X chromosoom een intrinsieke kans heeft om te 
inactiveren. Dit model is gebaseerd op de observatie dat XCI sneller verloopt in XXXX 
tetraploïde cellen, in vergelijking met XXXY tetraploïde cellen. In hoofdstuk 2 worden 
experimenten beschreven die  het stochastisch model van XCI bevestigen. De dynamiek van XCI 
werd bestudeerd in XXY triploïde embryonale stam (ES) cellen en deze laat zien dat de 
intrinsieke kans van een X chromosoom om te inactiveren afhankelijk is van de ratio tussen X 
chromosomen en autosomen. Daarnaast wordt gedemonstreerd dat XCI onafhankelijk is van 
celdeling. Omdat XCI in triploïde cellen plaatsvindt met een erg vertraagd tempo, moet de 
concentratie van een hypothetische activator van XCI maar minimaal de vereiste treshold voor 
initiatie van XCI  overstijgen. Computer simulatie wordt gebruikt om te demonstreren dat 
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observationele experimentele data van XCI compatibel zijn met een stochastisch model, waarin 
XCI wordt gereguleerd door de concentratie van een activator van XCI en een X chromosoom-
specifieke treshold voor XCI. De gesimuleerde data voorspellen dat de kans van een X 
chromosoom om te inactiveren niet statisch is, maar in plaats daarvan veranderd tijdens cel-
differentiatie. 
De genetische elementen en diffundeerbare factoren die nodig zijn voor een correctie 
initiatie van XCI zijn geïdentificeerd in de muis, maar of deze elementen ook een rol spelen in 
humane XCI is vaak onbekend. In de muis is het genetische locus wat noodzakelijk is om XCI op 
te laten treden het X-inactivatie centrum (Xic). Het Xic van de muis kan onderverdeeld worden 
in een in-cis werkend gedeelte en een in-trans werkend gedeelte. Het cis-werkende gedeelte is 
noodzakelijk voor inactivatie van een X chromosoom in-cis en de niet-coderende genen Xist en 
Tisx zijn cruciaal voor het juist functioneren van dit gedeelte. Xist produceert een niet-
coderend RNA, dat uitsluitend associeert met het inactieve X chromosoom (Xi). Tsix is 
antisense ten opzichte van Xist georiënteerd en functioneert als een negatieve regulator van 
Xist. De trans-Xic telt het aantal X chromosomen in een cel en zorgt ervoor dat er per diploïd 
genoom maar één X chromosoom niet geïnactiveerd wordt. Op dit moment is de enige 
geïdentificeerde trans-werkende activator van de trans-Xic het E3 ubiquitine-ligase Rnf12. 
Rnf12 activeert Xist indirect, door de XCI-repressor REX1 te markeren voor afbraak door het 
proteasoom. Deze elementen die essentieel zijn voor de Xic van de muis, zijn in verschillende 
mate geconserveerd in de mens. Humaan XIST is matig geconserveerd, maar functioneert 
analoog aan muizen Xist waarbij het XIST RNA ook associeert met de Xi in-cis. TSIX is slecht 
geconserveerd en lijkt niet langer functioneel. RNF12 is sterk geconserveerd, maar of RNF12 
een functie heeft in humane XCI is nog onbekend. Ook was het nog onbekend of de humane 
XIC, net als de Xic in muis, onderverdeeld kan worden in een cis-werkend gedeelte en een 
trans-werkend gedeelte. In hoofdstuk 3 worden resultaten getoond, die laten zien dat ook de 
humane XIC in een cis-werkend gedeelte en een trans-werkend gedeelte kan worden 
onderverdeeld. Dit hoofdstuk beschrijft een vrouw, waarbij een deletie van de XIC werd 
geïdentificeerd. Deze deletie werd tot op de nucleotide nauwkeurig geïdentificeerd met een 
techniek gebaseerd op chromatin conformation capture, en representeert de cis-XIC. Een 
humane trans-werkende activator van XCI moet gelokaliseerd zijn in een kleine regio 
telomerisch ten opzichte van de cis-XIC, waarin ook RNF12 gelokaliseerd is. Daarnaast is er bij 
de vrouw die in dit hoofdstuk beschreven wordt sprake van een hypergonadotroop 
hypogonadisme. Dit fenotype wordt volgens ons mogelijk verklaart door een reductie van 50% 
in de dosering DMRT1C.  
Hoofdstuk 4 beschrijft drie families met missense mutaties in verschillende functionele 
domeinen van RNF12. Deze verschillende mutaties segregeren in mannen met verstandelijke 
beperking en leiden in vrouwen tot XCI met inactivatie van uitsluitend het aangedane X 
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chromosoom. De in vitro experimenten die worden beschreven laten zien dat een mutatie in 
het interactiedomein van RNF12 leidt tot toegenomen functionele capaciteit, wat blijkt uit de 
toename in de hoeveelheid geübiquitineerd REX1. Twee mutaties in het RING domein van 
RNF12 leiden tot een afgenomen functionele capaciteit, met een verminderd vermogen tot 
ubiquitinatie. Omdat bij draagsters van deze RNF12 mutaties uitsluitend het X chromosoom 
met het aangedane RNF12 geïnactiveerd is, is het niet onwaarschijnlijk dat humaan RNF12, net 
als muizen Rnf12, functioneert als een trans-activator van XCI. Om een trans-activerende 
functie van RNF12 aan te tonen zijn echter verdere experimenten nodig. 
Als gevolg van XCI bestaat iedere vrouw uit twee cel populaties, die ieder een ander 
actief X chromosoom (Xa) hebben. In de meeste vrouwen zal de verhouding tussen de cellen 
met een actief paternaal X chromosoom (Xp) en de cellen met een actief maternaal X 
chromosoom (Xm) ongeveer 50:50 zijn. Deviatie van deze 50:50 X-inactivatie ratio (XIR) komt 
frequent voor en de situatie waar meer dan 80% van alle cellen dezelfde Xi hebben, wordt 
skewed XCI genoemd. In een gezonde vrouwelijke populatie volgt de XIR een normale 
verdeling. Het percentage vrouwen met skewed XCI in  een populatie neemt toe met de 
leeftijd, waarschijnlijk al vanaf de geboorte. De XIR is klinisch relevant, wanneer er sprake is 
van een X-gecodeerde eigenschap, of X-chromosomale aandoening. Voor een aantal 
aandoeningen, zoals Rett syndroom en Fragiele X syndroom, wordt het fenotype in vrouwelijke 
draagsters van deze aandoening gemoduleerd door de XIR. Daarnaast zijn er een aantal 
aandoeningen waar geen X-chromosomale oorzaak voor geïdentificeerd is, die geassocieerd 
zijn met een verhoogde prevalentie van skewed XCI. Klinische testen gericht op het bepalen 
van de XIR worden vaak uitgevoerd op perifere bloedsamples, ook al is dit niet altijd het 
aangedane weefsel. Om de correlatie te testen tussen de XIR van makkelijk toegankelijke 
weefsels zoals bloed, wangslijmvlies en haarfollikel, en de XIR van de vaak ontoegankelijke 
aangedane weefsels, hebben we de XIR van verschillende weefsels met elkaar vergeleken. De 
resultaten hiervan worden beschreven in hoofdstuk 5, waar we een goede correlatie vinden 
tussen de weefselspecifieke XIR’s van een vrouw, ook al is er een substantiële variatie 
aanwezig. Van de gemakkelijk toegankelijke weefsels bloed, wangslijmvlies en haarfollikel had 
wangslijmvlies de beste correlatie met de ontoegankelijke weefsels. Het enige ontoegankelijke 
weefsel met een slechte correlatie met wangslijmvlies was ovarium, waarvoor wel een goede 
correlatie met haarfollikel gevonden werd. 
Ondanks de klinische implicaties van XCI, is er geen goed modelsysteem beschikbaar 
om humaan XCI te bestuderen. Na de beschrijving van de eerste geïnduceerde pluripotente 
stamcellen (iPSC) leek dit modelsysteem aanstaande, omdat deze nieuwe pluripotente 
stamcellen mogelijk twee actieve X chromosomen bevatten. Maar het reprogrammeren van 
somatische cellen naar een naïeve staat, waarbij beide X chromosomen actief zijn, is moeizaam 
gebleken en vele studies hebben verschillende uitkomsten beschreven wat betreft de activiteit 
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van de twee X chromosomen. In hoofdstuk 6 is de reactivatie van de Xi geanalyseerd tijdens 
het reprogrammeren van huidfibroblasten naar iPS cellen. De Xi wordt inderdaad gereactiveerd 
vroeg tijdens het proces van reprogrammeren, maar deze reactivatie is instabiel en leidt tot re-
inactivatie. Als gevolg hiervan bestaat een gereprogrammeerde cel populatie uit zowel cellen 
met twee Xa’s als cellen met een Xi en een Xa. Wanneer deze gereprogrammeerde cellen in 
naïef medium gekweekt worden, wordt het reactivatie-inactivatie proces van de Xi 
gestabiliseerd. Hierdoor is expansie van de cel-klonen met twee Xa’s mogelijk. Deze resultaten 
laten zien dat humane iPS cellen een modelsysteem voor XCI zijn, ook al is het genereren van 
deze cellen een inefficiënt proces. 
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Dankwoord 
 
Lieve vrienden, familie en collega’s, mijn promotietraject zit er nu bijna op en het is geweldig 
om dit te kunnen afsluiten met dit proefschrift. Ik wil iedereen bedanken die mij geholpen 
heeft bij het tot stand komen van dit proefschrift. Even dankbaar ben ik voor alle hulp bij de 
experimenten die dit proefschrift niet bereikt hebben. Ik wil jullie allemaal heel erg bedanken 
voor deze onvergetelijke tijd.  
 
Beste Professor Gribnau, beste Joost, dit promotietraject is voor mij al begonnen toen ik als 
master student bij jouw groep kwam. Ik heb je leren kennen als een goede wetenschapper, 
maar bovenal als iemand met een hartelijke persoonlijkheid. Sinds dat begin is er veel 
veranderd, maar voor mij ben jij altijd die begeleider gebleven met wie ik pipetteer-helmen 
moest maken om te celkweken. In de afgelopen jaren heeft jouw deur altijd voor mij open 
gestaan.  Bedankt voor je opbeurende gesprekken wanneer ik deze nodig had. Bedankt ook, 
voor je geduld met mij als ik weer een keer onaangekondigd je kamer binnenliep, of als je mij 
bij herhaling iets uit moest leggen, omdat ik het na een paar slapeloze nachten met de 
kinderen weer vergeten was. Ik hoop dat onze paden elkaar in de toekomst nog vaak mogen 
kruisen. 
 
Beste Professor Laven, beste Joop, ik heb je de afgelopen jaren leren kennen als een begeleider 
die volledig achter zijn promovendi staat. Het was mooi om jou de resultaten van mijn basale 
experimenten voor te leggen en te zien hoe jij deze in een ander daglicht plaatste. 
Ook al hebben we misschien niet zo vaak overleg gehad als we gewild zouden hebben, ik heb 
me altijd één van jouw team gevoeld. Dank je voor je steun en je mentorschap op de 
momenten dat ik deze nodig had.  
 
In het bijzonder wil ik ook de leden van mijn kleine commissie bedanken voor het nauwkeurig 
lezen van dit proefschrift. Dank ook aan de leden van de grote commissie dat u hier deel van 
uit wil maken. 
 
Beste Professor Grootegoed, beste Anton, zonder jou was dit proefschrift er nooit gekomen. En 
wie weet hoe mijn loopbaan zich dan gevormd zou hebben. Toen ik als master student het niet 
zag zitten om de master verder af te maken, was jij degene die me overtuigt heeft om dit toch 
te doen. Die keuze heeft me uiteindelijk geleid naar dit promotie-traject, waarvoor ik je nu nog 
dankbaar ben. 
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Lieve collega’s van het Albert Schweitzer ziekenhuis, bedankt voor jullie warme ontvangst. Ik 
geniet er nog iedere dag opnieuw van terug te zijn in de kliniek en met jullie samen te mogen 
werken. 
 
Dear members of lab 902, Adna, Andrea, Azi, Daphne, Dimitar, Esther, Elvira, Gaby, Joachim, 
Joke, Marja, Nilhan, Peng and  Stefan. It has been a great pleasure to work together with all of 
you! Thank you for all the fun, the interesting discussions and your help with experiments. 
Ruben, Ruby! Jij weet als geen ander hoe het is om te promoveren bij een klinische en een 
basaal wetenschappelijke afdeling. Jouw ontspannen manier van werken is altijd een mooie 
compensatie geweest voor mijn gehaastheid. Kim, bedankt voor je hulp en je altijd kritische 
beschouwing van bijna elke situatie. Het was mooi om in verschillende fasen van onze carrières 
samen te mogen werken. Hopelijk krijgen we deze kans in de toekomst nog een keer. Jos en 
Evelyne, jullie zijn vanaf het begin mijn buurtjes geweest. Ik heb genoten van de vele gezellige 
momenten die daarbij hoorden. Catherine, roomie, door jou denk ik soms nog steeds dat ik 
kattengeluiden achter me hoor. Cheryl, misschien heb je in het begin even moeten wennen 
aan mijn grappen, maar ik heb ervan genoten steeds meer weerwoord van jou te krijgen. 
Eskeww, it is a pity that we did not work together for a longer time. I always enjoyed our 
serious and also our hilarious conversations. Cristina, I think everything I learned from working 
with protein, I learned from you! Friedemann, thank you for our great discussions. Fabrizia, 
thank you for all your great stories. I am afraid I won’t remember them as accurately as you 
probably can. Agnese, it is great to see your enthusiasm for science. But please don’t talk to the 
closet anymore. Hegias, thanks for all the laughs we had. Fede, your cheerfulness seems to 
make all people around you happy. Godfried, soms mis ik onze gesprekken, die ineens een 
bizarre wending konden nemen. Aristea, thank you for helping me out so many times. Without 
you my cloning would still be unfinished. Willy, bedankt voor je kritische beschouwingen en 
suggesties tijdens onze onderzoeksbesprekingen. Maureen, jij was voor mij soms een extra 
begeleider. Dankjewel voor je steun en adviezen.  
 
Beste Guido, Bianca en Marialuisa, ontzettend bedankt voor al jullie hulp met de ABI genetic 
analyzer. Zonder jullie hulp was de HumARA nooit van de grond gekomen. Josja, je zal wel blij 
zijn dat je je computer weer helemaal voor jezelf hebt. Bert, Erwin en Hannie, bedankt voor al 
jullie hulp met experimenten. Jullie expertise is onmisbaar geweest.  
Jaap en Jaap, van de pathologie, bedankt voor de opvrolijkende telefoontjes iedere ochtend, 
zoveel dagen en jaren achter elkaar. 
Beste Cindy, Esther, Hikke, Ilse, bedankt voor het meedenken en de hulp bij experimenten. 
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Mehrnaz, Tracy, Dorota and Alex, many thanks for your advices and help with cell culture. Also 
many thanks to all other great people of the ErasmusMC that I have met over the past years 
and that I have forgotten to mention. 
 
Lieve (oud) arts-onderzoekers van de gynaecologie: Aleid, Amber, Anke, Babs,  Babette, 
Caroline, Christine, Cindy, Eline, Emilie, Evelyne, Fatima, Hein, Irene, Jashvant, Jacky, Jinke, 
John, Leonie, Lindy, Matthijs, Meertien, Melek, Nicole, Olivier, Paulien, Sabine, Wendy, Yvonne, 
en  Zoe, bedankt voor alle gezellige momenten! Sam, ook al was jij al klaar met je promotie, 
bedankt voor je steun en interesse als mede-arts in de basale wetenschap. Ik heb je 
enthousiasme en adviezen altijd erg gewaardeerd. 
 
Lieve Annegien en Eveline, bedankt dat jullie naast mij willen staan als mijn paranimfen. 
Eveline, (ik zal je naam nu een keer goed spellen) we kennen elkaar al sinds mijn begin op het 
lab als master student. Als mede-Breda-naars hadden wij elkaar al snel gevonden en in de jaren 
daarna hebben we vele gezellige momenten beleefd. Daarnaast is je enorme hulp bij mijn 
experimenten van onschatbare waarde geweest. Annegien, jij kwam pas halverwege mijn 
promotie, maar wij zaten al meteen op één lijn. Ik heb genoten van onze discussies en grappen. 
Dankjewel voor alle gezellige momenten. Het was inspirerend om te zien hoe gemotiveerd en 
gedreven jij met je onderzoek bezig bent. Vergeet je niet om onze plant nog terug te brengen?  
 
Bart en Bart, jongens van de co-groep Tilburg, bedankt voor het regelmatig bijpraten op 
persoonlijk vlak en vakinhoudelijk, natuurlijk onder het genot van een Belgisch biertje. Jongens 
van de Mojo Tilburg: Bart, Bob, Jaap,  Jordi, Niek, Rick, Rob B en Rob V. Bedankt voor de  
momenten van ontspanning en ongein tussen het werken door.  
 
Lieve schoonfamilie: oma Jet, Bert, Jos, Marloes, Emiel, Lauran, Joes, Quint, Jos, Carla, Anne en 
Marleen. Dankjewel voor jullie interesse en steun de afgelopen jaren. Lieve Ad en Rian, soms 
voel ik me echt als een zoon van jullie. Bedankt voor jullie enorme steun in de afgelopen jaren. 
Jullie zijn als een rots in de branding geweest tijdens de, soms onstuimige, gebeurtenissen de 
afgelopen jaren. 
 
Lieve papa en mama, jullie zijn mijn thuisbasis, waarop ik altijd kan terugvallen. Ook al is ons 
familieleven de afgelopen jaren behoorlijk druk geweest, jullie hebben altijd voor mij klaar 
gestaan. Dankjewel voor alle hulp en jullie steun in al mijn keuzes. Ben, broertje, het was mooi 
om te zien hoe snel jij begreep waar ik soms mee bezig was. Mariëlle, bedankt voor het 
beheren van de sociale agenda van mijn broertje, waardoor er vaker gezellige familie avonden 
zijn. Lieve Dorien, ik heb je de afgelopen jaren erg zien groeien. Houdt daar niet mee op, hoor! 
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Alice en Celeste, ik hoop dat jullie altijd zo open en spontaan mogen blijven en dat er nog vele 
speelmomenten met Stijn en Nina mogen zijn. 
 
Lieve Stijn en Nina, ik ben er ontzettend trots op om jullie papa te mogen zijn. Het is geweldig 
om jullie je eigen persoonlijkheid te zien ontwikkelen. Ik ben benieuwd naar wat er allemaal 
nog komen gaat en ik kijk ernaar uit om daar getuige van te mogen zijn. 
 
Lieve Judith, met jouw steun kan ik écht de hele wereld aan! Voor jou zijn de afgelopen jaren 
niet makkelijk geweest. Dankjewel voor je oneindige geduld, als ik thuis weer eens een 
experiment niet los kon laten. Er zal, naast mij, niemand zo naar het einde van dit boekje 
toegeleefd hebben als jij. Dankjewel voor je nooit aflatende steun. Ik hou van jou! 
 

